Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2019

Site- and Location-Adjusted Approaches to Adaptive Allocation
Clinical Trial Designs
Brian S. Di Pace
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Biostatistics Commons
© Brian S. Di Pace

Downloaded from
https://scholarscompass.vcu.edu/etd/5706

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

Site- and Location-Adjusted Approaches to Adaptive
Allocation Clinical Trial Designs
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.

by
Brian S. Di Pace, M.P.H.

Committee Members:
Roy T. Sabo, Ph.D., Associate Professor, Department of Biostatistics (Director)
David C. Wheeler, Ph.D., M.P.H.,Department of Biostatistics
Le Kang, Ph.D., Department of Biostatistics
Amir Toor, M.D., Department of Internal Medicine
Qiong Zhang, Ph.D., M.A., School of Mathematical and Statistical Sciences, Clemson University

Department of Biostatistics
Virginia Commonwealth University
Richmond, Virginia

January 29, 2019

© Brian S. Di Pace

2019

All Rights Reserved.

ACKNOWLEDGMENTS
The last few years have been some of the most challenging and humbling times of my life. This
journey would not have been possible without the support of numerous people. I would first like
to acknowledge my dissertation advisor, Dr. Roy Sabo. I am extremely thankful for his patience
and his guidance throughout this process. He encouraged me to overcome all the challenges I have
encountered in my research and has supported me along the way. I would also like to thank Dr.
Tina D. Cunningham, my mentor from my master’s program. Without her, I would not have
discovered my interest in biostatistics or pursued this doctoral degree.
None of this would have been possible without the support and the team effort of my Fall
2014 cohort, BAMF – Yu Cao, Victoria Garcia, Camille Hochheimer, Alicia Johns and AnnyClaude Joseph. Thank you all for those late nights and long weekends working together to survive
graduate school. I do not believe I would be here today without you. I would be honored to work
with each of you in our future endeavors. I would also like to thank another colleague, Jordyn
Wallenborn, for all the baked goods and encouraging words over the years.
I would also like to acknowledge all of the students and faculty in the Biostatistics department.
Specifically, I would like to thank my committee members – Dr. Le Kang, Dr. Amir Toor, Dr.
David Wheeler and Dr. Qiong Zhang – for their guidance with my research. I am grateful for
all the help from Russ Boyle and Yvonne Hargrove, they always either knew the answer or knew
exactly who to ask to find out. I would also like to thank my coworker, Viviana Rodriguez, and
my boss, Dr. Adam Sima, for all their help and consulting advice in the last few years.
Finally, I would like to thank my family and friends for supporting me throughout the pursuit
of my academic career. This journey has had many ups and downs, but you all have been there
to keep pushing me forward. My mother has always believed in me and tells me how proud she is.
She has accompanied me every step of the way, though my education has found me hundreds of
miles away. I would also like to give a special thanks to WPC for all the support and love I have
received. You have been a source of great motivation and happiness in the last two years.
Again, I offer my deepest gratitude to all these individuals for guiding me along this path. I
look forward to beginning the next chapter of my life.

ii

TABLE OF CONTENTS

Acknowledgments

ii

Table of Contents

iii

List of Tables

vi

List of Figures

ix

Abstract

xi

1 Introduction
1.1 Background . . . . . . . .
1.2 Current Methods . . . . .
1.3 Proposed Methods . . . .
1.4 Specific Aims . . . . . . .
1.4.1 Aim 1: Accounting
1.4.2 Aim 2: Accounting
1.4.3 Aim 3: Accounting

. .
. .
. .
. .
for
for
for

. . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . .
Site-based Response Variability . . . .
Variability in Treatment Effectiveness
Location-based Variability . . . . . . .

2 Accounting for Site-based Response Variability
2.1 Background and Existing Methods . . . . . . . . . . . . . . . . . .
2.1.1 Response-Adaptive Allocation . . . . . . . . . . . . . . . . .
2.1.2 Covariate-Adjusted Response-Adaptive (CARA) Design . .
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2.1 CARA Model . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2.2 Site-Adjusted Response-Adaptive (SARA) Model 1 . . . . .
2.3 Simulation Study . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.3.1 Simulation Algorithm . . . . . . . . . . . . . . . . . . . . .
2.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.4.1 Scenario 1: Optimal Allocation, 3 Sites, p1 = 0.3 . . . . .
2.4.2 Scenario 2: Optimal Allocation, 6 Sites, p1 = 0.3 . . . . .
2.4.3 Scenario 3: Optimal Allocation, 3 Sites, p1 = 0.5 . . . . .
2.4.4 Scenario 4: Neyman Allocation, 3 Sites, p1 = 0.3 . . . . .
2.4.5 Scenario 5: Neyman Allocation, 6 Sites, p1 = 0.3 . . . . .
2.4.6 Scenario 6: Neyman Allocation, 3 Sites, p1 = 0.5 . . . . .
2.4.7 Empirical Type I Error and Power by Number of Sites (k) .
2.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 Accounting for Variability in Treatment Effectiveness
3.1 Background and Existing Methods . . . . . . . . . . . . . . . . .
3.1.1 Bayesian Covariate-Adjusted Response-Adaptive (CARA)
3.1.2 Treatment-by-Center Interactions in Clinical Trials . . . .
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.2.1 SARA Model 2 - No Treatment-by-Site Interaction . . . .
3.2.2 SARA Model 3 - Treatment-by-Site Random Interaction .
3.3 Simulation Study . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.3.1 Simulation Algorithm . . . . . . . . . . . . . . . . . . . .
iii

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.

.
.
.
.
.
.
.

.
.
.
.
.
.
.

.
.
.
.
.
.
.

.
.
.
.
.
.
.

.
.
.
.
.
.
.

.
.
.
.
.
.
.

.
.
.
.
.
.
.

.
.
.
.
.
.
.

1
1
3
3
4
4
5
5

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

6
6
6
9
12
13
14
15
20
21
22
27
32
35
38
43
49
62

.
.
.
.
.
.
.
.

65
65
65
66
68
68
70
71
77

. . . .
Design
. . . .
. . . .
. . . .
. . . .
. . . .
. . . .

.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.

3.4

3.5

Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.4.1 Scenario 1: No Interaction, 3 Sites, p1 = 0.3 . . . . . . . . .
3.4.2 Scenario 2: No Interaction, 6 Sites, p1 = 0.3 . . . . . . . . .
3.4.3 Scenario 3: No Interaction, 3 Sites, p1 = 0.5 . . . . . . . . .
3.4.4 Scenario 4: No Interaction, 6 Sites, p1 = 0.5 . . . . . . . . .
3.4.5 Scenario 5: No Interaction, 3 Sites, p1 = 0.7 . . . . . . . . .
3.4.6 Scenario 6: No Interaction, 6 Sites, p1 = 0.7 . . . . . . . . .
3.4.7 Incorporating a Treatment-by-Site Interaction . . . . . . . . .
Scenario: 3 sites, p1 = 0.3, δ = 0, 0.15 . . . . . . . . . . . .
Scenario: 3 sites, p1 = 0.5, 0.7, δ = 0.15 . . . . . . . . . . .
Scenario: 6 sites, p1 = 0.3, δ = 0, 0.15 . . . . . . . . . . . .
3.4.8 Simulation Time per Patient . . . . . . . . . . . . . . . . . .
Scenario: 3 sites, p1 = 0.3, δ = 0, 0.15 . . . . . . . . . . . .
Scenario: 3 sites, p1 = 0.5, 0.7, δ = 0.15 . . . . . . . . . . .
Scenario: 6 sites, p1 = 0.3, δ = 0, 0.15 . . . . . . . . . . . .
3.4.9 Sensitivity Analysis for Prior Specification of Random Effects
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4 Accounting for Location-based Variability
4.1 Background and Existing Methods . . . . . . . . . . . . . . .
4.1.1 Spatial Correlation . . . . . . . . . . . . . . . . . . . .
4.1.2 Existing Interpolation Methods . . . . . . . . . . . . .
4.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.2.1 Location-Adjusted Response-Adaptive (LARA) Model
4.3 Simulation Study . . . . . . . . . . . . . . . . . . . . . . . . .
4.3.1 Scenarios Considered . . . . . . . . . . . . . . . . . . .
4.3.2 Simulation Settings . . . . . . . . . . . . . . . . . . . .
4.3.3 Convergence Study . . . . . . . . . . . . . . . . . . . .
4.3.4 Simulation Algorithm . . . . . . . . . . . . . . . . . .
4.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.4.1 Mean Total Number of Treatment Successes . . . . . .
4.4.2 Expected Allocation Proportion - Treatment Group 1
4.4.3 Empirical Type I Error and Power . . . . . . . . . . .
4.4.4 Mean Squared Error (MSE) by Treatment . . . . . . .
4.4.5 Simulation Time per Patient . . . . . . . . . . . . . .
4.4.6 Convergence Simulation . . . . . . . . . . . . . . . . .
4.4.7 True and Estimated Treatment Success Surfaces . . .
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

78
78
82
86
89
92
96
99
100
101
103
105
105
106
107
108
109

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

113
113
114
117
121
123
125
126
129
132
133
134
134
135
136
137
138
139
140
146

5 Discussion
150
5.1 Future considerations: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
Appendix A R Code Relevant to Chapter 2

154

Appendix B Chapter 3 Additional Tables

156

Appendix C R Code Relevant to Chapter 3

159

Appendix D Geographically Adaptive Regression LARA Model

163

iv

Appendix E R Code Relevant to Chapter 4

165

References

168

Vita

175

v

LIST OF TABLES

2.1

Percentage (%) of Qualitative Treatment-by-Site Interactions . . . . . . . . . . . . . 17

2.2

Scenario 1 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 23

2.3

Scenario 1 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 24

2.4

Scenario 1 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 25

2.5

Scenario 2 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 28

2.6

Scenario 2 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 29

2.7

Scenario 2 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 30

2.8

Scenario 3 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 32

2.9

Scenario 3 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 33

2.10 Scenario 3 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 34
2.11 Scenario 4 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 36
2.12 Scenario 4 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 37
2.13 Scenario 4 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 38
2.14 Scenario 5 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 40
2.15 Scenario 5 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 41
2.16 Scenario 5 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 43
2.17 Scenario 6 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 45
2.18 Scenario 6 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 46
2.19 Scenario 6 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 47
3.1

Percentage (%) of Qualitative Treatment-by-Site Interactions . . . . . . . . . . . . . 72

3.2

Sensitivity Analysis: Priors Considered . . . . . . . . . . . . . . . . . . . . . . . . . . 73

3.3

Scenario 1 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 79

3.4

Scenario 1 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 80

3.5

Scenario 1 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 82

3.6

Scenario 2 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 83

3.7

Scenario 2 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 84

3.8

Scenario 2 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 86

vi

3.9

Scenario 3 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 87

3.10 Scenario 3 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 88
3.11 Scenario 3 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 89
3.12 Scenario 4 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 90
3.13 Scenario 4 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 91
3.14 Scenario 4 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 92
3.15 Scenario 5 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 93
3.16 Scenario 5 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 94
3.17 Scenario 5 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 96
3.18 Scenario 6 - Mean Total Number of Treatment Successes (Standard Error) . . . . . . 97
3.19 Scenario 6 - E[n1 /(n1 + n2 )] (Standard Error) . . . . . . . . . . . . . . . . . . . . . . 98
3.20 Scenario 6 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 99
3.21 Scenario - 3 sites, p1 = 0.3, δ = 0, 0.15 . . . . . . . . . . . . . . . . . . . . . . . . . . 101
3.22 Scenario - 3 sites, p1 = 0.5, 0.7, δ = 0.15 . . . . . . . . . . . . . . . . . . . . . . . . . 103
3.23 Scenario - 6 sites, p1 = 0.3, δ = 0, 0.15 . . . . . . . . . . . . . . . . . . . . . . . . . . 105
3.24 Simulation Time (seconds) per Patient . . . . . . . . . . . . . . . . . . . . . . . . . . 106
3.25 Simulation Time (seconds) per Patient . . . . . . . . . . . . . . . . . . . . . . . . . . 107
3.26 Simulation Time (seconds) per Patient . . . . . . . . . . . . . . . . . . . . . . . . . . 108
3.27 Sensitivity Analysis for Prior Specification of Random Effects . . . . . . . . . . . . . 109
4.1

Mean Total Number of Treatment Successes (SE) . . . . . . . . . . . . . . . . . . . . 135

4.2

E[n1 /(n1 + n2 )] (SE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136

4.3

Empirical Type I Error and Power (95% Confidence Interval) . . . . . . . . . . . . . 137

4.4

Mean Squared Error (MSE) by Treatment . . . . . . . . . . . . . . . . . . . . . . . . 138

4.5

Computation Time . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139

4.6

Convergence Simulation: Scenario 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . 140

B.1 Scenario - 3 sites, p1 = 0.3, 0.5, 0.7, δ = 0.1 . . . . . . . . . . . . . . . . . . . . . . . . 156
B.2 Scenario - 6 sites, p1 = 0.5, 0.7, δ = 0.15 . . . . . . . . . . . . . . . . . . . . . . . . . 157
B.3 Scenario - 3 sites, p1 = 0.5, δ = 0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
B.4 Scenario - 6 sites, p1 = 0.7, δ = 0.1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
vii

D.1 Comparing Low Rank Kriging and Inverse Distance Weighted Interpolation . . . . . 164

viii

LIST OF FIGURES

2.1

Simulated Success Probabilities for Center 1 . . . . . . . . . . . . . . . . . . . . . . . 16

2.2

Not Accounting for Clustering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22

2.3

Scenario 1 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 26

2.4

Scenario 2 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 31

2.5

Scenario 3 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 35

2.6

Scenario 4 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 39

2.7

Scenario 5 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 44

2.8

Scenario 6 - Empirical Type I Error and Power . . . . . . . . . . . . . . . . . . . . . 48

2.9

Empirical Type I Error by Site, P1 = 0.3, δ = 0 . . . . . . . . . . . . . . . . . . . . . 50

2.10 Empirical Power by Site, P1 = 0.3, δ = 0.10 . . . . . . . . . . . . . . . . . . . . . . . 51
2.11 Empirical Power by Site, P1 = 0.3, δ = 0.15 . . . . . . . . . . . . . . . . . . . . . . . 52
2.12 Empirical Type I Error by Site, P1 = 0.5, δ = 0 . . . . . . . . . . . . . . . . . . . . . 53
2.13 Empirical Power by Site, P1 = 0.5, δ = 0.10 . . . . . . . . . . . . . . . . . . . . . . . 54
2.14 Empirical Power by Site, P1 = 0.5, δ = 0.15 . . . . . . . . . . . . . . . . . . . . . . . 55
2.15 Empirical Type I Error by Site, P1 = 0.3, δ = 0 . . . . . . . . . . . . . . . . . . . . . 56
2.16 Empirical Power by Site, P1 = 0.3, δ = 0.10 . . . . . . . . . . . . . . . . . . . . . . . 57
2.17 Empirical Power by Site, P1 = 0.3, δ = 0.15 . . . . . . . . . . . . . . . . . . . . . . . 58
2.18 Empirical Type I Error by Site, P1 = 0.5, δ = 0 . . . . . . . . . . . . . . . . . . . . . 59
2.19 Empirical Power by Site, P1 = 0.5, δ = 0.10 . . . . . . . . . . . . . . . . . . . . . . . 60
2.20 Empirical Power by Site, P1 = 0.5, δ = 0.15 . . . . . . . . . . . . . . . . . . . . . . . 61
4.1

Scenario 1 True Surface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126

4.2

Scenario 2 True Surface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127

4.3

Scenario 3 True Surface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127

4.4

Scenario 4 True Surface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127

4.5

Scenario 5 True Surface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128

4.6

Scenario 6 True Surface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128

4.7

Scenario 7 True Surface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128

ix

4.8

Scenario 8 True Surface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129

4.9

Scenario 1 - Treatment Success Probabilities . . . . . . . . . . . . . . . . . . . . . . . 141

4.10 Scenario 2 - Treatment Success Probabilities . . . . . . . . . . . . . . . . . . . . . . . 141
4.11 Scenario 3 - Treatment Success Probabilities . . . . . . . . . . . . . . . . . . . . . . . 142
4.12 Scenario 4 - Treatment Success Probabilities . . . . . . . . . . . . . . . . . . . . . . . 142
4.13 Scenario 5 - Treatment Success Probabilities . . . . . . . . . . . . . . . . . . . . . . . 143
4.14 Scenario 6 - Treatment Success Probabilities . . . . . . . . . . . . . . . . . . . . . . . 144
4.15 Scenario 7 - Treatment Success Probabilities . . . . . . . . . . . . . . . . . . . . . . . 145
4.16 Scenario 8 - Treatment Success Probabilities . . . . . . . . . . . . . . . . . . . . . . . 145

x

ABSTRACT
SITE- AND LOCATION-ADJUSTED APPROACHES TO ADAPTIVE
ALLOCATION CLINICAL TRIAL DESIGNS
By Brian S. Di Pace, M.P.H.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2019
Director: Roy T. Sabo, Ph.D., Associate Professor, Department of Biostatistics
Response-Adaptive (RA) designs are used to adaptively allocate patients in clinical trials. These
methods have been generalized to include Covariate-Adjusted Response-Adaptive (CARA) designs,
which adjust treatment assignments for a set of covariates while maintaining features of the RA
designs. Challenges may arise in multi-center trials if differential treatment responses and/or effects
among sites exist. We propose Site-Adjusted Response-Adaptive (SARA) approaches to account
for inter-center variability in treatment response and/or effectiveness, including either a fixed site
effect or both random site and treatment-by-site interaction effects to calculate conditional probabilities. These success probabilities are used to update assignment probabilities for allocating
patients between treatment groups as subjects accrue. Both frequentist and Bayesian models are
considered. Treatment differences could also be attributed to differences in social determinants of
health (SDH) that often manifest, especially if unmeasured, as spatial heterogeneity amongst the
patient population. In these cases, patient residential location can be used as a proxy for these difficult to measure SDH. We propose the Location-Adjusted Response-Adaptive (LARA) approach to
account for location-based variability in both treatment response and/or effectiveness. A Bayesian
low-rank kriging model will interpolate spatially-varying joint treatment random effects to calculate
the conditional probabilities of success, utilizing patient outcomes, treatment assignments and residential information. We compare the proposed methods with several existing allocation strategies
that ignore site for a variety of scenarios where treatment success probabilities vary.
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CHAPTER 1
INTRODUCTION

1.1

Background

Response-Adaptive (RA) allocation designs are used in clinical trials to achieve one of two
aims: as an ethical approach to randomizing patients more effectively by minimizing treatment
failures, or as an optimizational approach to maximize statistical power. This approach has been
generalized to the Covariate-Adjusted Response-Adaptive (CARA) design with the goal to adjust
the treatment assignment for a set of covariates or to guard against differential treatment effects,
while maintaining the features of the adaptive design.
Clinical trials often recruit patients from multiple centers, where adaptive allocation algorithms,
if used, estimate treatment effectiveness using all available data, irrespective of site1 . This presents
several challenges since treatment responses and/or effects can vary across sites; an extreme example
may be where treatment effectiveness is reversed between sites. While the variability in treatment
responses does not necessarily affect the estimated treatment differences across centers in a trial,
variability in treatment effectiveness can result in treatment differences that cannot be applied
universally to all centers. Consider a clinical trial where patients at one center have different
success probabilities, and thus treatment effectiveness, than patients at all other sites where the
treatment is superior. If we ignore site and conclude that overall there is a superior treatment
effect, patients at the one site with different treatment effectiveness may be at risk [1].
Gallo (2008) refers to these differences in treatment effects as a treatment-by-center interaction
that can be classified into two categories based on the direction and magnitude of the effects:
quantitative and qualitative. Quantitative interactions result in treatment effects that differ in
magnitude across centers yet have the same sign, while qualitative interactions result in both
differences in magnitude and direction across centers [1]. A treatment-by-center interaction inhibits
researchers from estimating a single treatment effect for all sites in the trial. However, knowledge
of varying treatment effects can be advantageous because it provides researchers with information
1

Site and center will be used interchangeably to define the location where patients receive medical treatment.
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on the site and patient characteristics, such as where the treatment effect is largest, smallest or
reversed [2].
Treatment differences could also be attributed to differences in social determinants of health
(SDH), including variability in socioeconomic status (SES) among patients, population size/type,
and quality of health care, for example, along with other lifestyle and landscape factors that drive
heterogeneity between patient populations. There are some instances where SES has been associated with treatment adherence. For example, in a study of adjuvant systemic therapy guideline
adherence in early breast cancer patients living in the Netherlands, women with medium and low
SES were significantly less likely to be over-treated with adjuvant chemotherapy compared to those
with high SES [3]. Treatment effectiveness could be affected by SES or other SDH although we may
not have accurate measurements to capture them. Especially when unmeasured, these differences
often manifest as spatial heterogeneity amongst the patient population. In these cases, trial site
or patient residential location could be used as proxies for these difficult to measure SDH. This
demonstrates the importance of incorporating location in adaptive allocation designs to account
for variability in treatment responses and/or effectiveness.
A study by Longini Jr. et al. analyzed data from a placebo-controlled influenza vaccine multicenter trial (1996-1998) to estimate vaccine efficacy for susceptibility to culture-confirmed influenza
(VES ) in children. While adaptive randomization was not used, the goal was to account for intercenter variation along with additional covariates using a generalized linear mixed model (GLMM)
approach, where the cities included were assumed to be a random sample from a larger population.
The crude center-specific VES estimates for year 1 ranged from 0.72 in Baltimore to 1.00 in several
cities, resulting in an inter-center standard deviation of 0.08. When including the vaccination status
as a fixed effect and center as a random effect in the GLMM, the variability of the center effect
is 0.08 and the overall estimated VES = 0.94 (95% CI : 0.89, 0.97). Although the center effect did
not reach statistical significance, it was included in the model to account for an additional source
of variability in estimating the overall vaccine efficacy. The authors also considered models that
incorporated vaccine-by-center interaction effects. If RA randomization was used instead of a 2:1
allocation ratio, the pooled VES would have resulted in more children being randomized to the
vaccine group, regardless of the center-specific vaccine efficacy rates [4].
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1.2

Current Methods

Traditionally, a balanced design has been used in binary response clinical trials because it
often achieves high power for tests of treatment effects. Throughout a trial, this equal allocation
corresponds to “clinical equipoise”, or the stance that investigators have no preference for either
treatment group [5, 6]. As a trial progresses, there are at times data suggesting that one treatment is
more beneficial, though equal allocation ignores this information. This may benefit future patients
that otherwise have a fifty percent chance of being allocated to the inferior treatment group [5].
The allocation rules discussed here are appropriate for trials where the response is ascertained
shortly after treatment to allow for adaptation during the randomization process. An example of
such a trial is the evaluation of crystalloid preload in hypotension prevention following spinal anesthesia for elective cesarean sections which utilized the ‘play the winner’ rule [7]. Adaptive allocation
methods have been extended to handle delayed responses by calculating the joint distribution of
the delayed response and an earlier correlated outcome and using this joint distribution to estimate
allocation weights [8]; however, we will not cover these models here.

1.3

Proposed Methods

A potential method to account for inter-center variability in treatment effectiveness is to use
separate adaptive allocation algorithms for each center. Instead of an overall treatment effect estimated using data from all sites, only local patient data would be used resulting in site-specific
estimates of treatment effectiveness and assignment probabilities. The problem is that small samples sizes at centers would potentially result in convergence issues and unstable estimates, especially
in trials with a large number of sites. The benefits of adapting would be negatively affected even
with lead-in approaches to maintain balanced allocation until enough subjects are recruited to
prevent estimator instability.
Alternatively, one could account for inter-center variability in response-adaptive randomization
by extending the covariate-adjusted designs. In general, the CARA design estimates the predicted
value of treatment success for each treatment group given a set of observed covariates. One method
to account for inter-center variability in treatment effectiveness is to treat site as a fixed effect in
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a generalized linear model (GLM) [9], specifically a marginal model [10]. Treatment estimates
would be interpreted as a population-averaged treatment effect that applies only to the centers
participating in the study. However, our focus is to adopt a method where the sites are assumed
to come from a larger population, as in a previous study.
Another approach is to treat site as a random effect in a conditional model, where the treatment
effect is estimated for individuals by averaging across centers, allowing for heterogeneity in the
effects across centers. Here, sites are assumed to come from a larger population, as in several
previous studies [4, 11, 10]. A GLMM allows inferences to be more generalizable than to just the
centers chosen for the study, however, the assumption that centers are randomly selected from a
larger population is debatable [12, 13]. A GLMM requires that the number of sites being sufficiently
large for consistent estimation of the model parameters [11]. The consistency of the ordinary ML
estimators for the difference of proportions, and other difference measures, breaks down under
sparse large sample methods (asymptotics) for fixed effects models but not for random effects
models [14]. Covariate-adjusted response-adaptive approaches could be extended to use random
effects in a hierarchical framework. Due to the flexibility of the CARA approach, covariates can be
added to the GLMM to adjust the model and ultimately the allocation probabilities.

1.4
1.4.1

Specific Aims
Aim 1: A Site-Adjusted Approach to Adaptive Allocation in Clinical
Trials to account for site-based response variability.

Treatment responses can vary considerably across locations in a multi-center clinical trial due
to a variety of reasons such as heterogeneous patient populations and differences in health care
provider practices. We propose the Site-Adjusted Response-Adaptive (SARA) allocation approach
to account for site-based variability in treatment responses in the presence of slight quantitative
treatment-by-center interactions. A random site effect will be included in the generalized linear
mixed model (GLMM) framework. SARA incorporates readily available information, namely site,
about the subject so that conditional success probabilities are specific to each center. The allocation
weights will be updated with the predicted probabilities of success conditioned on the site specific
to the next patient enrolled.
4

1.4.2

Aim 2: A Bayesian Approach to Site-Adjusted Response-Adaptive Allocation in Clinical Trials to account for variability in treatment effectiveness.

This approach will extend the SARA design from Aim 1 by including a random treatment-by-site
interaction effect to account for inter-site variability in treatment effectiveness. Quantitative and
qualitative treatment-by-site interactions will be explored at both ‘low’ and ‘high’ magnitudes. A
Bayesian approach will be used to overcome computational challenges from modeling both random
site and treatment-by-site interaction effects.

1.4.3

Aim 3: A Bayesian Spatial Approach to Adaptive Allocation in Clinical
Trials to account for location-based variability in treatment responses
and/or effectiveness

This approach will focus on developing spatial statistical methods under the Bayesian framework to account for inter-site variability in both treatment response and effectiveness in the design phase. To adjust for the presence of a spatially heterogeneous treatment effect and/or response, spatially-varying joint treatment random effects will be estimated. The Location-Adjusted
Response-Adaptive (LARA) approach will utilize treatment and residential information to predict
a patient’s response to each treatment and in turn update the allocation weights for subsequent
patients.

5

CHAPTER 2
ACCOUNTING FOR SITE-BASED RESPONSE VARIABILITY

In this chapter, we introduce a site-adjusted approach to adaptive allocation in clinical trials
to account for site-based response variability. Current response-adaptive methods ignore potential
differences in treatment responses and/or effectiveness across sites, and as such are likely to translate
these phenomena into biased or improper patient allocation. In Section 2.1, we summarized the
existing adaptive methods and demonstrated that patient allocation and treatment effectiveness
are adversely affected when multiple sites are not accounted for during randomization. In Section
2.2, we introduce two approaches to account for site-based variability in treatment responses in
the presence of treatment-by-center interactions. A simulation study is conducted in Section 2.3 to
compare the performance of our proposed methods to both balanced and RA randomization. The
results are explored and a brief discussion of the implications follows.

2.1
2.1.1

Background and Existing Methods
Response-Adaptive Allocation

Response-adaptive (RA) randomization updates the allocation probabilities based on previous
treatment assignments and patient responses to meet some aim, such as maximizing power or
minimizing the number of patients assigned to an inferior treatment. Hu and Rosenberger (2006)
describe the three features that define RA randomization, namely that they are 1) myopic, 2)
fully randomized and 3) have a sample size fixed in advance. A myopic process is one which
incorporates accrued data to make decisions on subsequent patients. The RA design is defined as a
myopic process because both treatment assignments and responses of the previous subjects are used
to iteratively update the allocation weights (w1 , w2 ) for the next subject. The RA procedure is fully
randomized since each patient is randomly assigned to a treatment group. While the allocation
weights are dependent on data from the previous subjects, the assignment for each patient is random
and thus independent. Finally, sample sizes are fixed before the trial begins, though early stopping
rules may be implemented [15].
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While much work has been done to generalize Efron’s biased coin design (1971) [16] and Wei’s
urn design (1978) [17], we will focus on the RA procedure based on sequential maximum likelihood
(ML) methods (doubly-adaptive biased coin design) [15]. In the RA design, allocation probabilities
are skewed based on treatment successes with respect to the primary outcome. As such, it is necessary to have a single outcome that is ascertainable shortly after treatment so that the response
of the current patient is available prior to the recruitment of the next individual. Here, this practically instantaneous response allows a sufficient number of patients to be recruited in a reasonable
amount of time [18].
Consider two treatment groups, A and B, with a binary outcome (Y = 1 success, Y = 0 failure)
and a success probability, P (Yi = 1) = pi , for the ith patient, i = 1, . . . , n. A success probability is
the probability of observing patients responding favorably to the treatment, or treatment successes,
given the existing data. The model for n patients is specified as follows:

logit(pi ) = β0 + β1 Ti , i = 1, . . . , n,

(2.1)

where β0 is the overall intercept, β1 is the treatment effect and Ti is the treatment group indicator
(fixed effect),
Ti =




1

if treatment A,



0

otherwise.

The estimated success probabilities p̂t are defined for each treatment group, t = 1, 2, as follows:
p̂1 = logit−1 {β̂0 + β̂1 }
=

exp {β̂0 + β̂1 }
1 + exp {β̂0 + β̂1 }
−1

p̂2 = logit
=

,
(2.2)

{β̂0 }

exp {β̂0 }
1 + exp {β̂0 }

,

where β̂0 , β̂1 are the ML estimates of the intercept and treatment effect from the GLM. Prior to
implementing the RA design, a hard lead-in is initially used where equal allocation (wn = 0.5) is
used to randomize the first m patients between treatment groups until the regression parameters
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in equation (2.1) become estimable. No conclusive research exists for selecting the lead-in length
for balanced allocation, however, alternate treatment balancing methods [19], such as Pocock and
Simon’s procedure, or continual convergence checks [20] have been performed prior to adapting.
Desirable properties of the lead-in length include a balance of being 1) long enough to overcome
small sample estimation problems, but 2) short enough to allow for sufficient adaptation.
The RA design is used to allocate patients between treatment groups with various aims. For
example, two goals an investigator could have are to maximize power or minimize the number
of treatment failures. One way of achieving the latter goal is by allocating patients with higher
probability to the best performing treatment arm [15]. These aims can be achieved by choosing
different loss functions. When the simple difference measure (f {pA , pB } = pA − pB ) is used to
compare two binomial probabilities, the Optimal and Neyman allocation rules can be used. For a
fixed variance of the test statistic, Optimal allocation minimizes the expected number of treatment
failures. Let Fi be a function consisting of only treatment assignments and individual outcomes
for the accrued i = 1, . . . , n patients. The Optimal allocation equations are often functions of the
sample data as follows:
√

w1,O (Fi ) = √

p̂1
√ ,
p̂1 + p̂2

(2.3)

w2,O (Fi ) = 1 − w1,O ,
where p̂t is defined as the observed proportion of successes in treatment group t out of the total
number of patients in that group, t = 1, 2. Rosenberger et al. (2001) note that by having less
treatment failures, their optimal adaptive rule in equation (2.3) performs best with moderate success
probabilities. However, this adaptive rule is protective of patients when the treatment effect is larger
than expected at the beginning of the trial. Specifically, the adaptive design results in similar
power but with less treatment failures compared to balanced allocation. When there is little to no
treatment difference, there is no drawback to using this adaptive rule over equal allocation. Since
the allocation weights will be close to 0.5, both methods will result in similar type I error rates [5].
Neyman Allocation refers to when patients are allocated proportional to the standard deviation
of the parameter estimates with the goal to maximize power. For example, by allocating more
subjects to the treatment group with a larger variability, the standard error of the proportion for
8

that group is reduced. Consequently, the overall variability of the test statistic is reduced, as it is a
function of the standard errors for both proportions, increasing the magnitude of the test statistic
and thus power of the design. The Neyman allocation equations are often functions of the sample
data as follows:
√
p̂1 q̂1
√
,
w1,N (Fi ) = √
p̂1 q̂1 + p̂2 q̂2

(2.4)

w2,N (Fi ) = 1 − w1,N ,
where p̂t is defined as the observed proportion of successes in treatment group t out of the total
number of patients in that group and q̂t = 1 − p̂t is the proportion of treatment group t failures,
t = 1, 2. Neyman allocation is unethical from a patient safety point of view when p̂1 > (1− p̂2 ) since
more subjects would be allocated to the inferior treatment group [5]. It is important to note that
wt,O is proportional to p̂t while wt,N is proportional to the standard deviation of p̂t . While other
weight formulations could be used besides equations (2.3) and (2.4), their optimization criterion is
not certain.
Adaptive allocation designs can cause an imbalance in treatment groups which sometimes results
in lower power compared to balanced designs. However, there are exceptions where unbalanced
designs result in better performance (e.g. power, number of treatment failures) than balanced
allocation [19]. In cases where response rates are low (below 0.5), for example, the RA design may
increase power. It has been shown that an allocation ratio as extreme as 7:3 is needed to severely
impact power [18].

2.1.2

Covariate-Adjusted Response-Adaptive (CARA) Design

Adaptive randomization can result in skewed treatment groups which increases the likelihood
of an imbalance in covariates. Consequently, adaptive designs that rely completely on patient responses fail to capture the complexity of heterogeneous patient populations. Patient characteristics
or measurements may help to explain differential treatment efficacy or effectiveness. Some of these
covariates include prognostic factors and time effects. Stratified or covariate-adaptive1 randomization procedures can be performed to allocate patients within strata of an important characteristic
1

This is also known as a minimization procedure or dynamic allocation.
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in the design phase. These covariates can be adjusted for in a post-hoc manner through multiple
regression modeling or post-stratification, or strict eligibility criteria can be implemented for more
homogeneous populations [15, 19]. However, the feasibility of these methods is restricted to discerning — and thus having measures for — the appropriate covariates to use out of all information
available. It is also difficult to perform RA randomization if there are too many strata due to
potentially small sample sizes within strata.
The CARA design, a generalization of RA randomization, adjusts the allocation for a set of
covariates to get characteristic-specific assignments. Examples of these factors include subject age,
gender, race/ethnicity, baseline disease severity or risk score. Here, treatment assignments, patient
outcomes and covariates are used to update the allocation ratio. We will focus on extending CARA
randomization for binary outcomes [20, 21, 22]. However, the CARA design has also been created
for survival outcomes [23] and continuous treatment responses, where the outcome can be normal or
a general class of continuous responses [24, 25, 26, 27]. Note that this design differs from covariateadaptive randomization, which aims to balance treatment assignments among a set of covariates.
Accordingly, an adaptive design that allocates patients to the better performing treatment group
based on both treatment responses and patient characteristics is considered [15, 20].
Treatment effect mappings is a method that was previously developed for continuous [28], survival [29] and binary outcomes [20] to map the current treatment effect (treatment A - treatment
B) calculated from accrued patients to a probability wn ∈ [0, 1], which is then used to assign the
next patient to treatment group A. Balanced allocation occurs when wn = 0.5, indicating that
the two treatment groups are performing comparably and thus have similar numbers of successes.
Consider two treatment groups, A and B, with a binary outcome (Yi = 1 success, Yi = 0 failure)
and a success probability, pi , for the ith patient, i = 1, . . . , n. Rosenberger et al. (2001) specify a
standard logistic regression model as follows:
0

0

logit(pi ) = α + βTi + zi γ + Ti zi δ

(2.5)

where Ti is the treatment group (Ti = 1 if A, Ti = 0 if B), zi is a k × 1 vector of covariates, γ is a
k × 1 vector of coefficients and δ is a k × 1 vector of treatment-covariate interaction effects. The
logit function is appropriate for binary outcomes and is used for ease in interpretability, though
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other link functions (e.g. probit) can also be implemented.
Prior to implementing the CARA design, a hard lead-in is used where equal allocation (wn = 0.5)
is used to randomize the first m patients between treatment groups until the regression parameters in equation (2.5) become estimable. After this lead-in, adaptive allocation is implemented by
updating the allocation ratio using a function of the estimated treatment effect, adjusted by the
covariates included in the model (2.5). Let Fi be the accrued patient information including treatment assignments, covariates and responses for patients i = 1, . . . , m, m+1, . . . , n, where m+1 ≤ n.
The estimated adjusted odds ratio (OR) for treatment A compared to treatment B is defined as
0

0

0

0

OR(Fi ) = exp {α̂ + β̂ + zi+1 γ̂ + zi+1 δ̂}/ exp {α̂ + zi+1 γ̂} = exp {β̂ + zi+1 δ̂}.

(2.6)

Since the covariate-adjusted OR in equation (2.6) is always positive, x ∈ [0, ∞), the function,
f (x) = x/(x + 1) = (1 + x−1 )−1 ,

(2.7)

can be used to map the OR to a probability in [0, 1]. An odds ratio with the null value of 1, indicating
equivalent odds of success between the treatment groups, is thus mapped to a probability of 1/2
resulting in balanced allocation (w` = 0.5). Using equation (2.7) to map the odds ratio in equation
(2.6), this allocation rule assigns the next patient recruited to the study to treatment group A with
probability
0

wi+1,A (Fi ) = E(Ti+1 |Fi ) = {1 + exp {−(β̂ + zi+1 δ̂)}}−1
0

=

exp {β̂ + zi+1 δ̂}
0

1 + exp {β̂ + zi+1 δ̂}

,

(2.8)

assuming the model converged, and with probability wi+1 = 0.5 otherwise. Alternatively, the last
weight wi that converged could be used until a sequential model successfully converges. Likewise,
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the estimated probability of success in treatment group B is


0
wi+1,B (Fi ) = E(Ti+1 |Fi ) = {1 + exp {− −(β̂ + zi+1 δ̂) }}−1
0

=

exp {−(β̂ + zi+1 δ̂)}
0

1 + exp {−(β̂ + zi+1 δ̂)}

= 1 − wi+1,A .

(2.9)
(2.10)

Rosenberger et al. provide a proof to show the MLE estimates of β̂ and δ̂ are consistent and
asymptotically normal. For large treatment effects, the adaptive rule has similar power to equal
allocation with a small reduction in the number of treatment failures [20].

2.2

Methods

Treatment responses and effectiveness can vary considerably across sites in a multi-center clinical
trial. First, we use the traditional CARA design where we suggest using site as a fixed covariate
to account for inter-center variability in treatment responses. Next, we propose the Site-Adjusted
Response-Adaptive (SARA) approach as an extension of the CARA design, where site is included
as a random effect instead of a fixed effect. The success probabilities, conditional on site, are used
to update the assignment probabilities for allocating patients between treatment groups as subjects
are accrued.
By including a random effect in a GLM with a fixed treatment effect, the resulting GLMM is
classified as a random intercept model. The random site effect adjusts the overall intercept, which
becomes a random intercept, and allows for site-specific success probabilities to be calculated for
each treatment group. A random intercept model accounts for site-based response variability, where
treatment responses are allowed to differ across centers. A random treatment-by-site interaction
could also be included in the model to allow the fixed treatment effect to vary across centers. Both
the site and treatment-by-site terms are treated as random effects. A GLMM of this form is called
a random coefficients model and accounts for inter-center variability in treatment effectiveness [10].
Previously, Rosenberger and colleagues fit a GLM with a logit link and mapped the covariateadjusted odds ratio to a treatment assignment probability (treatment effect mappings approach)
[20]. Alternatively, a natural approach is to calculate the estimated success probabilities for each
12

treatment group from the model and use these predicted probabilities to update one of the allocation
equations (e.g. Optimal, Neyman) depending on the objective desired. The allocation weights from
Rosenberger’s approach are slightly inflated compared to using the optimal allocation equations,
which naturally map the linear predictor to success probabilities. Using the odds ratio approach
results in more adaptation, where more subjects are being allocated to the superior treatment
group, but at an unknown cost. By increasing the number of treatment successes, more imbalance
between treatment groups could result in a trade-off in bias and power. While the effects on bias
and power could be severe, the magnitude is unclear. Because of these unknown ramifications, we
focused solely upon using success rates rather than odds ratios, as optimal allocation (Eq. 2.3)
was specifically designed to minimize treatment failures without increasing variability (e.g. optimal
allocation).
Due to the potential for inter-site variability in treatment responses, two separate models were
fit, one with a fixed site effect and another with a random site effect included in the linear predictor,
to get site-specific assignments.

2.2.1

CARA Model

First, a GLM is fit with both fixed site and treatment-by-site interaction effects, the traditional
CARA design where center is being treated as the covariate of interest. The model is specified as:
0

0

0

logit(pij ) = β0 + β1 Ti + Zi γ + Ti Zi δ + Xi θ,

(2.11)

where β0 is the overall intercept, β1 is the fixed treatment effect and Ti is the treatment group
indicator (Ti = 1 if A, Ti = 0 if B) for patients i = 1, . . . , n. Here, γ represents a (k − 1) × 1
vector of fixed site effects and δ is a (k − 1) × 1 vector of treatment-by-site interaction effects for
0

the j th site, j = 1, . . . , k − 1. In addition, Zi is a 1 × (k − 1) vector of site indicator variables for
0

the j th site, where k is the total number of sites. The Xi θ term is an optional set of individual
covariates that can be incorporated into the model to adjust the estimated success probabilities,
with corresponding slopes/effect sizes denoted by θ.
The conditional probability of success was calculated for each subject to be randomized to a
treatment group at a particular site by plugging the exponential of the linear predictor into the
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inverse-logit (Eq. 2.7). The estimated success probabilities p̂tij for the tth treatment group, t = 1, 2,
were defined as follows:
0

p̂1ij = logit−1 {β̂0 + β̂1 + γ̂j + δ̂j + Xi θ̂}
0

=

exp {β̂0 + β̂1 + γ̂j + δ̂j + Xi θ̂}
0

1 + exp {β̂0 + β̂1 + γ̂j + δ̂j + Xi θ̂}

,
(2.12)

0

p̂2ij = logit−1 {β̂0 + γ̂j + Xi θ̂}
0

=

exp {β̂0 + γ̂j + Xi θ̂}
0

1 + exp {β̂0 + γ̂j + Xi θ̂}

.

These predicted probabilities of success (Eq. 2.12) were plugged into one of the allocation equations
(Eqs. 2.3 + 2.4) to update the allocation probabilities for the next subject by using information
about their treatment center.

2.2.2

SARA Model 1

Next, the CARA design was extended by incorporating random site and treatment-by-site
interaction effects into the model.
0

logit(pijt ) = β0 + β1 Ti + gj + djt + Xi θ

(2.13)

Here, the fixed site effect in equation (2.11) is replaced with gj , a random site effect for the j th
site, where gj ∼ N (0, σg2 ) ∀j, j = 1, . . . , k and k is the number of sites. The fixed treatment-by-site
interaction is replaced with djt , a random interaction effect corresponding to the tth treatment,
where djt ∼ N (0, σd2 ) ∀j, t = 1, 2. In this model, the site for the next patient was used to calculate
the estimated success probabilities p̂tij as follows:
p̂1ij

0
exp {β̂0 + β̂1 + ĝj + dˆj + Xi θ̂}
=
,
0
1 + exp {β̂0 + β̂1 + ĝj + dˆj + X θ̂}

i

0

p̂2ij

=

exp {β̂0 + ĝj + Xi θ̂}
0

1 + exp {β̂0 + ĝj + Xi θ̂}

(2.14)

.

The allocation ratio is dependent on the previous subjects accrued, however, the current subject
is then randomized using these updated allocation probabilities so independence holds. If there is
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no true inter-site variability in the data, SARA Model 1 (Eq. 2.13) with no additional (optional)
covariates should decompose to the RA design (Eq. 2.1) as ĝj ' 0 and dˆjt ' 0, ∀j, t, where
adaptation is guided only by the treatment assignments and outcomes.
A treatment-by-center interaction was not included in the simulations due to (i) our initial
focus on heterogeneity in patient responses and not treatment effectiveness, and also (ii) issues in
estimating many parameters introduced by the additional variance components to estimate using
a Frequentist approach. The latter can occur early on in the study when sample sizes within the
centers are small or when all of the outcomes at a center are all successes or failures. ML estimates
of the parameters may be severely biased for highly sparse data [14]. We focus on simulations with
both random site and treatment-by-site interactions in Chapter 3.

2.3

Simulation Study

First, we need to show that existing randomization methods will be adversely affected when
site is not accounted for, particularly when inter-center variability exists. A small simulation
study will be performed to examine the performance of balanced allocation and response-adaptive
randomization in terms of the empirical power. We will consider trials with a small number of
centers (k = 3), a small treatment group 1 success probability (p1 = 0.3), a small effect size
(δ = 0.1) and several inter-site standard deviations (σ = 0, 0.025, 0.05, 0.075). When there is no
inter-center variability (σ = 0), meaning that there are no differences in treatment responses and/or
effects across centers, the site-specific treatment success probabilities are equal to the true success
probabilities (p1 = 0.3, p2 = 0.2). However, as we increase the amount of inter-center variability,
the distributions of the success probabilities and the corresponding effect size (p1 −p2 ) all spread out
considerably around the true success probabilities (Figure 2.1). To ensure the success probabilities
used in the simulations are contained in (0, 1), a function was used to bound the values between
(0.01, 0.99).
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Figure 2.1: Simulated Success Probabilities for Center 1
Scenario: N = 1000, p1 = 0.3, p2 = 0.2, σ = 0.025, 0.05, 0.1.
Next, we will examine the performance of our proposed CARA and SARA models to existing
allocation designs. The simulations were modeled as Phase 2 multi-center trials with a relatively
small number of centers (k = 3, 6, 9). A phase 2 trial can recruit several hundred patients to
examine efficacy and monitor side effects. The traditional sample size formula [6] for balanced two
independent samples is as follows:

2N =

2 × {Zα

p
p
2 × p̄(1 − p̄) + Zβ p2 (1 − p2 ) + p1 (1 − p1 )}2
,
(p2 − p1 )2

(2.15)

where 2N is the total sample size, p̄ = (p1 + p2 )/2, Zα is the critical value for the significance level
α, Zβ is the critical value for the power (1 − β) and p` is defined as the proportion of successes in
treatment group ` out of the total number of patients in that group, ` = 1, 2. The second square
root term represents the inherent variability. The total sample size (2N ) was rounded up to the
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nearest whole number to assure enough patients were recruited to achieve the desired power.
Alternatively, the sample size for a dichotomous outcome can be determined for each trial
by adding variability to account for clustering. Previous research has been conducted to power
multi-center trials where the center sample size or number of centers is fixed in advance [2]. This
approach ensures that balanced randomization achieves a nominal power level (e.g. 80%). However,
we decided not to account for the inter-site variability so that we could see the power loss when
site is not accounted for in the randomization, including in the balanced case.
Both the effect sizes and values of inter-site variability used in the simulation scenarios were
determined based on the results of a brief simulation study to ensure the presence of a slight
quantitative treatment-by-site interaction as defined by Gallo (2008). The number of sites (k =
3, 6, 9) and inter-site standard deviations in treatment response were varied with a 30% treatment
group 1 success probability (p1 = 0.3) and several effect sizes (δ = p1 − p2 = 0, 0.1, 0.15).
The percentages of flipped success probabilities, defined as P(at least one p̂1 < p̂2 )×100, were
averaged across 1000 iterations to indicate how frequent qualitative interactions occurred. The
results of the simulation are displayed in Table 2.1. As expected, the results show that as the effect
size increases, there are less qualitative treatment-by-site interactions. However, as the inter-site
standard deviation increases, the number of qualitative interactions increases regardless of effect
size. Accordingly, we select smaller values of inter-site SD to limit the amount of qualitative
interactions to study the operating characteristics of the proposed methods.
Table 2.1: Percentage (%) of Qualitative Treatment-by-Site Interactions

k
3

p1
0.3

Inter-Site Standard Deviation
0.025 0.0375 0.05 0.075
89.5
89.5
89.5
89.5
0.6
8.1
21.1
43.9
0
0.6
4.4
21.1

(σ)
0.1
89.5
56.0
36.9

δ
0
0.1
0.15

0
0
0
0

6

0
0.1
0.15

0
0
0

98.5
0.9
0

98.5
16.7
0.9

98.5
39.3
9.5

98.5
68.2
39.3

98.5
80.1
58.6

9

0
0.1
0.15

0
0
0

99.9
1.9
0

99.9
24.0
1.9

99.9
50.9
14.4

99.9
80.2
50.9

99.9
89.5
74.1

We considered small (p1 = 0.3), medium (p1 = 0.5) and large (p1 = 0.7) treatment group
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1 success probabilities. Null (δ = 0), small (δ = 0.1) and medium (δ = 0.15) effect sizes were
considered, where δ = p1 − p2 , to allow us to determine p2 = p1 − δ. Null effect sizes were
powered with δ = 0.1 to allow a reasonable sample size to be recruited. The variability in success
probabilities across centers was controlled by adjusting the amount of inter-site standard deviation
(σ = 0, 0.025, 0.05, 0.075), which controls the magnitude and direction of treatment-by-site
interactions.
The site-specific success probabilities p̂`j were simulated from a normal distribution with a
mean equal to the treatment group ` success probability p` and variance representing the intersite variability σ 2 , where ` = 1, 2 and j = 1, . . . , k sites. A function was implemented to ensure
success probabilities were bound between 0 and 1. A random variate v was generated from a
uniform(0, 1) distribution, denoted by U (0, 1), for each subject and assigned to site k if

z−1
k

<v≤

z
k

∀z = 1, . . . , k. All patient sites were calculated prior to adaptation to ensure that the estimated
success probabilities for the next patient could be calculated using their recruitment site. Next, as
each patient was recruited in the simulation, another U (0, 1) variate was drawn and compared to
the previous treatment group 1 allocation weight to determine the assignment and outcome of the
current patient being recruited. If the value was less than or equal to the previous weight (Eqns.2.3
and 2.4), the patient was assigned to treatment group 1, otherwise they were recruited to the
second treatment group. The patient outcomes were then assigned from a Bernoulli distribution
with success probability p̂`j which depends on the j th site they are being recruited from.
An artificial lead-in was used in the simulations to prevent estimator instability or convergence
issues. This hard lead-in required that balanced allocation be performed for the first m = 20
subjects irrespective of the design. Additionally, for the CARA and SARA models, both outcomes
must be observed in each group prior to adapting to ensure the GLMM can be fit using the glmer
{lme4} function [30] in R, otherwise the function produces a constant response error. This is not
a requirement for the RA/CARA models using the glm {stats} function [31], however, separation
issues may arise so this lead-in criterion was implemented. For both CARA/SARA, an additional
criterion required that all centers be observed to ensure that allocation weights could be calculated
using the next patient’s site. Alternatively, we could have used balanced allocation for patients
recruited from unobserved sites to potentially adapt sooner. Due to the artificial lead-in, results
may slightly under represent the adaptation effect of the allocation design, particularly with the
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CARA/SARA designs which have additional criteria to be satisfied prior to adapting.
The GLM was fit in the glm function which obtains the ML estimates through iteratively
reweighted least squares (IRLS) method. The GLMM model was fit in the glmer function with
ML estimation using the adaptive Gauss-Hermite quadrature approximation (quadrature nodes
= 10) of the likelihood for the mixed model, which is an integral over the random effect space.
The variance-covariance matrices of the random effects were estimated using Powell’s BOBYQA
method, a nonlinaer optimizer [30]. A variance component was modeled for the random site effect.
If convergence warnings arose when fitting the SARA models iteratively for each trial, the
previous allocation weights were used until the model successfully converged again [20]. This
allows previous information about the trial to be used to update the allocation weights. Instead,
an alternative approach we could have implemented is to use balanced allocation (w1 = 0.5) until the
model converges again, however, this ignores any previous patient data. The try {base} function
[31] may be used to suppress any errors from terminating loops, such as non positive-definite
variance/covariance matrices or for those that contain null values, when using the linux cluster. All
simulations were coded using R [31] statistical software.
In our experience, fitting these iterative models for each parameter template (trial scenario)
required significant computation time. Accordingly, R scripts were submitted on the departmental
Beowulf Cluster using the most recent update of R available. To facilitate faster computation times,
the trial scenarios were split up to be run on the cluster simultaneously and the results compiled.
To evaluate the proposed allocation designs, we use the conceptual framework established by
Rosenberger et al. (2008). When comparing methods, the authors interpreted the operating characteristics in terms of balance (allocation proportion), efficiency (power, type I error) and ethics
(total number of treatment successes) [19]. We are particularly interested in the mean total number
of successes/failures (± standard error), empirical power (P {reject H0 |H1 true}) and type I error
rate (P {reject H0 |H0 true}). The type I error rate and empirical power were plotted to summarize
patterns in the operating characteristics across sites among the methods. These figures were calculated using the naive BC/RA estimates, which do not account for site, while the CARA/SARA
approaches use estimates from the GLMMs, which incorporate site effects, to assess whether they
perform as intended. We compared the results of the balanced case, RA (Eq. 2.1), CARA (Eq.
2.11) and SARA 1 (Eq. 2.13) designs for all scenarios considered. The balanced and RA designs do
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not account for site variability while both the CARA and SARA designs account for the clustering differently, through either a fixed or random site effect, respectively. We hypothesize that the
CARA and SARA methods, which account for inter-center variability, will reduce the variability
of treatment responses in multi-center trials, thus reducing biased or improper patient allocation.
There were 1000 trials simulated for each scenario and the results aggregated. Both Optimal
and Neyman allocation were considered. For a single trial scenario, the following metrics were
stored: sample size, number of patients assigned to each treatment, number of successes for each
treatment, total number of successes and the number of convergence issues (indicates previous
allocation weights were used until model converged). The allocation proportion calculated at the
 h
i
1
and examined to compare
end of each trial was averaged across the simulated trials E n1n+n
2
both the amount and variability of adaptation, where ni is the number of patients allocated to
treatment group `, ` = 1, 2.
After all patients were recruited, a two-sided chi-squared test for the treatment effect was
performed. For the BC/RA designs, a naive Wald’s chi-square test from the GLM was used to
test the treatment effect (H0 : β̂1 = 0). This approach ignores site when testing the treatment
effect as this is convention when analyzing multi-center trials. For the CARA/SARA designs, in
addition to a naive chi-squared test, a chi-squared test from a GLM or GLMM, which incorporates
fixed or random site effects, respectively, was used. Specifically, for the naive approach used in the
CARA/SARA methods, the proportions of successes were compared using a Pearson’s chi-squared
(H0 : p1 = p2 ) test to assess the treatment effect. There was no need to worry about violating
assumptions due to low expected cell counts for the CARA/SARA approaches. However, RA
randomization may result in severely skewed treatment groups and not satisfy the assumptions for
a chi-squared test. An indication of whether or not the null hypothesis (H0 : no treatment effect)
was rejected was retained in order to calculate the operating characteristics of the method. These
metrics were averaged over all iterations.

2.3.1

Simulation Algorithm

The basic algorithm for our simulation study is as follows.

20

1. Hard lead-in for the first m patients, where individuals are allocated equally between the two
treatment groups.
2. Let Fi be accrued information which includes treatment assignments, observed patients outcomes and center information. Use Fi for patients i = 1, . . . , m, m + 1, . . . , n to begin adaptation, starting with patient m + 1.
3. Using the center for patient m + 1, calculate the conditional probability of success p̂tij for the
tth treatment using the CARA (Eqns. 2.11, 2.12) or SARA model (Eqns. 2.13, 2.14).
4. Using the estimated success probabilities p̂1i , p̂2i , update the allocation weights W1 , W2 and
assign the next patient to a treatment.

W1 (Fi ) =

q q
p̂1i / p̂1i + p̂2i , W2 (Fi ) = 1 − W1 .

5. Repeat Steps 2-4 to randomize patients m + 2, . . . , n.
For a single scenario, this algorithm is repeated for N = 1000 trials.

2.4

Results

The results of our simulation study of existing methods shows that the allocation probabilities
and treatment effectiveness for the balanced case and RA design are adversely affected when multiple sites are not accounted for during randomization, particularly when inter-site variability exists.
This is demonstrated by the simulations presented in Figure 2.2. When there is no variability
across centers, the two approaches perform similarly and achieve close to nominal levels of power.
Balanced allocation results in slightly more power due to equal sample sizes in the two treatment
groups. However, as the inter-site variability increases, the empirical power decreases when we
do not adjusts for this clustering. Thus, adaptive methods should be flexible enough to address
potential variability across centers.
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Figure 2.2: Not Accounting for Clustering

Next, we explore the the mean total number of treatment successes (SE), the expected allocation
proportions to treatment group 1 (SE) and the empirical type I error and power for SARA 1 (Eqn.
2.13) compared to three existing allocation designs.

2.4.1

Scenario 1: Optimal Allocation, 3 Sites, p1 = 0.3

The mean total number of treatment successes for Scenario 1 are displayed in Table 2.2. When
the effect size is null (δ = p1 − p2 = 0), the four methods are comparable. There is a slight increase
in the total number of successes for the adaptive designs as the amount of inter-site standard
deviation (σ) increases, since the success probabilities are simulated from a right skewed binomial
distribution (more mass above 0.3 since left truncated at 0) and are more likely to vary greater in
one direction (e.g. values greater than P1 , P2 ).
When the effect size is increased to 10% (p1 = 0.3, p2 = 0.2), the adaptive designs result in more
treatment successes than the balanced case, however, the improvement is lower for SARA compared
to the RA/CARA designs. SARA has lower variability than the other adaptive approaches and it
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is similar to the variability from the balanced case. For an effect size of 15%, the pattern is similar
to the medium effect size. The adaptive designs result in more treatment successes than the BC
and there are fewer treatment successes for SARA compared to the other adaptive approaches.
SARA maintains variability similar to the balanced case, both of which have less variability than
the RA/CARA designs. In addition, as σ increases, the variability in the expected total number of
treatment successes increases for all methods.
Table 2.2: Scenario 1 - Mean Total Number of Treatment Successes (Standard Error)

1

k

p1

δ

σ

BC

RA

CARA

SARA 1

3

0.3

0

0

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

(n=587)

0.025

175.7 (12.6)

175.8 (12.7)

175.8 (12.6)

175.8 (12.6)

0.05

175.5 (16.3)

176.1 (16.6)

176.0 (16.4)

176.0 (16.3)

0.075

175.3 (21.0)

176.7 (21.5)

176.5 (21.4)

176.3 (21.1)

0.1

0

146.6 (10.6)

151.1 (14.3)

150.7 (12.5)

149.5 (10.7)

(n=587)

0.025

146.2 (12.3)

150.5 (15.7)

150.3 (13.6)

149.2 (12.3)

0.05

146.0 (16.1)

151.0 (19.6)

150.7 (17.3)

149.5 (16.3)

0.075

145.9 (20.8)

152.5 (24.0)

151.8 (22.0)

150.0 (20.8)

0.15

0

54.2 (6.7)

59.1 (9.1)

58.4 (7.8)

57.2 (6.8)

(n=241)

0.025

54.3 (6.8)

59.1 (9.6)

58.5 (8.5)

57.4 (7.1)

0.05

54.4 (7.9)

59.6 (10.4)

58.9 (9.4)

57.7 (8.1)

0.075

54.7 (9.5)

60.1 (11.9)

59.5 (10.7)

58.2 (9.6)

Trial Scenario: 3 Sites, p1 = 0.3, Optimal Allocation

The allocation proportions are displayed in Table 2.3. For a null effect size, the four methods
have comparable allocation proportions. The SARA design has lower variability in allocating than
the other adaptive designs, while the RA design has the highest variability. When δ = 0.10, the
adaptive designs have a larger allocation ratio relative to the balanced case, though the improvement
is lower for SARA compared to the other adaptive approaches. This explains the increase in
expected treatment successes in the adaptive methods with a slightly lower increase in the SARA
approach. SARA is less variable than the RA/CARA designs in all cases. For δ = 0.15, the
23

adaptive designs have larger allocation ratios than the BC, particularly RA randomization, but the
improvement is lower for CARA and SARA. SARA has lower variability compared to the other
adaptive designs. Overall, the amount of inter-site standard deviation does not affect the allocation
proportions or the variability in allocation proportions.
Table 2.3: Scenario 1 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

3

0.3

0

0

0.50 (0.02)

0.50 (0.13)

0.50 (0.09)

0.50 (0.03)

(n = 587)

0.025

0.50 (0.02)

0.49 (0.12)

0.50 (0.08)

0.50 (0.03)

0.05

0.50 (0.02)

0.49 (0.13)

0.50 (0.09)

0.50 (0.04)

0.075

0.50 (0.02)

0.49 (0.13)

0.50 (0.08)

0.50 (0.04)

0.1

0

0.50 (0.02)

0.58 (0.17)

0.57 (0.12)

0.55 (0.03)

(n = 587)

0.025

0.50 (0.02)

0.57 (0.17)

0.57 (0.11)

0.55 (0.04)

0.05

0.50 (0.02)

0.57 (0.18)

0.57 (0.12)

0.55 (0.05)

0.075

0.50 (0.02)

0.58 (0.18)

0.57 (0.12)

0.55 (0.05)

0.15

0

0.50 (0.03)

0.63 (0.19)

0.62 (0.13)

0.58 (0.05)

(n = 241)

0.025

0.50 (0.03)

0.63 (0.18)

0.61 (0.13)

0.58 (0.05)

0.05

0.50 (0.03)

0.63 (0.19)

0.61 (0.14)

0.58 (0.06)

0.075

0.50 (0.03)

0.63 (0.20)

0.61 (0.13)

0.58 (0.07)

1

SARA 1

Trial Scenario: 3 Sites, p1 = 0.3, Optimal Allocation

The empirical type I error and power results are displayed in Table 2.4 and Figure 2.3. For
δ = 0, all four methods perform similarly where there is an inflation in the type I error rate as σ
increases. RA randomization appears to control the type I error rate slightly better than the other
designs particularly when there is more inter-site variability. The pattern is similar for small and
medium effect sizes, where the power decreases with increasing σ. Specifically, for δ = 0.10, the
CARA design is similar to balanced randomization and gains back some of the power lost with RA
randomization. The SARA design outperforms the balanced case for smaller σ and is comparable
when σ = 0.075. For δ = 0.15, the SARA design is similar to balanced randomization and thus
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gains back some of the power lost with the other adaptive methods. There is a notable loss of
power for RA randomization relative to the other methods.
We now discuss the results from the GLM/GLMM approach, where either a fixed (CARA) or
random (SARA) site effect is incorporated into the modeling to account for clustering. For a null
effect size, the type I error results are comparable to the naive approach. When δ = 0.10, the
SARA design performs similarly, where there is a slight improvement over balanced randomization,
but the CARA has more of a loss of power relative to the BC. For δ = 0.15, the CARA design has
an even more notable loss of power relative to the BC/SARA approaches using the GLM/GLMM
results.
Table 2.4: Scenario 1 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

CARA

SARA 1

3

0.3

0

0

0.06

0.06

0.07

0.06

0.06

0.06

(n = 587)

0.025

0.09

0.08

0.09

0.09

0.08

0.09

0.05

0.20

0.19

0.21

0.20

0.20

0.20

0.075

0.31

0.29

0.32

0.32

0.30

0.31

0.1

0

0.78

0.68

0.76

0.79

0.73

0.79

(n = 587)

0.025

0.73

0.64

0.72

0.75

0.69

0.74

0.05

0.68

0.57

0.67

0.68

0.63

0.68

0.075

0.64

0.53

0.62

0.63

0.58

0.63

0.15

0

0.80

0.61

0.78

0.81

0.70

0.80

(n = 241)

0.025

0.76

0.58

0.73

0.76

0.67

0.75

0.05

0.73

0.54

0.69

0.72

0.63

0.72

0.075

0.67

0.50

0.66

0.69

0.59

0.68

1

Trial Scenario: 3 Sites, p1 = 0.3, Optimal Allocation
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Figure 2.3: Scenario 1 - Empirical Type I Error and Power
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2.4.2

Scenario 2: Optimal Allocation, 6 Sites, p1 = 0.3

The mean total number of treatment successes for Scenario 2 are displayed in Table 2.5. When
the effect size is null, the four methods are comparable with respect to the expected number
of treatment successes and variability. There is a slight increase in the expected successes as σ
increases for the adaptive approaches. When the effect size is increased to 10%, the adaptive
designs all produce greater expected treatment successes than the balanced case, however, the RA
design results in slightly more treatment successes than CARA/SARA. The CARA/SARA designs
have lower variability in treatment successes than RA randomization, with SARA having more
improvement than CARA with variabilities closer to the BC. For an effect size of 15%, while all
of the adaptive designs result in more treatment successes than the balanced case, the RA design
performs better than both the CARA/SARA approaches with respect to treatment successes. The
variability in treatment successes for the RA method is higher than that of the variability for
the other methods which perform similarly while the variability for SARA is closest to the BC.
Overall, as the inter-site standard deviation increases, the variability in the expected total number
of treatment successes increases for all of the designs.
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Table 2.5: Scenario 2 - Mean Total Number of Treatment Successes (Standard Error)

1

k

p1

δ

σ

BC

RA

CARA

SARA 1

6

0.3

0

0

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

(n=587)

0.025

176.3 (11.8)

176.3 (11.8)

176.3 (11.8)

176.3 (11.8)

0.05

176.3 (14.1)

176.6 (14.1)

176.5 (14.2)

176.5 (14.1)

0.075

176.1 (17.2)

176.7 (17.3)

176.6 (17.2)

176.6 (17.2)

0.1

0

146.6 (10.6)

151.1 (14.3)

149.8 (10.9)

149.5 (10.7)

(n=587)

0.025

146.9 (11.3)

151.2 (14.8)

150.0 (11.8)

149.8 (11.4)

0.05

146.9 (13.6)

151.6 (16.9)

150.4 (14.4)

150.0 (13.8)

0.075

146.9 (16.6)

151.6 (19.8)

150.6 (17.4)

150.2 (16.9)

0.15

0

54.2 (6.7)

59.1 (9.1)

57.5 (7.0)

57.2 (6.9)

(n=241)

0.025

54.2 (6.6)

59.1 (9.4)

57.4 (7.2)

57.1 (7.0)

0.05

54.1 (7.2)

59.1 (9.9)

57.4 (7.8)

57.1 (7.7)

0.075

54.4 (8.2)

59.5 (10.9)

57.8 (8.9)

57.4 (8.7)

Trial Scenario: 6 Sites, p1 = 0.3, Optimal Allocation

The allocation proportions are displayed in Table 2.6. For δ = 0, the four approaches have
comparable allocation proportions. The CARA/SARA designs have lower variability in allocation
proportions than the RA design, with SARA closer to balanced randomization. When δ = 0.10,
the adaptive designs have larger allocation ratios relative to the BC, with the improvement lower
for the CARA/SARA designs than that of RA randomization. While the CARA/SARA designs
are less variable than the RA design, SARA maintains the lowest variability, which is closer to
the BC. For an effect size of 15%, while all of the adaptive designs have larger allocation ratios
than the balanced case, the RA design performs better than both the CARA/SARA designs. The
CARA/SARA approaches here are less than half the variability of the RA design, however, the
SARA approach has more of an improvement with variability closer to balanced randomization.
The amount of inter-site standard deviation does not affect the allocation proportions, though there
is a slight increase in the variability of the allocation proportions.
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Table 2.6: Scenario 2 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

6

0.3

0

0

0.50 (0.02)

0.50 (0.13)

0.50 (0.06)

0.50 (0.04)

(n = 587)

0.025

0.50 (0.02)

0.49 (0.12)

0.50 (0.04)

0.50 (0.03)

0.05

0.50 (0.02)

0.49 (0.12)

0.50 (0.04)

0.50 (0.04)

0.075

0.50 (0.02)

0.49 (0.13)

0.50 (0.05)

0.50 (0.04)

0.1

0

0.50 (0.02)

0.58 (0.17)

0.55 (0.06)

0.55 (0.03)

(n = 587)

0.025

0.50 (0.02)

0.57 (0.16)

0.55 (0.05)

0.55 (0.04)

0.05

0.50 (0.02)

0.57 (0.17)

0.55 (0.06)

0.55 (0.04)

0.075

0.50 (0.02)

0.57 (0.17)

0.55 (0.06)

0.55 (0.05)

0.15

0

0.50 (0.03)

0.63 (0.19)

0.59 (0.07)

0.58 (0.06)

(n = 241)

0.025

0.50 (0.03)

0.63 (0.18)

0.59 (0.07)

0.58 (0.06)

0.05

0.50 (0.03)

0.63 (0.18)

0.59 (0.07)

0.58 (0.06)

0.075

0.50 (0.03)

0.63 (0.19)

0.59 (0.08)

0.58 (0.06)

1

SARA 1

Trial Scenario: 6 Sites, p1 = 0.3, Optimal Allocation

The empirical type I error and power results are displayed in Table 2.7 and Figure 2.4. For
δ = 0, the type I error rate increases as the amount of inter-site variability increases. For smaller σ,
the four methods perform similarly. However, as σ increases, RA randomization controls the type
I error rate slightly better than all of the other approaches which perform similarly. For δ = 0.10,
the RA design has a notable loss of power compared to the other methods. Before σ = 0.05, the
CARA/SARA designs have marginally higher power than the balanced case. For larger σ, the three
methods are comparable. As the amount of inter-site variability increases, the power decreases for
all methods though it is maintained better by BC/SARA/CARA. For δ = 0.15, the CARA/SARA
methods gain back most of the power lost with the RA design, but the improvement is slightly
lower for CARA for σ = 0.075. Overall, as σ increases, there is a slight loss of power for all four
approaches.
For a null effect size under the GLM/GLMM approach, the CARA design has the highest
inflation in type I error while RA randomization has the lowest, particularly as σ increases. The
29

SARA design performs similarly to the balanced case. For δ = 0.10, the CARA/SARA designs
have marginally higher power than the balanced case, with a slight improvement for the SARA
design, before σ = 0.05. For larger σ, the methods are comparable to the naive approach, where
the CARA/SARA designs have marginally higher power than the BC before σ = 0.05 but all
perform similarly for larger σ. RA randomization has a notable loss of power compared to the
other methods. For δ = 0.15, the CARA/SARA methods gain back most of the power lost with the
RA design, though they perform similarly to balanced allocation, but the improvement is slightly
lower for CARA.
Table 2.7: Scenario 2 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

CARA

SARA 1

6

0.3

0

0

0.06

0.06

0.06

0.06

0.06

0.06

(n = 587)

0.025

0.08

0.08

0.08

0.08

0.08

0.08

0.05

0.12

0.11

0.12

0.12

0.13

0.12

0.075

0.18

0.17

0.18

0.18

0.19

0.18

0.1

0

0.78

0.68

0.78

0.79

0.78

0.78

(n = 587)

0.025

0.76

0.68

0.78

0.78

0.77

0.78

0.05

0.73

0.64

0.73

0.72

0.72

0.72

0.075

0.69

0.61

0.69

0.69

0.69

0.68

0.15

0

0.80

0.61

0.81

0.80

0.79

0.80

(n = 241)

0.025

0.79

0.61

0.78

0.79

0.78

0.78

0.05

0.76

0.58

0.76

0.76

0.74

0.75

0.075

0.71

0.54

0.71

0.72

0.70

0.71

1

Trial Scenario: 6 Sites, p1 = 0.3, Optimal Allocation
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Figure 2.4: Scenario 2 - Empirical Type I Error and Power
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2.4.3

Scenario 3: Optimal Allocation, 3 Sites, p1 = 0.5

The mean total number of treatment successes for Scenario 3 are displayed in Table 2.8. When
the effect size is null, the four methods perform similarly with respect to both the expected total
number of treatment successes and the variability in successes. As the inter-site standard deviation
increases, there is a slight increase in treatment successes accompanied by a greater increase in
treatment success variability. When the effect size is increased to 10%, the adaptive methods
increase the expected treatment successes relative to the BC and they maintain the same variability.
For δ = 0.15, the pattern is similar to a small effect size, where the adaptive approaches result in
more treatment successes. SARA has a slightly smaller variability in expected successes similar to
the balanced case compared to the other adaptive designs. As σ increases, there is a slight increase in
expected treatment successes along with a greater increase in the variability in treatment successes.
Table 2.8: Scenario 3 - Mean Total Number of Treatment Successes (Standard Error)

1

k

p1

δ

σ

BC

RA

CARA

SARA 1

3

0.5

0

0

387.5 (13.9)

387.5 (13.9)

387.5 (13.9)

387.5 (13.9)

(n=775)

0.025

388.5 (15.9)

388.6 (15.9)

388.5 (15.9)

388.6 (15.9)

0.05

389.1 (20.9)

389.4 (20.9)

389.4 (20.9)

389.4 (20.9)

0.075

389.3 (27.1)

390.1 (27.0)

390.1 (27.0)

390.1 (27.0)

0.1

0

348.9 (14.1)

351.2 (14.1)

351.2 (14.1)

351.0 (14.0)

(n=775)

0.025

349.0 (15.8)

351.5 (16.0)

351.5 (16.0)

351.4 (15.9)

0.05

349.3 (21.1)

352.1 (21.2)

352.2 (21.2)

352.0 (21.1)

0.075

350.0 (27.5)

353.4 (27.8)

353.4 (27.6)

353.2 (27.5)

0.15

0

143.9 (9.1)

146.3 (9.4)

146.3 (9.2)

146.1 (9.1)

(n=339)

0.025

143.7 (9.8)

146.1 (10.2)

146.1 (10.0)

145.8 (9.8)

0.05

143.8 (11.6)

146.4 (11.9)

146.4 (11.7)

146.1 (11.5)

0.075

143.7 (13.9)

146.6 (14.3)

146.5 (14.1)

146.3 (13.9)

Trial Scenario: 3 Sites, p1 = 0.5, Optimal Allocation

The allocation proportions are displayed in Table 2.9. For δ = 0, the four approaches have
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comparable allocation proportions. The SARA design has lower variability similar to the BC
compared to the RA/CARA designs. As the amount of inter-site variability increases, the allocation
proportions remain constant but there is a marginal increase in variability in allocation. When
δ = 0.10, the adaptive designs have a larger allocation ratio relative to the BC. SARA is less
variable than the RA/CARA designs with variabilities comparable to the balanced case. For an
effect size of 15%, the adaptive methods have higher allocation ratios, however, the improvement is
lower for SARA compared to the RA/CARA designs. SARA has lower variability compared to the
other adaptive designs but has marginally higher variability than the BC. The amount of inter-site
standard deviation does not affect the allocation proportions and only has the slightest of effects
in the variability in allocation for medium effect sizes.
Table 2.9: Scenario 3 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

3

0.5

0

0

0.50 (0.02)

0.50 (0.03)

0.50 (0.03)

0.50 (0.02)

(n = 775)

0.025

0.50 (0.02)

0.50 (0.04)

0.50 (0.04)

0.50 (0.02)

0.05

0.50 (0.02)

0.50 (0.04)

0.50 (0.04)

0.50 (0.02)

0.075

0.50 (0.02)

0.50 (0.04)

0.50 (0.04)

0.50 (0.03)

0.1

0

0.50 (0.02)

0.53 (0.04)

0.53 (0.04)

0.53 (0.02)

(n = 775)

0.025

0.50 (0.02)

0.53 (0.04)

0.53 (0.04)

0.53 (0.02)

0.05

0.50 (0.02)

0.53 (0.05)

0.53 (0.04)

0.53 (0.03)

0.075

0.50 (0.02)

0.53 (0.05)

0.53 (0.04)

0.53 (0.03)

0.15

0

0.50 (0.03)

0.55 (0.07)

0.55 (0.06)

0.54 (0.04)

(n = 339)

0.025

0.50 (0.03)

0.55 (0.08)

0.55 (0.06)

0.54 (0.04)

0.05

0.50 (0.03)

0.55 (0.08)

0.55 (0.06)

0.54 (0.04)

0.075

0.50 (0.03)

0.55 (0.08)

0.55 (0.06)

0.54 (0.04)

1

SARA 1

Trial Scenario: 3 Sites, p1 = 0.5, Optimal Allocation

The empirical type I error and power results are displayed in Table 2.10 and Figure 2.5. For
δ = 0, the four approaches perform similarly where the type I error rate increases as the amount
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of inter-site variability increases. For small and medium effect sizes, there is a loss of power for all
four methods as σ increases. For δ = 0.10, RA randomization has slightly lower power than the
other designs for smaller σ and this pattern is more pronounced when δ = 0.15. For σ = 0.075,
SARA begins to have marginally more power than the other methods. For an effect size of 15%,
the BC/CARA/SARA designs perform comparably, whereas the RA design has a notable loss of
power relative to the other designs.
For a null effect size, the type I error results from the GLM/GLMM are comparable to the
naive approach. For δ = 0.10, RA randomization has slightly lower power than the other designs
for smaller σ as before, however, SARA outperforms the other methods for larger σ. For an effect
size of 15%, the BC/SARA designs have higher power compared to the RA/CARA approaches.
As σ increases, SARA maintains slightly more power than the balanced case along with the other
methods, whereas the RA design has the greatest loss of power.
Table 2.10: Scenario 3 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

CARA

SARA 1

3

0.5

0

0

0.06

0.05

0.06

0.05

0.06

0.05

(n = 775)

0.025

0.09

0.09

0.09

0.09

0.08

0.09

0.05

0.20

0.20

0.21

0.20

0.20

0.20

0.075

0.33

0.34

0.34

0.34

0.34

0.34

0.1

0

0.78

0.78

0.79

0.79

0.78

0.79

(n = 775)

0.025

0.77

0.76

0.77

0.77

0.77

0.77

0.05

0.72

0.71

0.72

0.71

0.71

0.72

0.075

0.66

0.66

0.66

0.67

0.66

0.67

0.15

0

0.80

0.78

0.80

0.80

0.79

0.80

(n = 339)

0.025

0.76

0.74

0.77

0.77

0.75

0.76

0.05

0.74

0.72

0.74

0.75

0.73

0.75

0.075

0.71

0.69

0.71

0.71

0.70

0.71

1

Trial Scenario: 3 Sites, p1 = 0.5, Optimal Allocation
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Figure 2.5: Scenario 3 - Empirical Type I Error and Power

2.4.4

Scenario 4: Neyman Allocation, 3 Sites, p1 = 0.3

The mean total number of treatment successes for Scenario 4 are displayed in Table 2.11. When
the effect size is null, the four approaches are comparable, with a slight increase in the average
total number of treatment successes for the adaptive designs as the amount of inter-site standard
deviation increases. There is a slight increase in variability for RA/CARA over the BC but not for
SARA. For δ = 0.10, the adaptive designs have more expected successes than the balanced case,
however, the improvement is lower for SARA compared to the RA/CARA designs. SARA has
slightly less variability than the balanced case while RA randomization is the most variable. For
an effect size of 15%, the adaptive methods result in more treatment successes than the BC but the
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improvement is slightly lower for CARA and even less for SARA. The BC/SARA approaches have
similarly low variability while the other designs have higher variability, particularly the RA design.
Overall, as σ increases, the variability in expected treatment successes increases for all methods.
Table 2.11: Scenario 4 - Mean Total Number of Treatment Successes (Standard Error)

1

k

p1

δ

σ

BC

RA

CARA

SARA 1

3

0.3

0

0

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

(n=587)

0.025

175.7 (12.6)

175.8 (12.7)

175.8 (12.7)

175.7 (12.6)

0.05

175.5 (16.3)

176.0 (16.6)

175.8 (16.5)

175.8 (16.2)

0.075

175.3 (21.0)

176.3 (21.4)

176.1 (21.5)

175.9 (20.9)

0.1

0

146.6 (10.6)

150.3 (14.3)

149.8 (12.5)

148.6 (10.6)

(n=587)

0.025

146.2 (12.3)

149.7 (15.6)

149.5 (13.7)

148.2 (12.2)

0.05

146.0 (16.1)

150.1 (19.4)

149.8 (17.3)

148.4 (16.0)

0.075

145.9 (20.8)

151.5 (23.8)

150.8 (22.1)

148.8 (20.5)

0.15

0

54.2 (6.7)

58.5 (9.1)

57.8 (7.8)

56.4 (6.7)

(n=241)

0.025

54.3 (6.8)

58.5 (9.6)

57.9 (8.5)

56.6 (6.8)

0.05

54.4 (7.9)

59.0 (10.3)

58.3 (9.4)

56.9 (7.8)

0.075

54.7 (9.5)

59.5 (11.9)

58.9 (10.7)

57.3 (9.3)

Trial Scenario: 3 Sites, p1 = 0.3, Neyman Allocation

The allocation proportions are displayed in Table 2.12. For δ = 0, the four approaches have
comparable allocation proportions. SARA has low variability, comparable to the balanced case,
while the RA design has the largest variability. When δ = 0.10, the adaptive designs have larger
allocation ratios compared to the balanced case, however, the improvement is lower for SARA
compared to the RA/CARA designs. While SARA is less variable than the other adaptive designs,
similar to the balanced case, the RA method has the highest variability. When the effect size is
15%, the adaptive designs have even higher allocation ratios, especially RA randomization, but
the improvement is lower for the CARA and SARA designs. Although SARA adapts less than
the RA/CARA designs, it has the lowest variability similar to the balanced case while the RA
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design has the largest variability. The amount of inter-site standard deviation does not affect the
allocation proportions but slightly increases the variability in allocation.
Table 2.12: Scenario 4 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

3

0.3

0

0

0.50 (0.02)

0.51 (0.13)

0.50 (0.09)

0.50 (0.02)

(n = 587)

0.025

0.50 (0.02)

0.49 (0.12)

0.50 (0.08)

0.50 (0.03)

0.05

0.50 (0.02)

0.49 (0.13)

0.50 (0.09)

0.50 (0.03)

0.075

0.50 (0.02)

0.50 (0.13)

0.50 (0.08)

0.50 (0.03)

0.1

0

0.50 (0.02)

0.56 (0.17)

0.55 (0.12)

0.53 (0.03)

(n = 587)

0.025

0.50 (0.02)

0.56 (0.17)

0.55 (0.12)

0.53 (0.03)

0.05

0.50 (0.02)

0.56 (0.18)

0.56 (0.12)

0.54 (0.04)

0.075

0.50 (0.02)

0.57 (0.18)

0.56 (0.12)

0.54 (0.05)

0.15

0

0.50 (0.03)

0.62 (0.19)

0.60 (0.13)

0.56 (0.05)

(n = 241)

0.025

0.50 (0.03)

0.61 (0.18)

0.60 (0.14)

0.56 (0.05)

0.05

0.50 (0.03)

0.62 (0.19)

0.60 (0.14)

0.56 (0.05)

0.075

0.50 (0.03)

0.62 (0.20)

0.60 (0.14)

0.56 (0.06)

1

SARA 1

Trial Scenario: 3 Sites, p1 = 0.3, Neyman Allocation

The empirical type I error and power results are displayed in Table 2.13 and Figure 2.6. For a
null effect size, the four methods perform similarly where there is an inflation in type I error rate
as σ increases. RA randomization has marginal improvement in the type I error as σ increases
while SARA begins to show slight improvement at σ = 0.075. For both small and medium effect
sizes, the power decreases as σ increases. For δ = 0.10, the BC/SARA approaches have similar
power, with a slight advantage for SARA, while CARA has less improvement. RA randomization
maintains the lowest power. For δ = 0.15, the BC/CARA/SARA designs have higher power than
the RA method, but SARA slightly outperforms the balanced case. The CARA design has slightly
less power than the BC/SARA designs whereas RA randomization has a notable loss of power.
Using the results from the GLM/GLMM approach, both CARA/SARA show slight improve-
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ment in type I error rate at σ = 0.075 for a null effect size. For δ = 0.10, the SARA design gains
back even more power than the balanced case but CARA has a notable loss of power compared to
the naive approach. For δ = 0.15, the SARA design maintains similar power to balanced randomization, however, SARA only slightly outperforms the balanced case for large σ. The CARA design
has a greater loss of power relative to the BC/SARA designs.
Table 2.13: Scenario 4 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

CARA

SARA 1

3

0.3

0

0

0.06

0.05

0.07

0.05

0.06

0.05

(n = 587)

0.025

0.09

0.09

0.10

0.09

0.08

0.09

0.05

0.20

0.18

0.20

0.20

0.20

0.21

0.075

0.31

0.28

0.31

0.31

0.30

0.31

0.1

0

0.78

0.69

0.76

0.79

0.73

0.79

(n = 587)

0.025

0.73

0.63

0.73

0.74

0.68

0.73

0.05

0.68

0.57

0.66

0.68

0.62

0.68

0.075

0.64

0.53

0.62

0.64

0.58

0.64

0.15

0

0.80

0.61

0.79

0.80

0.69

0.80

(n = 241)

0.025

0.76

0.60

0.74

0.78

0.66

0.76

0.05

0.73

0.56

0.70

0.73

0.62

0.73

0.075

0.67

0.50

0.66

0.68

0.59

0.68

1

Trial Scenario: 3 Sites, p1 = 0.3, Neyman Allocation

2.4.5

Scenario 5: Neyman Allocation, 6 Sites, p1 = 0.3

The mean total number of treatment successes for Scenario 4 are displayed in Table 2.14. When
the effect size is null, the four approaches are comparable with respect to the expected number of
treatment successes and variability in treatment successes. For an effect size of 10%, the adaptive
designs perform better than the balanced case with respect to expected treatment successes. The
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Figure 2.6: Scenario 4 - Empirical Type I Error and Power
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RA design has slightly more expected treatment successes than the CARA/SARA designs, which
perform similarly. The CARA/SARA designs have lower variability than RA randomization, with
SARA having a slight improvement towards the balanced case, while the RA method has the highest
variability. For δ = 0.15, the adaptive designs result in more treatment successes than the balanced
case, however, RA randomization has a greater improvement over the CARA/SARA designs, which
both perform similarly. The CARA/SARA designs are less variable than the RA method. Overall,
as the amount of inter-site standard deviation increases, the variability in the mean total number
of treatment successes increases for all methods. However, SARA maintains less variability than
the other methods and keeps the variance closest to the balanced case.
Table 2.14: Scenario 5 - Mean Total Number of Treatment Successes (Standard Error)

1

k

p1

δ

σ

BC

RA

CARA

SARA 1

6

0.3

0

0

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

(n=587)

0.025

176.3 (11.8)

176.3 (11.8)

176.3 (11.8)

176.3 (11.8)

0.05

176.3 (14.1)

176.5 (14.1)

176.4 (14.1)

176.4 (14.1)

0.075

176.1 (17.2)

176.6 (17.3)

176.3 (17.2)

176.4 (17.1)

0.1

0

146.6 (10.6)

150.3 (14.3)

149.0 (10.9)

148.6 (10.6)

(n=587)

0.025

146.9 (11.3)

150.4 (14.8)

149.2 (11.6)

148.9 (11.3)

0.05

146.9 (13.6)

150.7 (16.8)

149.5 (14.2)

149.0 (13.6)

0.075

146.9 (16.6)

150.7 (19.6)

149.6 (17.2)

149.1 (16.6)

0.15

0

54.2 (6.7)

58.5 (9.1)

56.8 (6.8)

56.4 (6.7)

(n=241)

0.025

54.2 (6.6)

58.5 (9.4)

56.7 (7.0)

56.3 (6.7)

0.05

54.1 (7.2)

58.5 (9.8)

56.7 (7.6)

56.3 (7.4)

0.075

54.4 (8.2)

58.9 (10.8)

57.1 (8.7)

56.6 (8.4)

Trial Scenario: 6 Sites, p1 = 0.3, Neyman Allocation

The allocation proportions are displayed in Table 2.15. For δ = 0, RA randomization has a
slightly higher allocation proportion when there is no inter-site standard deviation, however, as σ
increases, the four approaches have comparable allocation proportions. The CARA/SARA designs
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have variability similar to the balanced case, with better performance for SARA, while the RA
design has the highest variability. When δ = 0.10, the adaptive designs have larger allocation
ratios compared to the balanced case, however, the improvement is lower for SARA compared
to the RA/CARA designs. The SARA approach is less variable than the other adaptive designs
and has variance similar to the balanced case, while the RA design has the highest variability.
For δ = 0.15, RA randomization has a higher allocation ratio than the CARA/SARA methods.
Although SARA has a smaller allocation ratio compared to the other adaptive designs, it has similar
variability to balanced randomization while the RA design has the highest variability. As the effect
size increases, the allocation proportions increase for the adaptive designs while the variability in
allocation increases for all four methods. Additionally, the amount of inter-site variability does not
affect the allocation proportions or variability.
Table 2.15: Scenario 5 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

6

0.3

0

0

0.50 (0.02)

0.51 (0.13)

0.50 (0.06)

0.50 (0.03)

(n = 587)

0.025

0.50 (0.02)

0.49 (0.11)

0.50 (0.05)

0.50 (0.03)

0.05

0.50 (0.02)

0.50 (0.12)

0.50 (0.05)

0.50 (0.03)

0.075

0.50 (0.02)

0.49 (0.13)

0.50 (0.05)

0.50 (0.03)

0.1

0

0.50 (0.02)

0.56 (0.17)

0.54 (0.06)

0.53 (0.03)

(n = 587)

0.025

0.50 (0.02)

0.56 (0.16)

0.54 (0.06)

0.53 (0.03)

0.05

0.50 (0.02)

0.56 (0.17)

0.54 (0.06)

0.53 (0.04)

0.075

0.50 (0.02)

0.55 (0.16)

0.54 (0.06)

0.53 (0.04)

0.15

0

0.50 (0.03)

0.62 (0.19)

0.57 (0.07)

0.56 (0.05)

(n = 241)

0.025

0.50 (0.03)

0.62 (0.18)

0.57 (0.07)

0.56 (0.05)

0.05

0.50 (0.03)

0.62 (0.18)

0.57 (0.07)

0.56 (0.06)

0.075

0.50 (0.03)

0.62 (0.19)

0.57 (0.08)

0.56 (0.06)

1

SARA 1

Trial Scenario: 6 Sites, p1 = 0.3, Neyman Allocation

The empirical type I error and power results are displayed in Table 2.16 and Figure 2.7. For a null
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effect size, there is an inflation of the type I error rate as the amount of inter-site standard deviation
increases for all methods. When there is no inter-site variability, there is a slight improvement in
the type I error rate for the RA/SARA designs. As σ increases, RA randomization maintains the
lowest type I error rate. The BC/SARA designs perform similarly while the CARA approach has
the highest inflation in type I error rate. For small and medium effect sizes, the power decreases
as σ increases. When δ = 0.10, RA randomization has a notable loss of power compared to the
other approaches. For small σ, the CARA/SARA designs perform comparably while for larger
values of σ, the BC/SARA perform similarly. When δ = 0.15, the BC/CARA/SARA designs
perform comparably while there is a notable loss of power for the RA method relative to the other
designs. For larger σ, both the CARA/SARA designs outperform balanced randomization, with
slight improvement for the SARA approach.
For a null effect size, the type I error results from the GLM/GLMM are comparable to the
naive approach, where CARA maintains the highest inflation in type I error for increasing σ. When
δ = 0.10, the SARA design has a slight improvement in power compared to CARA. For δ = 0.15,
the BC/SARA approaches have comparable performance, with slightly less improvement for SARA
when σ is small and marginal improvement for larger σ. There is slightly less improvement for the
CARA design relative to the BC/SARA approaches.
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Table 2.16: Scenario 5 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

CARA

SARA 1

6

0.3

0

0

0.06

0.05

0.06

0.05

0.06

0.05

(n = 587)

0.025

0.08

0.08

0.08

0.08

0.08

0.08

0.05

0.12

0.12

0.13

0.13

0.14

0.13

0.075

0.18

0.17

0.19

0.18

0.18

0.18

0.1

0

0.78

0.69

0.78

0.79

0.78

0.79

(n = 587)

0.025

0.76

0.68

0.78

0.78

0.78

0.78

0.05

0.73

0.64

0.72

0.73

0.72

0.73

0.075

0.69

0.62

0.68

0.69

0.69

0.7

0.15

0

0.8

0.61

0.8

0.8

0.78

0.8

(n = 241)

0.025

0.79

0.6

0.78

0.79

0.77

0.78

0.05

0.76

0.6

0.76

0.77

0.75

0.76

0.075

0.71

0.54

0.72

0.72

0.71

0.72

1

Trial Scenario: 6 Sites, p1 = 0.3, Neyman Allocation

2.4.6

Scenario 6: Neyman Allocation, 3 Sites, p1 = 0.5

The mean total number of treatment successes for Scenario 4 are displayed in Table 2.17.
When the effect size is null, the four approaches perform similarly with respect to the expected
total number of treatment successes and the variability in treatment successes. When the effect size
is increased to 10%, the adaptive designs result in slightly more expected treatment successes than
the balanced case. While all approaches have similar variability, SARA has a slight improvement
over the others, including the balanced case. For δ = 0.15, the adaptive designs result in more
treatment successes than the balance case. SARA has the lowest variability while the RA design
has the highest variability. As σ increases, there is an increase in the variability in treatment
successes for all methods.
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Figure 2.7: Scenario 5 - Empirical Type I Error and Power
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Table 2.17: Scenario 6 - Mean Total Number of Treatment Successes (Standard Error)

1

k

p1

δ

σ

BC

RA

CARA

SARA 1

3

0.5

0

0

387.5 (13.9)

387.5 (13.9)

387.5 (13.9)

387.5 (13.9)

(n=775)

0.025

388.5 (15.9)

388.5 (15.8)

388.6 (15.8)

388.5 (15.9)

0.05

389.1 (20.9)

389.1 (20.8)

389.1 (20.9)

389.1 (20.8)

0.075

389.3 (27.1)

389.4 (27.0)

389.2 (27.3)

389.3 (26.9)

0.1

0

348.9 (14.1)

349.5 (14.1)

349.4 (14.1)

349.3 (13.9)

(n=775)

0.025

349.0 (15.8)

349.5 (15.9)

349.5 (16.1)

349.5 (15.7)

0.05

349.3 (21.1)

349.9 (21.0)

349.9 (21.4)

349.7 (20.9)

0.075

350.0 (27.5)

350.8 (27.4)

350.5 (27.7)

350.6 (27.1)

0.15

0

143.9 (9.1)

144.7 (9.2)

144.7 (9.1)

144.4 (8.9)

(n=339)

0.025

143.7 (9.8)

144.6 (10.1)

144.5 (10.0)

144.3 (9.5)

0.05

143.8 (11.6)

144.9 (11.8)

144.7 (11.6)

144.5 (11.3)

0.075

143.7 (13.9)

144.8 (14.1)

144.7 (13.9)

144.5 (13.5)

Trial Scenario: 3 Sites, p1 = 0.5, Neyman Allocation

The allocation proportions are displayed in Table 2.18. For δ = 0, the four methods have
comparable allocation proportions. The BC/SARA approaches have similarly lower variability in
allocation proportions while the RA/CARA designs have comparably higher variability. When
the effect size is increased to 10%, the adaptive designs have larger allocation ratios compared to
the balanced case. The BC/SARA approaches have similarly low variability while the RA/CARA
designs have comparably high variability. For δ = 0.15, the adaptive designs have larger allocation
ratios compared to the BC, however, the improvement is marginally lower for SARA compared to
the other designs. The BC/SARA approaches are comparable with respect to lower variability in
allocation proportions compared to the other designs, particularly RA randomization. The amount
of inter-site variability does not affect the allocation proportions or the variability in allocation.
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Table 2.18: Scenario 6 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

3

0.5

0

0

0.50 (0.02)

0.50 (0.04)

0.50 (0.04)

0.50 (0.02)

(n = 775)

0.025

0.50 (0.02)

0.50 (0.05)

0.50 (0.05)

0.50 (0.02)

0.05

0.50 (0.02)

0.50 (0.04)

0.50 (0.05)

0.50 (0.02)

0.075

0.50 (0.02)

0.50 (0.05)

0.50 (0.05)

0.50 (0.02)

0.1

0

0.50 (0.02)

0.51 (0.04)

0.51 (0.04)

0.51 (0.02)

(n = 775)

0.025

0.50 (0.02)

0.51 (0.05)

0.51 (0.06)

0.51 (0.02)

0.05

0.50 (0.02)

0.51 (0.05)

0.51 (0.06)

0.51 (0.02)

0.075

0.50 (0.02)

0.51 (0.05)

0.51 (0.05)

0.51 (0.02)

0.15

0

0.50 (0.03)

0.52 (0.07)

0.52 (0.06)

0.51 (0.03)

(n = 339)

0.025

0.50 (0.03)

0.52 (0.08)

0.52 (0.07)

0.51 (0.03)

0.05

0.50 (0.03)

0.52 (0.08)

0.52 (0.07)

0.51 (0.03)

0.075

0.50 (0.03)

0.52 (0.08)

0.52 (0.06)

0.51 (0.03)

1

SARA 1

Trial Scenario: 3 Sites, p1 = 0.5, Neyman Allocation

The empirical type I error and power results are displayed in Table 2.19 and Figure 2.8. For
a null effect size, the four methods perform similarly where the type I error rate increases as the
amount of inter-site standard deviation increases. As σ increases, CARA has a slight inflation
in the type I error rate compared to the other approaches. Overall, for small and medium effect
sizes, there is a loss of power for all methods as σ increases. Specifically, when the effect size is
increased to 10%, the BC/CARA/SARA designs maintain slightly higher power relative to the RA
randomization for smaller σ. As σ increases, the four approaches perform similarly. For δ = 0.15,
the BC/CARA/SARA approaches have the highest power. There is a notable loss of power for RA
randomization.
For a null effect size, the type I error results from the GLM/GLMM are comparable to the naive
approach, where there is an inflation in the type I error rate as σ increases. When the effect size
is increased to 10%, the CARA design has notably lower power compared to the other approaches.
The BC/RA/SARA methods perform similarly with marginal improvement in power for the SARA
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design. For δ = 0.15, the BC/SARA approaches have the highest power, with slight improvement
for SARA with increasing σ. There is a notable loss of power for the RA/CARA designs, where
CARA has worst performance when accounting for clustering.
Table 2.19: Scenario 6 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

CARA

SARA 1

3

0.5

0

0

0.06

0.06

0.06

0.06

0.06

0.06

(n = 775)

0.025

0.09

0.09

0.10

0.09

0.09

0.09

0.05

0.20

0.20

0.21

0.20

0.20

0.20

0.075

0.33

0.33

0.33

0.33

0.32

0.33

0.1

0

0.78

0.78

0.79

0.79

0.77

0.79

(n = 775)

0.025

0.77

0.76

0.77

0.77

0.74

0.77

0.05

0.72

0.72

0.72

0.72

0.69

0.72

0.075

0.66

0.66

0.66

0.66

0.64

0.66

0.15

0

0.80

0.78

0.80

0.80

0.77

0.79

(n = 339)

0.025

0.76

0.74

0.76

0.76

0.73

0.76

0.05

0.74

0.72

0.74

0.74

0.71

0.74

0.075

0.71

0.69

0.71

0.71

0.68

0.71

1

Trial Scenario: 3 Sites, p1 = 0.5, Neyman Allocation
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Figure 2.8: Scenario 6 - Empirical Type I Error and Power

48

2.4.7

Empirical Type I Error and Power by Number of Sites (k)

In Section 2.4.7, we explore the relationship between the number of sites and both empirical
type I error and power. The GLM/GLMM approach, which incorporates either fixed or random
site effects, is used to test the treatment effect (H0 : β̂1 = 0) to account for inter-center variability
in treatment responses. An indication of whether the null hypothesis was rejected was retained to
calculate the operating characteristics of the methods.

Scenario: Allocation = Optimal, P1 = 0.3
The empirical type I error results for δ = 0 are displayed in Figure 2.9. For k = 3, there is an
inflation in the type I error rate as σ increases for all four methods. RA randomization appears
to control the type I error rate slightly better than the other designs particularly when there is
more inter-site variability. When k = 6, the four methods are comparable for lower inter-site
variability. For larger σ, the BC/SARA designs perform similarly whereas the CARA method has
the highest type I error rate and RA randomization has the lowest. For k = 9, all methods are
comparable regardless of the inter-site variability. As the number of sites increases, the type I error
rate decreases, particularly in cases where there is more inter-site standard deviation. When σ is
low, the methods perform close to the nominal level of 0.05 regardless of k.
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Figure 2.9: Empirical Type I Error by Site, P1 = 0.3, δ = 0
The empirical power results for δ = 0.10 are displayed in Figure 2.10. For k = 3, the SARA design is similar to balanced case and thus gains back some of the power lost with the other adaptive
methods, particularly RA randomization. For k = 6, the RA design has a notable loss of power
relative to the other methods which perform comparably. Before σ = 0.05, the CARA/SARA
designs have marginally higher power than the balanced case, where SARA has a slightly improvement. For larger σ, the three methods are comparable. When k = 9, the RA method maintains a
notable loss of power relative to the other methods which perform comparably. As the number of
sites increases, there is less of a decrease in power for all four methods though power is maintained
better by BC/SARA/CARA, particularly as the inter-site variability increases.
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Figure 2.10: Empirical Power by Site, P1 = 0.3, δ = 0.10
The empirical power results for δ = 0.15 are displayed in Figure 2.11. For k = 3, there is a
notable loss of power for the CARA/RA designs while the SARA approach gains back most, if not
all, of the power lost with the other adaptive methods. For k = 6, the CARA/SARA methods gain
back most of the power lost with the RA design, but the improvement is slightly lower for CARA.
When k = 9, RA randomization has the lowest power while the BC/CARA/SARA methods have
comparable power when there is little inter-site variability. SARA has the highest power when
there is no variability, however, there is slight loss of power for the SARA design compared to the
BC/CARA methods as σ increases. As k increases, there is less of a power loss for all four methods,
especially as σ increases.
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Figure 2.11: Empirical Power by Site, P1 = 0.3, δ = 0.15
Scenario: Allocation = Optimal, P1 = 0.5
The empirical type I error results for δ = 0 are displayed in Figure 2.12. For k = 3, the
four approaches perform similarly where the type I error rate increases as the amount of intersite variability increases. For k = 6, the four methods are comparable, however, there is a slight
improvement for the BC/RA/SARA designs when σ = 0.075. When k = 9, there is a slight increase
in type I error for the CARA design for larger values of σ compared to the other methods which
perform similarly. As the number of sites increases, the type I error rate decreases, particularly
with higher σ. When σ is low, the methods perform closer to the nominal level of 0.05 regardless
of the number of sites.
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Figure 2.12: Empirical Type I Error by Site, P1 = 0.5, δ = 0
The empirical power results for δ = 0.10 are displayed in Figure 2.13. For k = 3, RA randomization has slightly lower power than the other designs for smaller σ and this pattern is more
pronounced with increasing k. For larger inter-site standard deviation, SARA has marginally more
power than the other methods which perform similarly. For k = 6, the CARA/SARA designs gain
back the power lost with RA randomization, particularly for smaller σ. For larger σ, the SARA
design has slightly higher power than the other approaches, include the BC. When k = 9, the
CARA/SARA designs gain back most, if not all, of the power lost with the RA design, compared
to the balanced case. There is a slight improvement in power for the CARA method. As k increases,
the power loss stabilizes for all four methods, especially for larger σ.
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Figure 2.13: Empirical Power by Site, P1 = 0.5, δ = 0.10
The empirical power results for δ = 0.15 are displayed in Figure 2.14. For k = 3, the BC/SARA
designs have higher power compared to the RA/CARA approaches. As σ increases, SARA maintains slightly more power than balanced randomization, whereas the RA design has the lowest
power. When k = 6, the BC/CARA/SARA approaches have higher power than RA randomization. For smaller inter-site standard deviation, there is less improvement for SARA. However, as
σ increases, the SARA design gains back most of the power while there is a loss of power for the
CARA method. For k = 9, the BC/CARA designs perform comparably when there is no inter-site
variability. There is a loss of power for the RA/SARA approaches, with a slight improvement for
the SARA design. As σ increases, the CARA/SARA designs outperform the balanced case with
respect to power, however, the improvement is lower for SARA. There is a consistent loss of power
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for the RA method compared to balanced allocation. Overall, as k increases, there is less of a power
loss for all four approaches. For a larger number of sites and smaller σ, there are instances where
there is an increase in power but, as σ increases, there is a slight loss of power for all methods.

Figure 2.14: Empirical Power by Site, P1 = 0.5, δ = 0.15
Scenario: Allocation = Neyman, P1 = 0.3
The empirical type I error results for δ = 0 are displayed in Figure 2.15. For k = 3, the four
methods perform similarly where there is an inflation in type I error rate as the amount of inter-site
standard deviation increases. The adaptive designs have marginal improvement in the type I error
rate as σ increases, although there is less improvement for the CARA/SARA approaches compared
to RA randomization. For k = 6, the four methods perform comparably when σ is small. As σ
increases, the BC/SARA approaches have similar type I error rates with a marginal improvement
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over CARA. RA Randomization has a slightly lower type I error relative to the other methods with
increasing inter-site variability. For k = 9, the CARA design performs comparable to balanced
allocation with the highest type I error rates when there is little to no inter-site standard deviation.
However, as σ increases, the BC/RA/SARA approaches perform similarly with slight improvement
compared to CARA. As the number of sites increases, the type I error rate decreases, particularly
in the presence of inter-site variability.

Figure 2.15: Empirical Type I Error by Site, P1 = 0.3, δ = 0
The empirical power results for δ = 0.10 are displayed in Figure 2.16. For k = 3, the BC/SARA
approaches have comparable power, with a slight advantage for SARA, while there is a notable
loss of power for the other adaptive designs. RA randomization has the lowest power. For k = 6,
the BC/CARA/SARA approaches perform similarly while the RA method maintains a notable
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decrease in power. In cases with little to no inter-site variability, the CARA/SARA designs have a
slight increase in power, however, as σ becomes larger, the BC/SARA approaches have a marginal
improvement compared to CARA. When k = 9, the BC/CARA/SARA designs have similar power
and outperform RA randomization. As k increases, the power loss stabilizes for all methods,
particularly for larger inter-site variability.

Figure 2.16: Empirical Power by Site, P1 = 0.3, δ = 0.10
The empirical power results for δ = 0.15 are displayed in Figure 2.17. For k = 3, the BC/SARA
designs have higher power than the other adaptive methods, but SARA slightly outperforms the
balanced case as the inter-site standard deviation increases. The CARA design has notably less
power than the BC/SARA designs but performs better than RA randomization. For k = 6, there is
notable loss of power for the RA method relative to the other designs. For smaller σ, the BC/SARA
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approaches have marginal improvement over the CARA design. However, as σ increases, the SARA
approach has the highest power. When k = 9, BC/CARA/SARA perform comparably, particularly
for lower σ, while RA randomization maintains a notable loss of power. As σ increases, balanced
randomization and the CARA design slightly outperform SARA. As k increases, the power loss
stabilizes for the BC/CARA/SARA approaches, especially as σ increases. For RA randomization,
there is less of a stabilizing effect on power as the number of sites increases.

Figure 2.17: Empirical Power by Site, P1 = 0.3, δ = 0.15
Scenario: Allocation = Neyman, P1 = 0.5
The empirical type I error results for δ = 0 are displayed in Figure 2.18. For k = 3, all methods
perform similarly where the type I error rate increases as the amount of inter-site standard deviation
increases. For larger σ, the adaptive designs have a marginal improvement in type I error compared
58

to balanced randomization. For k = 6 and k = 9, the four approaches perform comparably. For
k = 9, there is a slight improvement for the RA/SARA designs for larger σ. As the number of sites
increases, the type I error rate decreases, especially when larger inter-site variability exists.

Figure 2.18: Empirical Type I Error by Site, P1 = 0.5, δ = 0
The empirical power results for δ = 0.1 are displayed in Figure 2.19. When k = 3, the CARA
design has lower power compared to the other approaches. The BC/RA/SARA methods perform
similarly with marginal improvement in power for the SARA design. For k = 6, SARA gains back
all of the power lost with the other adaptive designs and has comparable power to the balanced case.
The RA/CARA approaches perform similarly, both with less power than the BC/SARA designs.
When k = 9 and there is no inter-site variability, the CARA/SARA designs outperform the balanced
case while there is a slight loss of power for the RA method. As σ increases, the BC/CARA/SARA
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approaches perform comparably while there is a slight loss of power for RA randomization. As the
number of sites increases, the power loss stabilizes, particularly as σ increases. In some cases, there
appears to be a slight increase in power for a larger number of sites and little inter-site variability.

Figure 2.19: Empirical Power by Site, P1 = 0.5, δ = 0.10
The empirical power results for δ = 0.15 are displayed in Figure 2.20. For k = 3, the BC/SARA
approaches have the highest power, with SARA performing marginally better with increased σ.
There is a notable loss of power for the RA/CARA designs, with slight improvement for RA randomization. For k = 6, the BC/SARA designs have comparably higher power than the RA/CARA
methods. CARA outperforms RA randomization and is more similar to the other deigns when
there is a no inter-site variability or when σ is high. For k = 9, the BC/CARA designs have
comparable power when σ = 0 while there is a slight loss of power for SARA. As the amount
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of inter-site variability increases, the CARA/SARA designs outperform the balanced case, with a
slight improvement for CARA. RA randomization maintains a notable loss of power relative to
the other designs for all σ. As k increases, there is a stabilizing effect on the power loss for all
approaches. When k = 9, there is a slight improvement in power for all methods when inter-site
variability is small, however, the power continues to decline as σ increases.

Figure 2.20: Empirical Power by Site, P1 = 0.5, δ = 0.15
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2.5

Discussion

We proposed two methods to account for site-based response variability by calculating conditional success probabilities specific to each center that were incorporated in a novel approach to
skew the treatment allocations. When there is a null effect size, the results show that the four
allocation designs (equal allocation, RA, CARA, SARA) perform similarly in terms of mean total
number of successes, allocation proportions, and type I error rates, regardless of the true success
rates and amount of inter-site standard deviation. The SARA approach outperforms the other
designs for small success probabilities with both small and medium effect sizes. In these cases, the
other adaptive designs result in slightly more treatment successes and larger allocation proportions,
however, the SARA design has more treatment success and adaptation than balanced allocation
while also achieving lower variability compared to RA randomization and the CARA approach.
SARA gains back most, if not all, of the power lost with the other adaptive designs. It is encouraging to note that the adaptive designs work best at lower success probabilities, when reducing
treatment failures is more important.
For larger success probabilities with small and medium effect sizes, the adaptive designs outperform the balanced case in regards to treatment successes and adaptation, with slightly less
improvement for SARA, with all methods achieving similar variability. SARA may result in less
adaptation than the other adaptive methods due to accounting for site heterogeneity. As the
amount inter-site variability increases, SARA maintains slightly more power than the other designs, including the balanced case. SARA may have gained back power relative to the other adaptive
designs since here we are accounting for additional variability introduced from the centers. By
incorporating the random site effects in the model to account for between-center variability, we
better control the type I error and increase power.
For small and medium success probabilities, Neyman allocation performs similarly to Optimal
Allocation because for p1 , p2 < 0.5, the variance is greater in the more successful treatment group.
Accordingly, Neyman allocation produces a larger allocation weight to the superior treatment. For
large success probabilities, the balanced case outperforms the adaptive designs with respect to
treatment successes for small and medium efficacy, however, SARA has a slight improvement in
expected treatment successes and the lowest variability compared to the other methods, including
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equal allocation, even in the presence of inter-site variability.
Overall, for increasing inter-site standard deviation, the variability in expected treatment successes increases, the type I error rate increases and the power decreases for all methods. However,
as you increase the number of sites, the variability in average treatment successes decreases and
there is less of an inflation in type I error and loss of power, particularly as σ increases. The
variability in expected treatment successes may decrease with increasing sites because there is less
variability in the site-specific success probabilities as they regress towards the true mean success
probabilities.
Selvaratnam et. al (2018) established the consistency and asymptotic normality (multivariate Gaussian distribution) of the ML estimators of GLMs implemented in adaptive randomization
designs. A simulation study was conducted to compare the performance of the completely randomized, RA and CARA approaches for a binary outcome and categorical covariates. The results
showed that the RA method is more ethical (success rates) and has higher statistical efficiency
(ML estimates) if a treatment-by-covariate interaction does not exist. However, the CARA design
is more ethical in the presence of a interaction, particularly later on in a trial when a significant
covariate interaction is detected [11].
In this chapter, the CARA and SARA designs incorporated fixed and random site effects,
respectively, to account for site-based response variability when allocating patients in a multi-center
trial. We expect that as the inter-site standard deviation increases, the magnitude of qualitative
interactions increases regardless of effect size. The effect of not accounting for potential variability
in effect sizes between centers is unknown. Accordingly, a random treatment-by-site interaction
could be included in the model. We did not do so because another limitation of this approach
is issues in estimating many random effects, particularly early on in the study when sample sizes
within centers are small or when there is a constant response. Because the simulations were modeled
as a Phase 2 efficacy trial, there are a small number of centers that require that enough patients be
recruited to each. We expect there would be additional convergences issues when including a random
treatment-by-site interaction in the frequentist setting. Finally, the simulations were designed with
80% power, assuming no inter-site variability, which requires a relatively large sample size which
may be unrealistic when conducting a clinical trial in real life.
The trade-off between power and treatment failures is an expected consequence of adaptive
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designs. By accounting for an extra source of variation in the randomization process, the variability
in the allocation weights and thus assignments were reduced. Since adaptive methods skew the
allocation ratio depending on the aim, the sample sizes for the groups are often unbalanced and
may result in a loss of power compared to balanced randomization. However, the loss of power
for the SARA approach was not as notable as the other methods, including RA randomization.
Therefore, our methods reduced variability but only at the slight cost of power in some cases
compared to the balanced case. Though SARA gains back much of the power lost when using
either the RA or CARA approaches, it does not gain back all of the power lost due to inter-site
variability. Thus, it is imperative to account for inter-site variability in the design stage by inflating
the anticipated response variability, which will increase the required sample size.
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CHAPTER 3
ACCOUNTING FOR VARIABILITY IN TREATMENT EFFECTIVENESS

In this chapter, we introduce a Bayesian approach to the SARA design to account for variability in treatment effectiveness in the presence of qualitative interactions. A Bayesian approach
is considered to be flexible enough to overcome any computational challenges from modeling a
large number of centers as well as the additional parameters introduced by the treatment-by-site
interaction effects. In Section 3.1, we summarized the existing Bayesian adaptive methods and
treatment-by-center interactions in clinical trials. In Section 3.2, we introduce two approaches,
one that extends Chapter 2 under the Bayesian framework and another that models a random
treatment-by-site interaction effect to account for inter-site variability in treatment effectiveness
in addition to site-based response variability. A simulation study is conducted in Section 3.3 to
compare the performance of our proposed methods to those in Chapter 1 as well as both balanced
and RA randomization. The results are explored and a brief discussion of the implications follows.

3.1
3.1.1

Background and Existing Methods
Bayesian Covariate-Adjusted Response-Adaptive (CARA) Design

Thall and Wathen (2005) use a between-patient adaptive rule, namely outcome-adaptive randomization1 , a generalization of Thompson’s (1933) method for two binomial distributions with
beta priors specified [32, 33]. Thompson randomized the next patient to treatment group A with
probability wn+1,A (Fn ) = Pr(pB < pA |Fn ), where pi = treatment group i success probability,
i = A, B, given the previous subjects’ data (Fn ). Similarly, the next patient is randomized to
treatment group B with probability wn+1,B (Fn ) = 1 − wn+1,A (Fn ). Thall and Wathen’s generalization of this approach estimates the posterior probabilities used to calculate the allocation weights
using a model that includes treatment-covariate interactions [33]. This ensures that covariates are
not ignored and separate trials for each covariate subgroup are not necessary. In their follow-up
paper reviewing Bayesian Adaptive Randomization, the allocation probabilities were stated to be
1

This is a less commonly used name for response-adaptive randomization.
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highly variable and may favor the inferior treatment [22]. Instead, they suggest to randomize the
next patient to treatment group A with the following probability:

wn+1,A (Fn ) =

{PA>B (Fn )}c
,
{PA>B (Fn )}c + {PA<B (Fn )}c

where c is a positive tuning parameter. Similarly, the next patient should be randomized to
treatment B with probability wn+1,B (Fn ) = 1 − wn+1,A (Fn ). They suggest to use c = n/2N
to preserve power and reduce variability, where n is the current sample size and N is the total
planned sample size. The authors discuss the ‘drift’ phenomenon and express the importance of
adjusting for covariates to reduce negative effects on the adaptive randomization [22].
Using the posterior probability that p1 > p2 is an intuitively appealing quantity to use, however,
i
h
p̂1 −p̂2
that optimizes
theoretical justification requires a standardized treatment difference φ SE(p̂
1 −p̂2 )
the allocation, where φ is a link function (e.g. probit) [34]. Instead, while a different approach than
efficacy comparisons (p1 > p2 ), we choose to plug the estimated probabilities of success into the
allocation equations (Eqns. 2.3 and 2.4) since they were designed to minimize treatment failures
or maximize power, for example.

3.1.2

Treatment-by-Center Interactions in Clinical Trials

Clinical trials are typically performed at several centers in to recruit a sufficient number of
patients in a relatively short amount of time. This is often difficult to do with a single site.
An added benefit of multi-center trials is that they reflect natural differences in clinical practice
between sites. A wider population of patients receive treatments in a variety of settings that are
often expected to differ slightly due to patient, provider and clinic characteristics. Multi-center
trials often use stratified randomization to balance allocation within each center at the design
phase but rarely adjust for center in the analysis. In fact, Pocock et al. (2002) go as far to
anecdotally claim that adjusting for centers in multi-center trials rarely makes a difference [35].
The added heterogeneity introduced in these trials may lead to a significant treatment-by-center
interaction effect where the treatment effects vary across locations. Consequently, any inference
made is subject to problems with interpretability of the treatment effects and generalizability of
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the results to a broader population. This requires further investigation into the identification of
group-specific effects [1, 36].
In 1998, the Food and Drug Administration published guidance for the pharmaceutical industry
on the “Statistical Principles for Clinical Trials”, developed by the International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
[36]. Included in the ICH-E9 statements are guidance for how to investigate the presence and cause
of treatment-by center interactions. First, the main treatment effect should be fit in a model
that allows center differences but does not include a treatment-by-center interaction. Including
the interaction would use up degrees of freedom and reduce the power of the test for the main
treatment effect if it were truly homogeneous. In the presence of true treatment heterogeneity,
graphical displays and/or significance testing should be used to help explore characteristics that
vary across sites. However, these hypothesis tests may be underpowered if the interaction effects are
not powered for in advance; some have suggested using a higher significance level (p = 0.10) than
convention for significance testing [1]. A significant interaction can be caused by the measurement
scale of the data or outliers caused by extreme values of the response variable, neither of which
are clinically relevant. Patient characteristics not accounted for in the analysis and/or variable
conditions among the clinical centers could also be the source [1].
Without a specific explanation for these site differences, further trials may be needed when a
significant qualitative interaction is observed. Alternatively, weighting centers in the analysis to
justify the robustness of the treatment effect estimates may be necessary for a significant quantitative interaction [36]. In a typical fixed-effects analysis of variance (ANOVA) model, this weighting
is performed by the inclusion of a treatment-by-center interaction effect. By including the interaction in the model, equal weight is given to the within-center effect estimates to produce an overall
treatment effect where patient responses are weighted according to cluster size. Without the interaction term, within-center estimates are weighted by their precision, a function of the within-center
sample sizes, and thus patient responses are equally weighted. Gallo (2000) recommends omitting
the interaction term for the primary analysis in trials with unbalanced centers for a more precise
overall treatment effect as discussed in the ICH-E9 guidance document [1, 12].
In multi-center trials, both the RA and CARA algorithms use all available data irrespective of
site to calculate the allocation assignments. However, these existing methods do not account for
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inter-site variability in treatment effectiveness. However, the effect of not accounting for potential
variability between centers is unknown.

3.2

Methods

We considered a slightly more complex modeling approach under the Bayesian framework to
overcome the anticipated issues in estimating many parameters as in previous research (e.g. noted
in Rosenberger et al., 2001 [20]). Gelman et al. recommend using Bayesian inference to overcome
probable issues with non-identifiability and separation that are commonplace when fitting frequentist logistic regression models [37]. The proposed CARA model (Eqn. 2.11) which accounts for
clustering with a fixed site effect was not considered because all regression parameters are considered to be random in the Bayesian setting. SARA Model 1 (Eqn.2.13) was extended to a Bayesian
GLMM by incorporating priors on the model parameters. Two models were fit: one model without
an interaction and one model that includes a treatment-by-site interaction. The performance of
these models will be assessed under scenarios that promote ‘high’ magnitude qualitative interactions
based on varying effect sizes and inter-site standard deviations.
First, we extended SARA Model 1 (Eqn.2.13) to account for site-based response variability
under the Bayesian framework.

3.2.1

SARA Model 2 - No Treatment-by-Site Interaction

0

logit(pij ) = β0 + β1 Ti + gj + Xi θ

(3.1)

Here, β0 is the overall intercept, β1 is the treatment effect, Ti is the treatment group indicator
(Ti = 1 if A, Ti = 0 if B), for patients i = 1, . . . , n. Here, gj is a random site effect for the j th site,
0

where gj ∼ N (0, σg2 ) ∀j, j = 1, . . . , k and k is the number of sites. The Xi θ is an optional set of
covariates that can be incorporated into the model to adjust the estimated success probabilities,
with corresponding slopes/effect sizes denoted by θ.
The priors for the regression coefficients and random effects are specified as N (µ, σ 2 ), where µ
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is the mean and σ 2 is the variance. The prior on the overall intercept and the treatment effect is
an informative normal: βl ∼ N (0, 5), l = 0, 1. In addition, the prior for the site random effects
is specified as an informative normal: gj ∼ N (0, 1) ∀j. For a normal distribution, N (µ, σ 2 ), this
implies that 99.7% of the probability mass for the prior distribution would fall within 3σ (σ = 1) of
the mean (µ = 0). In our experience, more informative priors with smaller variances were necessary
on the random site effects to avoid issues with convergence as the effect for each site was small
relative to traditional non-informative Gaussian priors, as demonstrated in a previous study by
Longini et al. [4].
Traditionally, a noninformative or flat prior distribution is specified for parameters in a generalized linear model, such as a uniform prior density, so that the posterior distribution depends
mostly on the data and not prior knowledge. Accordingly, the posterior mode of this noninformative density is the ML estimate of the parameter. However, with logistic regression, Gelman et
al. suggest selecting priors under the assumption that effects will typically be relatively small and
that coefficients are independent, thus more informative. An example is provided where separation
occurs, particularly with binary predictors, resulting in unstable ML estimates. Using Bayesian
inference, specifying a uniform prior distribution is shown to also fail in certain scenarios. Instead,
the t family, such as the normal distribution (a special case when the degrees of freedom equals
infinity), is recommended for regression coefficients because flat-tailed distributions allow for more
robust inference. An approximate EM algorithm using a t prior distribution is also provided by
the authors but not used for our purposes [37].
Spiegelhalter (2004) refers to these informative priors as ‘skeptical’ since there are doubts that
large effects exist [38]. As such, the prior distribution is centered as zero with the scale parameter
controlling the degree of skepticism to incorporate. Gelman et al. describes these priors as ‘weakly
informative’ priors, where enough previous information is provided through the prior to keep the
posterior distribution within reasonable bounds (‘regularized’) without dominating it with the prior
specification. As the sample size approaches infinity, the posterior distribution will depend less on
the prior specified. As an example, the authors consider a logistic regression model, where the
predictors are either binary or standardized, and assume that an effect size will be no larger than
10 for most scenarios. This difference corresponds to a shift on the logit scale in a probability from
logit−1 (−5) = 0.01 to logit−1 (5) = 0.99. It should be noted that a weakly informative prior may
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affect inference when there is not enough data (i.e. small sample size) and skew it in a particular
direction [37].
After the chains converge to the stationary distribution, the posterior medians of the model
parameters were used to calculate the conditional probability of success for each subject to be
randomized to a treatment group at a particular site. These estimated success probabilities p̂tij for
the tth treatment, t = 1, 2, conditional on the site for the next patient were defined as follows:
0

p̂1ij =

exp {β̂0 + β̂1 + ĝj + Xi θ̂}
0

1 + exp {β̂0 + β̂1 + ĝj + Xi θ̂}

,
(3.2)

0

p̂2ij

=

exp {β̂0 + ĝj + Xi θ̂}
0

1 + exp {β̂0 + ĝj + Xi θ̂}

.

Two methods were considered in the instance that a patient was being recruited from a particular
site with no previous subjects. First, a hard lead-in criterion could require that all sites be observed
prior to adapting, however, this may limit the benefits of adaptation. Alternatively, balanced
allocation could be used to calculate the predicted probabilities for subjects coming from these
‘new’ sites. We decided to use a lead-in that required all sites be observed prior to beginning
adaptation. While this is not a requirement for the Bayesian models, this ensures the results will
be consistent with Chapter 2 and that a sufficient number of patients will be randomized prior to
adapting.
Naturally, additional parameters can include treatment-by-covariate interactions [20, 25]. In
addition to a random site effect, a random quantitative or qualitative treatment-by-site interaction,
depending on the parameter template, was included to extend SARA Model 2 to allow the treatment
effects to vary across sites.

3.2.2

SARA Model 3 - Treatment-by-Site Random Interaction

0

logit(pijt ) = β0 + β1 Ti + gj + djt + Xi θ

(3.3)

Here, we incorporated a random treatment-by-site interaction δjt corresponding to the j th site and
the tth treatment, t = 1, 2, into equation (3.1). Priors were specified for the 2+2k model parameters,
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excluding the optional set of covariates. In addition to the previous priors for SARA Model 2, an
additional prior was specified for the interaction term:
djt ∼ N (0, σd2 ) ∀j, t.
We expect the treatment-by-site effects to be small similar to the site effects. Accordingly,
a ‘weakly informative’ normal prior is used for the treatment-by-site interaction effects: djt ∼
N (0, 1) ∀j, t. Sensitivity analyses will be performed with other specifications and larger variances to
see how convergence and robustness are affected. In this model, the estimated success probabilities
p̂tij were calculated as follows:
p̂1ij =

0
exp {β̂0 + β̂1 + ĝj + dˆj + Xi θ̂}
,
0
1 + exp {β̂0 + β̂1 + ĝj + dˆj + X θ̂}

i

0

p̂2ij

=

exp {β̂0 + ĝj + Xi θ̂}
0

1 + exp {β̂0 + ĝj + Xi θ̂}

(3.4)

.

These conditional probabilities of success will be substituted into the Optimal allocation equations
to update the site-specific randomization probabilities.

3.3

Simulation Study

The methods of Chapter 2 were extended to incorporate a treatment-by-site interaction under
the Bayesian framework. The simulation template is similar, however, ‘low’ and ‘high’ magnitudes
of both qualitative and quantitative treatment-by-site interactions were considered by adjusting the
amount of inter-site standard deviation (σ) appropriately. We conducted a brief simulation study to
explore scenarios that promote more qualitative treatment-by-site interactions as defined by Gallo to
select our parameter template. The number of sites (k = 3, 6, 9) and inter-site standard deviations
in treatment response (σ = 0, 0.025, 0.0375, 0.05, 0.075, 0.1, 0.125, 0.15) were varied with a 30%
treatment group 1 success probability (p1 = 0.3) and several effect sizes (δ = p1 − p2 = 0, 0.1, 0.15).
The percentages of flipped success probabilities, defined as P(at least one p̂1 < p̂2 )×100, were
averaged across 1000 iterations to indicate how frequent qualitative interactions occurred.
The results of the interaction simulation are displayed in Table 3.1. As expected, the results
show that as the effect size increases, there are less qualitative treatment-by-site interactions.
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However, as the inter-site standard deviation increases, the number of qualitative interactions
increases regardless of effect size. Accordingly, we selected smaller values of inter-site SD for Chapter
2, to limit the amount of qualitative interactions, and use larger values for Aim 2, to promote more
qualitative interactions, to study the operating characteristics of the proposed methods.
Table 3.1: Percentage (%) of Qualitative Treatment-by-Site Interactions

k
3

p1
0.3

Inter-Site Standard Deviation (σ)
0.025 0.0375 0.05 0.075 0.1 0.125
89.5
89.5 89.5
89.5 89.5
89.5
0.6
8.1 21.1
43.9 56.0
65.0
0
0.6
4.4
21.1 36.9
49.4

δ
0
0.1
0.15

0
0
0
0

0.15
89.5
69.5
55.9

6

0
0.1
0.15

0
0
0

98.5
0.9
0

98.5
16.7
0.9

98.5
39.3
9.5

98.5
68.2
39.3

98.5
80.1
58.6

98.5
86.5
73.3

98.5
89.7
79.8

9

0
0.1
0.15

0
0
0

99.9
1.9
0

99.9
24.0
1.9

99.9
50.9
14.4

99.9
80.2
50.9

99.9
89.5
74.1

99.9
94.2
85.2

99.9
95.8
89.5

Selecting large enough values for the inter-site standard deviation (σ = 0, 0.05, 0.1, 0.15) will
result in differences in both the magnitude and direction of the treatment effectiveness across
centers, indicating a qualitative interaction. Accordingly, we considered small (p1 = 0.3), medium
(p1 = 0.5) and large (p1 = 0.7) treatment group 1 success probabilities along with null (δ = 0),
small (δ = 0.1) and medium (δ = 0.15) effect sizes. The simulated Phase 2 multi-center trials were
limited to a relatively small number of centers (k = 3, 6).
By specifying priors on the model parameters, the joint posterior distribution of the regression
coefficients and random effects were estimated using the MCMC techniques coded in OpenBUGS
through the BRugs interface in R. Based on our experiences, we specified ‘weakly informative’ prior
distributions on the random site and treatment-by-site interaction effects. Accordingly, a sensitivity
analysis was performed to explore different prior specifications, including slightly larger variances
(less informative), for both SARA 2/SARA 3 models. The priors considered are displayed in Table
3.2. Prior C was the specification used for both the random site and interaction effects in our
simulation study. In the sensitivity analysis, Bayesian GLMM models were fitted as subjects were
randomized for trials with a small number of centers (k = 3), a small treatment group 1 success
probability (p1 = 0.3), a medium effect size (δ = 0.15) and larger values for the inter-site standard
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deviation (σ = 0.1, 0.15). Due to the anticipated significant computation time, we simulated only
10 trials and for each, estimated the model parameters using 2000 iterations for burn-in and 4000
iterations from two parallel chains with no thinning from the joint posterior distribution. Gelman
and Rubin’s convergence diagnostic was used as the criteria for evaluating convergence of the
two Markov chains generated [39, 40]. We examined the robustness of the mean total number of
treatment successes (SE), expected allocation proportions for treatment 1, empirical power and the
average number of non-convergence warnings per trial to compare the priors being considered.
Table 3.2: Sensitivity Analysis: Priors Considered
Prior

Specification

A

gj ∼ N (0, σg2j ), σg2j ∼ G(1, 1) ∀j

B

gj ∼ U (−2, 2)

C

gj ∼ N (0, σg2j ), σg2j = 1 ∀j

D

gj ∼ N (0, σg2j ), σg2j = 5 ∀j

E

gj ∼ N (0, σg2j ), σg2j ∼ U (0, 2) ∀j

1

The normal priors are specified as N (µ, σ 2 ), where µ is the mean and σ 2 is
the variance.

The models were implemented into the adaptive design using the BRugsFit {BRugs} function
[41]. The initial values must be specified for the random site and treatment-by-site interaction effects
to ensure they are reasonable and within the bounds of the more informative priors that were used.
Instead of using fixed starting values throughout all of the simulations, ML estimates were used
to begin and then the posterior estimates were used for subsequent individuals randomized in an
attempt to reduce computation time by allowing the chains to converge faster to the stationary
distribution. For each scenario, a frequentist GLM was fit, which ignores the site effect, after the
first subject is randomized following the lead-in (e.g. patient 21) to get ML estimates to initialize
the starting values for the Markov chains. The estimates of the intercept and treatment effect were
used as the initial values for the first chain, while 0.5 was added to the regression coefficients for
the starting values for the second chain. For both chains, a fixed starting value of zero was used
for the random site effects. For subsequent patients, the previous individual’s posterior estimates
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were used to initialize chain 1. For the second chain, 0.5 was added to the posterior estimates for
both the intercept and treatment effect while 0.05 was added for the site effects. However, if the
model did not converge, the last subject’s estimates to converge were used for the starting values.
We estimated the posterior median of the model parameters using 2000 iterations for burnin and 4000 iterations from two parallel Markov chains from the joint posterior distribution. The
posterior median, which minimizes the expected posterior absolute loss function, was used for point
estimates because it is equivalent to the mean for symmetric posterior densities. For asymmetric
posteriors, the median lies between the mean and the mode (which considers only the maximum
value) and is not skewed by extreme values [42]. Thinning was not performed because it has been
shown to be unnecessary and inefficient, particularly due to the cost associated with increased
computation time in simulations [43].
An artificial lead-in was used in the simulations to prevent estimator instability or convergence
issues. This hard lead-in required that balanced allocation be performed for the first m = 20
subjects irrespective of the design. An advantage of the Bayesian framework is that it no longer
requires lead-in criteria, specifically that both responses or that all sites be observed prior to
adapting. Gelman and Rubin’s convergence diagnostic R̂, or the potential scale reduction factor
(PSRF), was used as the criteria for evaluating convergence of the two Markov chains generated.
This was implemented in R using the gelman.diag {coda} function [44]. Adaptation continued
with the more strict cutoff of R̂ < 1.1 for all parameters [39, 40], otherwise, the previous patient’s
allocation weights were used until convergence was achieved [20]. In practice, visual assessment of
trace plots should be examined for convergence in addition to looking at convergence diagnostic
test statistics, however, this was not feasible in our simulation study.
To evaluate the proposed allocation designs, we use the operating characteristics established by
Rosenberger et al. (2008), namely balance (allocation proportion), efficiency (power, type I error)
and ethics (total number of treatment successes) [19]. We are particularly interested in the mean
total number of successes/failures (± standard error), empirical power (P {reject H0 |H1 true}) and
type I error rate (P {reject H0 |H0 true}). In addition, we are interested in comparing the computation times for the proposed competing approaches. Based on our previous simulations in Chapter
2, each scenario for SARA Model 1 takes a significant amount of time to run. We expect that the
Bayesian extensions will require even more computation time due to the added complexity of the
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two models. Therefore, for all SARA models, we calculate the average simulation time (seconds)
per subject to compare the effect of the increasing complexity of the models on computation times.
Balanced allocation, RA and CARA randomization are not considered because these models are
fit almost instantaneously for each patient. The simulation times represent the amount of time
(seconds) to fit each model and update the allocation probabilities to randomize the subsequent
patient in a trial. The times only account for the n − 20 patients adaptively randomized after the
initial lead-in.
As a natural comparator, the performance of SARA Model 2 (Eqn. 3.1) was compared to SARA
Model 1 (Eqn. 2.13), its equivalent under the frequentist framework in Chapter 2. In addition,
SARA Model 3 (Eqn. 3.3) was compared to SARA Model 2. These methods were also compared
to the CARA model (Eqn. 2.11), where we treat site as a fixed effect instead and do not include
an interaction, as well as the existing designs, balanced and RA randomization (Eqn. 2.1). Due
to our focus on accounting for treatment-by-site interactions in this chapter, we selected larger
values of inter-site SD to promote the amount of qualitative interactions and thus had to extend
the simulations for BC, RA, CARA and SARA Model 1. The balanced and RA designs do not
account for site variability while both the CARA and SARA designs account for the clustering
differently. We hypothesize that SARA Model 3, which accounts for inter-center variability in
treatment responses and effectiveness, will reduce the variability in multi-center trials, especially
in the presence of qualitative interactions, thus reducing improper patient allocation.
There were 1000 trials simulated for each scenario and the results aggregated. Due to our
focus on ethics, we only considered Optimal allocation in Aim 2. For a single trial scenario, the
following metrics were stored: sample size, number of patients assigned to each treatment, number
of successes for each treatment, total number of successes and the number of convergence issues
(indicates previous allocation weights were used until the model converged with additional data).
After all patients were recruited in a trial, several methods were considered to test the treatment
group, site and treatment-by-site interaction effects.
To be consistent with Chapter 2, the proportions of successes were compared using a Pearson’s
chi-squared test to assess the treatment effect and an indication of whether the null hypothesis
(H0 : p1 = p2 ) was rejected was retained to calculate the operating characteristics of the method.
The expected cell counts were checked (> 5) to ensure the assumptions of a chi-squared test were
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satisfied, otherwise, a Fisher’s Exact test was performed. This approach ignores site when testing
the treatment effect as this is convention when analyzing multi-center trials. In addition to a naive
chi-squared test, a chi-squared test from the GLMM, which incorporates random site effects to
account for inter-center variability in treatment responses, was performed. A random treatmentby-site interaction effect was not included in the GLMM for SARA 3 model due to concerns of
non-convergence.
The frequentist GLMMs were fit in the glmer function using ML estimation with an Laplace
approximation (quadrature nodes = 1) of the likelihood for the mixed model, which is an integral
over the random effect space. The variance-covariance matrices of the random effects were estimated
using Powell’s BOBYQA method, a nonlinear optimizer [30]. A separate variance component was
modeled for each random effect, the site and treatment-by-site interaction effects, separately. A
likelihood-ratio test (LRT) was used to test the random site and treatment-by-site interaction
effects for models that successfully converged, otherwise, the LRT was not performed. To test the
random site effect, a GLM was fit using the GLM function for the null model. The frequency
of statistically significant site and treatment-by-site interaction effects were used to confirm the
presence of quantitative and qualitative interactions for each scenario and will not be reported
here.
The LRT statistic [10] used to compare two models is shown to be the difference in the deviances
as follows:

D = −2 ln

likelihood of M0
likelihood of M1



= −2 [L0 − L1 ]

(3.5)

= −2 [L0 − Ls ] − {−2 [L1 − Ls ]}
= D0 − D1 ∼ χs(df1 −df0 )
where L0 is the maximized log likelihood for the null model, L1 is the maximized log likelihood
for the alternative model, Ls is the maximized log likelihood for the saturated model and M0 is a
simpler model nested within M1 . The difference in deviances follows approximately a chi-squared
null distribution with degrees of freedom equal to the difference in the number of parameters
between the two models. A convergence indicator was used to determine the proportion of trials
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where the LRT was performed.
A Bayesian approach was also considered to test the treatment, site and treatment-by-site
interaction effects but not reported here as frequentist inferences are typically used in practice for
adaptive designs. A z-test statistic was calculated using the posterior mean and variance of the
treatment group to test the treatment effect βˆ1 = 0. The posterior mean and variance estimates
were calculated as follows:

Ê(θi ) = θ̂i =

m
∗
X
θij

m

,

j=1
m
X

1
V ˆar(θi ) =
m−1

(3.6)

∗
(θij
− θ̂i )2 ,

j=1

∗ is the observed estimate for the ith parameter and the j th iteration for j = 1, . . . , m draws
where θij

from the posterior distribution. An LRT was used to perform hypothesis testing on the random site
and treatment-by-site interaction effects using the difference in the posterior mean of the deviance
from the models, regardless of whether the posterior estimates converged after all subjects had
been randomized. To account for the difference in the additional parameters estimated (regressions
coefficients, variances for priors) between the nested models, the effective degrees of freedom (pD)
from each model was used to calculate the estimated difference in parameters (df1 − df0 ). The
effective degrees of freedom, pD = D̄ − D̂, is the difference in the posterior mean of the deviance
(D̄) and the point estimate of the deviance (D̂) when plugging in the posterior means of the
parameters [45].

3.3.1

Simulation Algorithm

The basic algorithm for our simulation study is as follows.
1. Hard lead-in for the first m patients, where individuals are allocated equally between the two
treatment groups.
2. Let Fi be accrued information which includes treatment assignments, observed patients outcomes and center information. Use Fi for patients i = 1, . . . , m, m + 1, . . . , n to begin adaptation, starting with patient m + 1.
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3. Using the center for patient m + 1, calculate the conditional probability of success p̂tij for the
tth treatment using the SARA 2 (Eqns. 3.1, 3.2) or SARA 3 model (Eqns. 3.3, 3.4).
4. Using the estimated success probabilities p̂1i , p̂2i , update the allocation weights W1 , W2 and
assign the next patient to a treatment.

W1 (Fi ) =

q q
p̂1i / p̂1i + p̂2i , W2 (Fi ) = 1 − W1 .

5. Repeat Steps 2-4 to randomize patients m + 2, . . . , n.
For a single scenario, this algorithm is repeated for N = 1000 trials.

3.4

Results

In Sections 3.4.1 - 3.4.6, we compare our two proposed approaches from Chapter 2, which account for clustering through either a fixed or random site effect, and an extension under the Bayesian
framework with the two existing approaches, balanced randomization and response-adaptive randomization. We investigate these methods in the presence of qualitative interactions. In Section 3.4.7, we then investigate the performance of our SARA model which incorporates a random
treatment-by-site interaction to account for variability in treatment effectiveness.

3.4.1

Scenario 1: No Interaction, 3 Sites, p1 = 0.3

The mean total number of treatment successes for Scenario 1 are displayed in Table 3.3. When
the effect size is null δ = p1 − p2 = 0 and there is no inter-site standard deviation (σ = 0), the
five methods are comparable. However, as σ increases, there is an increase in the total number
of successes for the adaptive designs, with the improvement slightly lower for both SARA designs.
The SARA 1 design has lower variability than the other adaptive approaches and matches the
variability from the balanced case. When the effect size is increased to 10% (p1 = 0.3, p2 = 0.2),
the adaptive designs result in more treatment successes than the balanced case, particularly as σ
increases. However, the improvement is lower for the SARA approaches compared to the RA/CARA
designs. Both SARA designs are similar in that they have lower variability than the other adaptive
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approaches and they are similar to the variability from the balanced randomization. For an effect
size of 15%, the pattern is similar to the medium effect size. The adaptive designs result in more
treatment successes than the BC but the improvement is lower for the SARA approaches. The
SARA designs perform similarly in terms of treatment successes and variability, both of which
have lower variability than the RA/CARA designs. Overall, as σ increases, there is an increase in
expected treatment successes along with a greater increase in the variability in treatment successes
for all methods.
Table 3.3: Scenario 1 - Mean Total Number of Treatment Successes (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

3

0.3

0

0

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

176.1 (10.7)

(n=587)

0.05

175.5 (16.3)

176.1 (16.6)

176.0 (16.4)

176.0 (16.3)

176.4 (16.6)

0.1

175.2 (26.3)

177.5 (27.1)

177.2 (26.6)

177.0 (26.2)

177.3 (26.9)

0.15

176.0 (36.5)

181.6 (37.8)

180.9 (37.1)

179.9 (36.5)

179.7 (37.6)

0.1

0

146.6 (10.6)

151.1 (14.3)

150.7 (12.5)

149.5 (10.7)

150.0 (10.2)

(n=587)

0.05

146.0 (16.1)

151.0 (19.6)

150.7 (17.3)

149.5 (16.3)

150.2 (16.3)

0.1

146.0 (25.7)

153.6 (28.8)

152.6 (27.1)

150.8 (25.9)

151.7 (26.5)

0.15

148.0 (35.6)

158.7 (39.9)

157.2 (38.3)

155.0 (36.3)

155.7 (37.0)

1

0.15

0

54.2 (6.7)

59.1 (9.1)

58.4 (7.8)

57.2 (6.8)

57.5 (6.7)

(n=241)

0.05

54.4 (7.9)

59.6 (10.4)

58.9 (9.4)

57.7 (8.1)

57.6 (8.2)

0.1

55.1 (11.4)

61.0 (13.4)

60.2 (12.4)

58.8 (11.5)

58.6 (11.6)

0.15

56.7 (15.0)

63.3 (16.9)

62.2 (16.3)

60.7 (15.5)

60.5 (15.4)

Trial Scenario: 3 Sites, p1 = 0.3, Optimal Allocation

The allocation proportions are displayed in Table 3.4. For a null effect size, the five methods have
comparable allocation proportions. The SARA designs perform similarly in that they have lower
variability in allocating than the other adaptive designs, while RA randomization has the highest
variability. When δ = 0.10, the adaptive designs have a larger allocation ratio relative to the
balanced case, though the improvement is lower for the SARA designs. This explains the increase
in expected treatment successes in the adaptive methods with a slightly lower increase for both
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SARA approaches. The SARA designs perform similarly with respect to variability in allocating
and are less variable than the RA/CARA designs in all cases. For δ = 0.15, the adaptive designs
have notably larger allocation ratios than balanced randomization, particularly RA randomization
followed by the CARA design. The improvement is lower for the SARA approaches, though SARA
2 results in slightly higher allocation ratios than SARA 1. The SARA designs have lower variability
compared to the other adaptive designs. The RA method has the highest variability in allocation
ratios across all effect sizes. Overall, there appears to be a marginal increase in the variability in
allocation proportion with as the amount of inter-site standard deviation increases.
Table 3.4: Scenario 1 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

3

0.3

0

0

0.50 (0.02)

0.50 (0.13)

0.50 (0.09)

0.50 (0.03)

0.50 (0.03)

(n=587)

0.05

0.50 (0.02)

0.49 (0.13)

0.50 (0.09)

0.50 (0.04)

0.50 (0.03)

0.1

0.50 (0.02)

0.49 (0.14)

0.49 (0.09)

0.50 (0.05)

0.50 (0.05)

0.15

0.50 (0.02)

0.49 (0.16)

0.49 (0.11)

0.50 (0.07)

0.50 (0.06)

0.1

0

0.50 (0.02)

0.58 (0.17)

0.57 (0.12)

0.55 (0.03)

0.56 (0.03)

(n=587)

0.05

0.50 (0.02)

0.57 (0.18)

0.57 (0.12)

0.55 (0.05)

0.55 (0.04)

0.1

0.50 (0.02)

0.58 (0.19)

0.57 (0.13)

0.55 (0.06)

0.56 (0.06)

0.15

0.50 (0.02)

0.57 (0.21)

0.57 (0.14)

0.55 (0.08)

0.55 (0.08)

0.15

0

0.50 (0.03)

0.63 (0.19)

0.62 (0.13)

0.58 (0.05)

0.59 (0.05)

(n=241)

0.05

0.50 (0.03)

0.63 (0.19)

0.61 (0.14)

0.58 (0.06)

0.59 (0.06)

0.1

0.50 (0.03)

0.63 (0.20)

0.61 (0.14)

0.58 (0.07)

0.59 (0.07)

0.15

0.50 (0.03)

0.63 (0.21)

0.61 (0.14)

0.58 (0.09)

0.59 (0.09)

1

Trial Scenario: 3 Sites, p1 = 0.3, Optimal Allocation

The empirical type I error and power results are displayed in Table 3.5. For δ = 0, all five
methods perform similarly where there is an inflation in the type I error rate as σ increases. When
there is no inter-site variability, SARA 2 appears to control the type I error rate slightly better
than the other designs. However, as σ increases, both RA/SARA 2 approaches control the type I
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error better than the other designs, with more improvement for RA randomization. For a small
and medium effect size, there is a notable loss of power for RA allocation relative to the other
adaptive designs. The CARA/SARA 1/SARA 2 designs gain back most of the power lost with the
RA randomization. Specifically, the SARA designs outperform the balanced case for most, if not
all, values of σ. Specifically, SARA 2 has the highest power compared to all other methods in all
cases.
We now discuss the results from the GLM/GLMM approach, where either a fixed (CARA) or
random (SARA 1/SARA 2) site effect is incorporated into the modeling to account for clustering.
For a null effect size, the type I error results are comparable to the Naive approach, where SARA
2 has the best control of the type I error rate. For small and medium effect sizes, the results
are similar to the naive approach, where RA randomization has the greatest power loss relative
to the BC. The other adaptive designs gain back most of the power lost, particularly the SARA
approaches. SARA 2 has a notable increase in power relative to all other methods, including the
balanced case.
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Table 3.5: Scenario 1 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

CARA

SARA 1

3

0.3

0

0

0.06

0.06

0.07

0.06

0.05

0.06

0.06

0.05

(n=587)

0.05

0.20

0.19

0.21

0.20

0.17

0.20

0.20

0.17

0.1

0.41

0.39

0.43

0.43

0.39

0.42

0.43

0.40

0.15

0.57

0.50

0.56

0.57

0.53

0.56

0.59

0.53

0.1

0

0.78

0.68

0.76

0.79

0.84

0.73

0.79

0.84

(n=587)

0.05

0.68

0.57

0.67

0.68

0.74

0.63

0.68

0.74

0.1

0.62

0.51

0.61

0.62

0.68

0.58

0.62

0.68

0.15

0.63

0.51

0.62

0.64

0.68

0.59

0.65

0.69

0.15

0

0.80

0.61

0.78

0.81

0.81

0.70

0.80

0.80

(n=241)

0.05

0.73

0.54

0.69

0.72

0.75

0.63

0.72

0.75

0.1

0.65

0.46

0.62

0.65

0.70

0.55

0.64

0.70

0.15

0.62

0.43

0.60

0.62

0.65

0.53

0.62

0.65

1

SARA 2

Trial Scenario: 3 Sites, p1 = 0.3, Optimal Allocation

3.4.2

Scenario 2: No Interaction, 6 Sites, p1 = 0.3

The mean total number of treatment successes for Scenario 2 are displayed in Table 3.6. When
the effect size is null and smaller values of inter-site standard deviation (σ = 0, 0.05), the five
methods are comparable with respect to the expected number of treatment successes and variability,
with slightly lower variability for SARA 2. For larger values of σ, the adaptive designs have a modest
improvement in treatment successes compared to the balanced case. SARA 2 has lower variability
than all other methods while RA randomization has the highest variability. When the effect size
is increased to 10%, the adaptive designs all produce greater expected treatment successes than
the balanced case, however, RA randomization has slightly more treatment successes than the
other methods. The CARA/SARA designs have lower variability in treatment successes than RA
randomization, with more improvement for the SARA approaches. Specifically, SARA 2 has the
lowest variability compared to all other designs, including the BC, particularly as σ increases. For
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an effect size of 15%, the adaptive designs result in more treatment successes than the balanced
case, with more improvement for RA randomization. The variability in treatment successes for the
RA method is higher than all other approaches. When there is no inter-site standard deviation, the
CARA/SARA designs perform similarly in terms of treatment success and variability. However, as
σ increases, SARA 2 results in slightly more treatment successes yet maintains similar variability
compared to CARA/SARA 1, while SARA 1 has slightly lower improvement in expected successes.
Overall, as the inter-site standard deviation increases, there is an increase in expected treatment
successes along with a greater increase in the variability in treatment successes for all methods,
particularly for null and small effect sizes.
Table 3.6: Scenario 2 - Mean Total Number of Treatment Successes (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

6

0.3

0

0

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

175.9 (11.2)

176.1 (10.7)

(n=587)

0.05

176.3 (14.1)

176.6 (14.1)

176.5 (14.2)

176.5 (14.1)

176.0 (13.5)

0.1

176.3 (20.8)

177.4 (21.1)

177.2 (20.8)

177.2 (20.7)

177.1 (19.8)

0.15

176.9 (27.7)

179.1 (28.6)

178.7 (27.8)

178.6 (27.7)

178.9 (26.7)

0.1

0

146.6 (10.6)

151.1 (14.3)

149.8 (10.9)

149.5 (10.7)

150.1 (10.2)

(n=587)

0.05

146.9 (13.6)

151.6 (16.9)

150.4 (14.4)

150.0 (13.8)

149.8 (13.2)

0.1

147.3 (20.2)

152.6 (23.2)

151.4 (21.1)

151.0 (20.5)

151.6 (19.5)

0.15

149.4 (27.0)

155.5 (30.1)

154.1 (27.9)

153.8 (27.7)

154.3 (25.9)

1

0.15

0

54.2 (6.7)

59.1 (9.1)

57.5 (7.0)

57.2 (6.9)

57.6 (6.8)

(n=241)

0.05

54.1 (7.2)

59.1 (9.9)

57.4 (7.8)

57.1 (7.7)

58.0 (7.7)

0.1

54.6 (9.2)

59.9 (11.5)

58.2 (9.8)

57.9 (9.8)

58.5 (9.7)

0.15

56.0 (11.4)

61.0 (13.5)

59.3 (12.0)

59.1 (12.0)

59.9 (12.0)

Trial Scenario: 6 Sites, p1 = 0.3, Optimal Allocation

The allocation proportions are displayed in Table 3.7. For a null effect size, the five approaches
have comparable allocation proportions. The CARA/SARA approaches have lower variability
in allocation ratios than RA randomization, with SARA 2 closer to the BC for smaller σ. When

83

δ = 0.10, the adaptive designs have larger allocation ratios relative to the BC, with the improvement
lower for the CARA/SARA 1/SARA 2 designs than that of the RA method. However, a trend
emerges where SARA 2 results in slightly more adaptation than SARA 1. The CARA/SARA
1/SARA 2 designs are less variable than the RA approach, though there is less improvement for
CARA. For an effect size of 15%, the pattern is similar to a small effect size, where the adaptive
designs result in slightly more adaptation, with less improvement for the CARA/SARA 1/SARA
2 designs. The CARA/SARA 2 approaches have slightly higher allocation ratios but the SARA
1/SARA 2 designs maintain lower variability. The RA method has more than double the variability
in allocation ratios across all effect sizes. The amount of inter-site standard deviation does not affect
the allocation ratios, though there is a marginal increase in the variability in allocation proportions
as σ increases.
Table 3.7: Scenario 2 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

6

0.3

0

0

0.50 (0.02)

0.50 (0.13)

0.50 (0.06)

0.50 (0.04)

0.50 (0.03)

(n=587)

0.05

0.50 (0.02)

0.49 (0.12)

0.50 (0.04)

0.50 (0.04)

0.50 (0.03)

0.1

0.50 (0.02)

0.50 (0.14)

0.50 (0.05)

0.50 (0.04)

0.50 (0.04)

0.15

0.50 (0.02)

0.49 (0.15)

0.50 (0.06)

0.50 (0.05)

0.50 (0.05)

0.1

0

0.50 (0.02)

0.58 (0.17)

0.55 (0.06)

0.55 (0.03)

0.56 (0.03)

(n=587)

0.05

0.50 (0.02)

0.57 (0.17)

0.55 (0.06)

0.55 (0.04)

0.55 (0.04)

0.1

0.50 (0.02)

0.57 (0.17)

0.55 (0.07)

0.55 (0.05)

0.56 (0.05)

0.15

0.50 (0.02)

0.56 (0.18)

0.55 (0.07)

0.55 (0.06)

0.55 (0.06)

0.15

0

0.50 (0.03)

0.63 (0.19)

0.59 (0.07)

0.58 (0.06)

0.59 (0.05)

(n=241)

0.05

0.50 (0.03)

0.63 (0.18)

0.59 (0.07)

0.58 (0.06)

0.59 (0.06)

0.1

0.50 (0.03)

0.63 (0.19)

0.59 (0.08)

0.58 (0.07)

0.59 (0.07)

0.15

0.50 (0.03)

0.62 (0.19)

0.58 (0.08)

0.57 (0.07)

0.58 (0.07)

1

Trial Scenario: 6 Sites, p1 = 0.3, Optimal Allocation

The empirical type I error and power results are displayed in Table 3.8. For δ = 0, the the
type I error rate increases as the amount of inter-site variability increases. For smaller σ, the five
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methods perform similarly, with slight improvement for SARA 2. However, as σ increases, the RA
design controls the type I error rate better than all of the other approaches which perform similarly.
For δ = 0.10, the RA design has a notable loss of power compared to all other methods. SARA 2
has higher power than balanced allocation in all cases while the CARA/SARA 1 designs perform
similarly and gain back most of the power lost. For δ = 0.15, the CARA approach outperforms all
other methods when there is no inter-site variability. However, as σ increases, the SARA designs
perform similarly to balanced randomization, with slight improvement for SARA 2. In all cases,
RA randomization has the lowest power compared to the other allocation designs. Overall, as σ
increases, there is a notable loss of power for all five approaches.
For a null effect size under the GLM/GLMM approach, SARA 2 has the smallest type I error
rate that is slightly below 0.05 when there is no inter-site variability. However, the other adaptive
designs perform marginally better with increasing σ, particularly RA randomization. For δ = 0.10,
the results are comparable to the naive approach where SARA 2 has the highest power and the
CARA/SARA 1 designs gain back most of the power lost with the RA method. For δ = 0.15,
the CARA/SARA methods perform similarly to balanced allocation, but improvement in is more
notable for SARA 2.
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Table 3.8: Scenario 2 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

CARA

SARA 1

6

0.3

0

0

0.06

0.06

0.06

0.06

0.05

0.06

0.06

0.04

(n=587)

0.05

0.12

0.11

0.12

0.12

0.11

0.13

0.12

0.11

0.1

0.28

0.24

0.26

0.27

0.27

0.27

0.27

0.29

0.15

0.43

0.40

0.42

0.43

0.42

0.44

0.43

0.44

0.1

0

0.78

0.68

0.78

0.79

0.84

0.78

0.78

0.84

(n=587)

0.05

0.73

0.64

0.73

0.72

0.75

0.72

0.72

0.75

0.1

0.65

0.58

0.65

0.65

0.69

0.65

0.66

0.70

0.15

0.64

0.54

0.63

0.63

0.67

0.64

0.64

0.67

0.15

0

0.80

0.61

0.81

0.80

0.80

0.79

0.80

0.80

(n=241)

0.05

0.76

0.58

0.76

0.76

0.76

0.74

0.75

0.76

0.1

0.68

0.50

0.68

0.68

0.70

0.68

0.68

0.71

0.15

0.62

0.47

0.60

0.62

0.63

0.62

0.62

0.65

1

SARA 2

Trial Scenario: 6 Sites, p1 = 0.3, Optimal Allocation

3.4.3

Scenario 3: No Interaction, 3 Sites, p1 = 0.5

The mean total number of treatment successes for Scenario 3 are displayed in Table 3.9. When
the effect size is null and there is no inter-site variability, the five methods perform similarly with
respect to both the expected total number of treatment successes and the variability in successes.
However, for larger values of σ, there is an increase in treatment successes for the RA/CARA/SARA
1 designs and a slight decrease in successes for SARA 2, relative to the BC. All methods have similar
variability in treatment successes. When the effect size is increased to 10%, the adaptive methods
increase the expected treatment successes relative to the BC and they maintain similar variability.
As the amount of inter-site standard deviation increases, there is slightly less improvement in
treatment successes for SARA 2. For δ = 0.15, the pattern is similar to a small effect size, where
the adaptive approaches result in more treatment successes relative to balanced randomization.
When σ = 0, SARA 2 results in slightly more treatment successes than the other adaptive designs
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but maintains similar variability in expected successes. For σ = 0.05, 0.1, the adaptive designs
perform similarly in terms of treatment successes, but SARA 2 has slightly lower variability. When
σ = 0.15, the SARA designs result in slightly lower expected treatment success relative to the
RA/CARA approaches, but SARA 3 has lower variability than all other methods, including BC.
Overall, there is an increase in the expected streamline successes along with a greater increase in
the variability in treatment successes as the amount of inter-site variability increases.
Table 3.9: Scenario 3 - Mean Total Number of Treatment Successes (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

3

0.5

0

0

387.5 (13.9)

387.5 (13.9)

387.5 (13.9)

387.5 (13.9)

387.8 (13.9)

(n=775)

0.05

389.1 (20.9)

389.4 (20.9)

389.4 (20.9)

389.4 (20.9)

387.3 (21.0)

0.1

389.7 (34.1)

391.0 (34.2)

391.0 (33.9)

391.0 (33.9)

388.1 (33.9)

0.15

390.3 (48.6)

393.2 (48.7)

393.3 (48.3)

393.2 (48.2)

389.8 (48.4)

0.1

0

348.9 (14.1)

351.2 (14.1)

351.2 (14.1)

351.0 (14.0)

351.4 (14.0)

(n=775)

0.05

349.3 (21.1)

352.1 (21.2)

352.2 (21.2)

352.0 (21.1)

350.9 (21.4)

0.1

350.6 (34.4)

354.5 (34.8)

354.5 (34.4)

354.3 (34.4)

351.3 (34.4)

0.15

351.7 (49.0)

357.8 (49.7)

357.8 (49.2)

357.3 (48.8)

353.3 (48.8)

0.15

0

143.9 (9.1)

146.3 (9.4)

146.3 (9.2)

146.1 (9.1)

147.0 (9.0)

(n=339)

0.05

143.8 (11.6)

146.4 (11.9)

146.4 (11.7)

146.1 (11.5)

146.3 (10.9)

0.1

143.7 (16.9)

146.9 (17.3)

146.9 (17.0)

146.6 (16.9)

146.5 (16.0)

0.15

144.0 (22.9)

148.5 (23.3)

148.4 (23.2)

147.8 (23.0)

147.5 (22.3)

1

Trial Scenario: 3 Sites, p1 = 0.5, Optimal Allocation

The allocation proportions are displayed in Table 3.10. For a null effect size, all five approaches
have the same allocation proportion. The two SARA designs have lower variability similar to the
BC compared to the other adaptive approaches. When δ = 0.10, the adaptive methods all share a
larger allocation ratio relative to the BC but the SARA approaches are maintaining less variability
than RA/CARA. For an effect size of 15%, the adaptive methods have higher allocation ratios,
though the improvement is lower for SARA 1/SARA 2. The SARA designs have lower variability
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compared to the other adaptive approaches, with slightly more improvement for SARA 2 in some
cases. The amount of inter-site standard deviation does not affect the allocation proportions and
only has the slightest of effects in the variability in allocation.
Table 3.10: Scenario 3 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

3

0.5

0

0

0.50 (0.02)

0.50 (0.03)

0.50 (0.03)

0.50 (0.02)

0.50 (0.02)

(n=775)

0.05

0.50 (0.02)

0.50 (0.04)

0.50 (0.04)

0.50 (0.02)

0.50 (0.02)

0.1

0.50 (0.02)

0.50 (0.05)

0.50 (0.04)

0.50 (0.03)

0.50 (0.03)

0.15

0.50 (0.02)

0.50 (0.06)

0.50 (0.05)

0.50 (0.04)

0.50 (0.04)

0.1

0

0.50 (0.02)

0.53 (0.04)

0.53 (0.04)

0.53 (0.02)

0.53 (0.02)

(n=775)

0.05

0.50 (0.02)

0.53 (0.05)

0.53 (0.04)

0.53 (0.03)

0.53 (0.03)

0.1

0.50 (0.02)

0.53 (0.05)

0.53 (0.04)

0.53 (0.03)

0.53 (0.03)

0.15

0.50 (0.02)

0.53 (0.07)

0.53 (0.06)

0.53 (0.04)

0.53 (0.04)

0.15

0

0.50 (0.03)

0.55 (0.07)

0.55 (0.06)

0.54 (0.04)

0.54 (0.03)

(n=339)

0.05

0.50 (0.03)

0.55 (0.08)

0.55 (0.06)

0.54 (0.04)

0.54 (0.04)

0.1

0.50 (0.03)

0.55 (0.08)

0.55 (0.06)

0.54 (0.04)

0.55 (0.04)

0.15

0.50 (0.03)

0.55 (0.10)

0.55 (0.08)

0.55 (0.06)

0.55 (0.05)

1

Trial Scenario: 3 Sites, p1 = 0.5, Optimal Allocation

The empirical type I error and power results are displayed in Table 3.11. For δ = 0, the
five approaches perform similarly where the type I error rate increases as the amount of inter-site
variability increases. SARA 2 appears to control the type I error rate slightly better than the other
methods. For small and medium effect sizes, there is a loss of power for all five methods with
the presence of inter-site variability. For δ = 0.10, five approaches are comparable, with slightly
lower power for the the BC/RA approaches when there is no inter-site variability and slightly
higher power for SARA 2 as σ increases. For δ = 0.15, the pattern is similar to a small effect size
but more pronounced. When there is no inter-site variability, the BC/CARA/SARA approaches
perform comparably, whereas the RA design has a loss of power relative to the other designs. As
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σ increases, the CARA/SARA approaches gain back the power lost with RA randomization, with
SARA 2 outperforming all other methods.
For a null effect size, the type I error results from the GLM/GLMM are comparable to the
naive approach. For δ = 0.10, the SARA approaches have slightly higher power when σ = 0
while RA randomization has the lowest power as σ increases. For an effect size of 15%, the results
for empirical power are comparable to the naive approach, where SARA 2 outperforms all other
methods with increasing amounts of inter-site standard deviation.
Table 3.11: Scenario 3 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

CARA

SARA 1

3

0.5

0

0

0.06

0.05

0.06

0.05

0.04

0.06

0.05

0.04

(n=775)

0.05

0.20

0.20

0.21

0.20

0.20

0.20

0.20

0.19

0.1

0.45

0.45

0.45

0.45

0.42

0.45

0.46

0.42

0.15

0.59

0.58

0.58

0.58

0.57

0.58

0.58

0.59

0.1

0

0.78

0.78

0.79

0.79

0.79

0.78

0.79

0.79

(n=775)

0.05

0.72

0.71

0.72

0.71

0.70

0.71

0.72

0.70

0.1

0.66

0.65

0.65

0.65

0.66

0.66

0.66

0.66

0.15

0.69

0.68

0.68

0.68

0.69

0.69

0.69

0.70

0.15

0

0.80

0.78

0.80

0.80

0.80

0.79

0.80

0.80

(n=339)

0.05

0.74

0.72

0.74

0.75

0.77

0.73

0.75

0.77

0.1

0.69

0.66

0.68

0.68

0.71

0.66

0.68

0.71

0.15

0.65

0.62

0.65

0.65

0.68

0.65

0.66

0.69

1

SARA 2

Trial Scenario: 3 Sites, p1 = 0.5, Optimal Allocation

3.4.4

Scenario 4: No Interaction, 6 Sites, p1 = 0.5

The mean total number of treatment successes for Scenario 4 are displayed in Table 3.12.
When the effect size is null, the five approaches are comparable, with a slight increase in the
average total number of treatment successes for the adaptive designs as the amount of inter-site
standard deviation increases. There is a slight decrease in variability for the RA/CARA/SARA
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1 designs relative to the balanced case. For δ = 0.10, the adaptive designs have more expected
successes than the balanced case, however, the improvement is slightly lower for SARA 2 compared
to the RA/CARA/SARA 1 designs, particularly with increasing inter-site standard deviation. The
variability in treatment successes is comparable for all of the methods. For an effect size of 15%, the
adaptive designs result in more treatment successes than the BC, with slightly more improvement
for SARA 2 when there is no inter-site variability. The variability in expected treatment successes is
similar for all five methods. Overall, the variability in treatment successes increases as σ increases.
Table 3.12: Scenario 4 - Mean Total Number of Treatment Successes (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

6

0.5

0

0

387.5 (13.9)

387.5 (13.9)

387.5 (13.9)

387.5 (13.9)

387.8 (13.9)

(n=775)

0.05

387.0 (17.6)

387.2 (17.4)

387.2 (17.5)

387.2 (17.5)

387.5 (17.9)

0.1

386.8 (25.9)

387.6 (25.7)

387.6 (25.7)

387.6 (25.7)

387.4 (26.1)

0.15

386.8 (35.5)

388.4 (35.3)

388.4 (35.3)

388.3 (35.3)

387.7 (35.9)

0.1

0

348.9 (14.1)

351.1 (14.0)

351.2 (14.1)

351.0 (14.0)

351.4 (14.0)

(n=775)

0.05

347.9 (18.1)

350.6 (18.1)

350.5 (18.4)

350.5 (18.0)

350.7 (17.3)

0.1

348.1 (26.4)

351.9 (26.9)

351.7 (26.2)

351.5 (26.2)

351.1 (25.9)

0.15

348.3 (35.8)

353.2 (36.3)

352.8 (35.5)

352.6 (35.5)

351.7 (36.1)

0.15

0

143.9 (9.1)

146.2 (9.1)

146.3 (9.4)

146.1 (9.1)

147.0 (9.0)

(n=339)

0.05

143.8 (10.2)

146.2 (10.3)

146.6 (10.7)

146.1 (10.3)

146.3 (10.6)

0.1

144.1 (13.3)

147.1 (13.4)

146.8 (13.3)

146.7 (13.3)

146.7 (13.4)

0.15

144.2 (17.1)

147.6 (17.3)

147.4 (17.3)

147.2 (17.2)

147.3 (17.3)

1

Trial Scenario: 6 Sites, p1 = 0.5, Optimal Allocation

The allocation proportions are displayed in Table 3.13. For δ = 0, the five methods have comparable allocation proportions. The SARA 1/SARA 2 approaches have similarly lower variability
in allocation while the RA/CARA designs have comparably higher variability. When the effect
size is increased to 10%, the adaptive designs result in larger allocation ratios compared to the balanced case. The SARA designs have lower variability than the RA/CARA methods, with marginal
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improvement for SARA 1 in some cases. For δ = 0.15, the pattern is similar to a small effect
size, however, the improvement in allocation for the adaptive approaches is marginally lower for
SARA 1/SARA 2 compared to the RA/CARA. The SARA 1/SARA 2 approaches have similarly
lower variability in allocation proportions compared to the other adaptive designs. The amount of inter-site standard deviation does not affect the allocation proportions or the variability in
allocation.
Table 3.13: Scenario 4 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

6

0.5

0

0

0.50 (0.02)

0.50 (0.02)

0.50 (0.03)

0.50 (0.02)

0.50 (0.02)

(n=775)

0.05

0.50 (0.02)

0.50 (0.03)

0.50 (0.05)

0.50 (0.02)

0.50 (0.02)

0.1

0.50 (0.02)

0.50 (0.05)

0.50 (0.03)

0.50 (0.03)

0.50 (0.03)

0.15

0.50 (0.02)

0.50 (0.05)

0.50 (0.03)

0.50 (0.03)

0.50 (0.03)

0.1

0

0.50 (0.02)

0.53 (0.02)

0.53 (0.04)

0.53 (0.02)

0.53 (0.02)

(n=775)

0.05

0.50 (0.02)

0.53 (0.03)

0.53 (0.06)

0.53 (0.02)

0.53 (0.03)

0.1

0.50 (0.02)

0.53 (0.07)

0.53 (0.04)

0.53 (0.03)

0.53 (0.03)

0.15

0.50 (0.02)

0.53 (0.07)

0.53 (0.04)

0.53 (0.03)

0.53 (0.04)

0.15

0

0.50 (0.03)

0.55 (0.04)

0.55 (0.07)

0.54 (0.04)

0.54 (0.04)

(n=339)

0.05

0.50 (0.03)

0.55 (0.04)

0.55 (0.08)

0.54 (0.04)

0.54 (0.04)

0.1

0.50 (0.03)

0.55 (0.07)

0.55 (0.04)

0.54 (0.04)

0.54 (0.04)

0.15

0.50 (0.03)

0.55 (0.08)

0.55 (0.05)

0.54 (0.05)

0.54 (0.05)

1

Trial Scenario: 6 Sites, p1 = 0.5, Optimal Allocation

The empirical type I error and power results are displayed in Table 3.14. For a null effect size,
the five methods perform similarly where the type I error rate increases as the amount of inter-site
standard deviation increases. When σ = 0, the adaptive designs control the type I error rate better,
with marginal improvement for SARA 2. When the effect size is increased to 10%, SARA 1 gains
back most of the power lost relative to the other adaptive designs. For δ = 0.15, the RA/CARA
designs have slightly lower power compared to the other designs when σ is small. As σ increases,
the five methods perform more similarly. Overall, there is a notable loss of power for all approaches
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as σ increases.
For a null effect size, the type I error results from the GLM/GLMM approach are comparable
to the naive approach, where there is an inflation in the type I error rate as σ increases. When
σ = 0, the RA/SARA designs control the type I error rate better, with minimal improvement for
SARA 2. For δ = 0.10, the five methods perform similarly, with a loss of power for SARA 2 relative
to the other designs with increasing inter-site variability. For δ = 0.15, there is a loss of power for
RA randomization compared to the other designs with increasing σ. This coincides with marginal
improvement in power for the CARA/SARA 1 methods.
Table 3.14: Scenario 4 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

CARA

SARA 1

6

0.5

0

0

0.06

0.05

0.05

0.05

0.04

0.06

0.05

0.04

(n=775)

0.05

0.14

0.13

0.14

0.14

0.13

0.13

0.14

0.14

0.1

0.31

0.31

0.31

0.31

0.31

0.32

0.32

0.31

0.15

0.45

0.45

0.44

0.45

0.46

0.46

0.46

0.48

0.1

0

0.78

0.79

0.78

0.79

0.79

0.79

0.79

0.79

(n=775)

0.05

0.78

0.76

0.76

0.77

0.76

0.77

0.77

0.77

0.1

0.69

0.69

0.69

0.70

0.67

0.70

0.70

0.68

0.15

0.68

0.67

0.67

0.68

0.65

0.68

0.67

0.65

0.15

0

0.80

0.79

0.78

0.80

0.80

0.80

0.80

0.80

(n=339)

0.05

0.76

0.75

0.73

0.76

0.76

0.74

0.76

0.76

0.1

0.71

0.69

0.71

0.70

0.70

0.72

0.71

0.70

0.15

0.67

0.66

0.67

0.68

0.66

0.69

0.69

0.67

1

SARA 2

Trial Scenario: 6 Sites, p1 = 0.5, Optimal Allocation

3.4.5

Scenario 5: No Interaction, 3 Sites, p1 = 0.7

The mean total number of treatment successes for Scenario 5 are displayed in Table 3.15. When
the effect size is null and there is little to no inter-site standard deviation, the five approaches
perform similarly with respect to he expected number of treatment successes and the variability
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in treatment successes. As σ increases, the adaptive designs result in more treatment successes
relative to the balanced case, however, the variability remains comparable for all methods. For an
effect size of 10%, the adaptive designs result in more treatment successes than the balanced case.
The variability in treatment successes is similar for all methods expect for SARA 2, where there is
slightly more variability in successes as σ increases relative to the other approaches. For δ = 0.15,
the adaptive designs increase the expected treatment successes relative to the BC, however the
improvement is slightly lower for SARA 2. The variability in treatment successes is comparable
for all five methods. Overall, as σ increases, there is a substantial increase in the variable in
treatment successes. For balanced randomization, there is a slight decrease in the average total
number of successes as the amount of inter-site standard deviation increases due to the nature of
the distribution of high success probabilities being left skewed (more mass below 0.7 since right
truncated at 1).
Table 3.15: Scenario 5 - Mean Total Number of Treatment Successes (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

3

0.7

0

0

498.3 (12.5)

498.3 (12.5)

498.3 (12.5)

498.3 (12.5)

498.9 (12.0)

(n=712)

0.05

498.4 (19.2)

498.6 (19.2)

498.6 (19.2)

498.6 (19.2)

498.5 (19.1)

0.1

498.3 (31.1)

499.2 (31.1)

499.2 (31.1)

499.2 (31.1)

499.2 (31.0)

0.15

497.2 (43.4)

499.1 (43.3)

499.2 (43.5)

499.1 (43.4)

499.1 (44.0)

0.1

0

462.6 (13.1)

464.0 (13.1)

464.0 (13.2)

464.0 (13.1)

464.5 (12.3)

(n=712)

0.05

463.0 (19.2)

464.6 (19.2)

464.7 (19.2)

464.6 (19.2)

464.3 (19.5)

0.1

462.8 (31.0)

465.1 (30.9)

465.2 (30.9)

465.1 (30.9)

464.4 (31.4)

0.15

461.9 (44.0)

465.5 (43.7)

465.7 (43.8)

465.5 (43.8)

465.3 (44.3)

0.15

0

203.8 (8.3)

205.3 (8.3)

205.3 (8.3)

205.3 (8.3)

204.0 (8.6)

(n=325)

0.05

203.2 (10.9)

204.7 (10.9)

204.7 (10.9)

204.7 (10.9)

204.1 (10.7)

0.1

202.9 (16.1)

204.8 (15.7)

204.8 (15.8)

204.7 (15.8)

204.1 (16.0)

0.15

202.7 (21.6)

205.2 (21.1)

205.4 (21.2)

205.2 (21.2)

204.7 (21.5)

1

Trial Scenario: 3 Sites, p1 = 0.7, Optimal Allocation
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The allocation proportions are displayed in Table 3.16. For δ = 0, the five approaches have
comparable allocation proportions and variability, particularly as the amount of inter-site standard
deviation increases. The CARA has slightly more variability than the other designs for smaller
σ. When δ = 0.10, the adaptive designs have a larger allocation ratio relative to balanced randomization. For smaller σ, CARA has slightly more variability compared to all other approaches.
However, as σ increases the SARA designs have slightly lower variability than the other adaptive
approaches, closer to the balanced case. For an effect size of 15%, the pattern is similar to a small
effect size where adaptive methods share a higher allocation ratio relative to balanced randomization. All five methods have comparable variability in allocation when the amount of inter-site
standard deviation is small. However, the adaptive designs are more variable than the BC for larger
σ, though CARA has slightly more variability than the other adaptive approaches.
Table 3.16: Scenario 5 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

3

0.7

0

0

0.50 (0.02)

0.50 (0.02)

0.50 (0.03)

0.50 (0.02)

0.50 (0.02)

(n=712)

0.05

0.50 (0.02)

0.50 (0.02)

0.50 (0.03)

0.50 (0.02)

0.50 (0.02)

0.1

0.50 (0.02)

0.50 (0.03)

0.50 (0.03)

0.50 (0.02)

0.50 (0.02)

0.15

0.50 (0.02)

0.50 (0.03)

0.50 (0.03)

0.50 (0.03)

0.50 (0.03)

0.1

0

0.50 (0.02)

0.52 (0.02)

0.52 (0.03)

0.52 (0.02)

0.52 (0.02)

(n=712)

0.05

0.50 (0.02)

0.52 (0.02)

0.52 (0.03)

0.52 (0.02)

0.52 (0.02)

0.1

0.50 (0.02)

0.52 (0.03)

0.52 (0.03)

0.52 (0.03)

0.52 (0.03)

0.15

0.50 (0.02)

0.52 (0.04)

0.52 (0.04)

0.52 (0.03)

0.52 (0.03)

0.15

0

0.50 (0.03)

0.53 (0.03)

0.53 (0.03)

0.53 (0.03)

0.53 (0.03)

(n=325)

0.05

0.50 (0.03)

0.53 (0.03)

0.53 (0.03)

0.53 (0.03)

0.53 (0.03)

0.1

0.50 (0.03)

0.53 (0.04)

0.53 (0.04)

0.53 (0.04)

0.53 (0.04)

0.15

0.50 (0.03)

0.53 (0.04)

0.53 (0.05)

0.53 (0.04)

0.53 (0.04)

1

Trial Scenario: 3 Sites, p1 = 0.7, Optimal Allocation

The empirical type I error and power results are displayed in Table 3.17. For a null effect size,
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the five methods perform similarly where the type I error rate increases with increasing inter-site
standard deviation. As σ increases, there is a slight improvement in the type I error rate for the
adaptive designs, particularly SARA 2, compared to the balanced case. When the effect size is
increased to 10%, there is a negligible loss of power for the adaptive designs relative to balanced
allocation, with less improvement for SARA 2. As σ increases, the adaptive designs maintain
similar, and in some cases more, power relative to the balanced case. There is a modest increase
in performance for SARA 2. For δ = 0.15, the adaptive designs outperform the balanced case for
smaller values of inter-site variability. As σ increases, the adaptive designs lose their advantage
and perform similarly to the BC. Overall, for small and medium effect sizes, there is loss of power
for all methods as the amount of inter-site variability increases.
For a null effect size, the results from the GLM/GLMM are similar to the naive approach.
When the amount of inter-site variability is large, the RA/SARA 2 designs have lower type I
error rates but this improvement is more notable for SARA 2. For δ = 0.10, the pattern is more
pronounced relative to the naive results, where the adaptive designs have less power when σ = 0,
but outperform the balanced case as σ increases. SARA 2 has the highest power in the presence
of the most inter-site variability. For an effect size of 15%, the pattern is similar to the naive
results where the adaptive methods outperform the balanced allocation for smaller σ, particularly
the RA/SARA 2 designs. For larger σ, the five methods perform more comparably to the balanced
case.
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Table 3.17: Scenario 5 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

CARA

SARA 1

3

0.7

0

0

0.06

0.06

0.06

0.06

0.05

0.06

0.05

0.05

(n=712)

0.05

0.23

0.21

0.22

0.22

0.22

0.22

0.22

0.22

0.1

0.45

0.45

0.45

0.45

0.45

0.46

0.46

0.45

0.15

0.62

0.61

0.61

0.61

0.58

0.62

0.62

0.59

0.1

0

0.81

0.80

0.80

0.80

0.79

0.80

0.80

0.79

(n=712)

0.05

0.71

0.71

0.71

0.71

0.72

0.72

0.72

0.72

0.1

0.67

0.67

0.67

0.67

0.67

0.68

0.68

0.68

0.15

0.67

0.68

0.68

0.68

0.70

0.69

0.68

0.71

0.15

0

0.80

0.82

0.82

0.81

0.82

0.81

0.81

0.82

(n=325)

0.05

0.72

0.74

0.73

0.73

0.77

0.73

0.73

0.76

0.1

0.68

0.68

0.68

0.68

0.68

0.69

0.69

0.68

0.15

0.67

0.67

0.66

0.66

0.66

0.67

0.67

0.67

1

SARA 2

Trial Scenario: 3 Sites, p1 = 0.7, Optimal Allocation

3.4.6

Scenario 6: No Interaction, 6 Sites, p1 = 0.7

The mean total number of treatment successes for Scenario 6 are displayed in Table 3.18. When
the effect size is null, the BC/RA/CARA/SARA 1 methods perform similarly with respect to both
the expected total number of treatment successes and the variability in successes. When there is no
inter-site standard deviation, SARA 2 results in slightly more treatment successes while maintaining
lower variability compared to all other approaches. However, as σ increases, the adaptive designs
result in slightly more treatment successes while maintaining similar variability relative to the
balanced case. There is slightly less improvement in both treatment successes and variability for
SARA 2. When the effect size is increased to 10%, the RA/CARA/SARA 1 methods increase the
expected treatment successes relative to the BC and they maintain the same variability. There is
negligible improvement in treatment successes for SARA 2 compared to balanced randomization.
For δ = 0.15, the pattern is similar to a small effect size, where the RA/CARA/SARA 1 approaches
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result in more treatment successes and comparable variability relative to balanced allocation. There
is a marginal improvement in expected successes for SARA 2 compared to the BC, particularly as
the amount of inter-site standard deviation increases. In addition, the variability in treatment
successes for SARA 2 is slightly higher than the variability for all other methods.
Table 3.18: Scenario 6 - Mean Total Number of Treatment Successes (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

6

0.7

0

0

498.3 (12.5)

498.3 (12.5)

498.3 (12.5)

498.3 (12.5)

498.9 (12.0)

(n=712)

0.05

499.0 (16.0)

499.1 (16.0)

499.1 (16.0)

499.1 (16.0)

498.0 (15.8)

0.1

498.8 (23.8)

499.3 (23.7)

499.3 (23.7)

499.3 (23.7)

498.1 (23.8)

0.15

497.5 (32.5)

498.4 (32.4)

498.4 (32.4)

498.4 (32.4)

497.8 (32.5)

0.1

0

462.6 (13.1)

464.0 (13.1)

464.0 (13.2)

464.0 (13.1)

464.5 (12.3)

(n=712)

0.05

463.5 (16.5)

465.0 (16.4)

465.0 (16.4)

465.0 (16.4)

463.5 (16.5)

0.1

463.3 (24.4)

464.9 (24.3)

465.1 (24.3)

465.0 (24.3)

463.6 (24.3)

0.15

463.0 (32.6)

465.1 (32.6)

465.4 (32.6)

465.3 (32.6)

463.6 (33.2)

0.15

0

203.8 (8.3)

205.3 (8.3)

205.3 (8.3)

205.3 (8.3)

204.0 (8.6)

(n=325)

0.05

203.3 (9.7)

204.9 (9.6)

204.8 (9.7)

204.7 (9.7)

204.1 (9.9)

0.1

203.0 (12.6)

204.6 (12.4)

204.7 (12.3)

204.6 (12.4)

204.4 (12.7)

0.15

202.6 (15.9)

204.3 (15.7)

204.6 (15.7)

204.4 (15.7)

204.4 (16.5)

1

Trial Scenario: 6 Sites, p1 = 0.7, Optimal Allocation

The allocation proportions are displayed in Table 3.19. For δ = 0, the five approaches have
comparable performance. In some cases, the CARA/SARA 1/SARA 2 designs have a slight increase
in the amount of variability in allocation relative to the other methods. When δ = 0.10, the adaptive
designs have larger allocation ratios compared to the balanced case. When the amount of inter-site
standard deviation is low, CARA has more variability than all other approaches. However, as
we increase σ, there is an increase in the variability for all adaptive designs relative to the BC.
For δ = 0.15, the pattern is similar where the adaptive approaches have larger allocation ratios
compared to balanced randomization. As the amount of inter-site standard deviation increases,
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there is slightly more variability in allocation for RA randomization and, at some point, the other
adaptive designs.
Table 3.19: Scenario 6 - E[n1 /(n1 + n2 )] (Standard Error)
k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

6

0.7

0

0

0.50 (0.02)

0.50 (0.02)

0.50 (0.03)

0.50 (0.02)

0.50 (0.02)

(n=712)

0.05

0.50 (0.02)

0.50 (0.02)

0.50 (0.02)

0.50 (0.02)

0.50 (0.02)

0.1

0.50 (0.02)

0.50 (0.02)

0.50 (0.02)

0.50 (0.02)

0.50 (0.02)

0.15

0.50 (0.02)

0.50 (0.02)

0.50 (0.03)

0.50 (0.03)

0.50 (0.03)

0.1

0

0.50 (0.02)

0.52 (0.02)

0.52 (0.03)

0.52 (0.02)

0.52 (0.02)

(n=712)

0.05

0.50 (0.02)

0.52 (0.02)

0.52 (0.03)

0.52 (0.02)

0.52 (0.02)

0.1

0.50 (0.02)

0.52 (0.02)

0.52 (0.02)

0.52 (0.02)

0.52 (0.02)

0.15

0.50 (0.02)

0.52 (0.03)

0.52 (0.03)

0.52 (0.03)

0.52 (0.03)

0.15

0

0.50 (0.03)

0.53 (0.03)

0.53 (0.03)

0.53 (0.03)

0.53 (0.03)

(n=325)

0.05

0.50 (0.03)

0.53 (0.03)

0.53 (0.03)

0.53 (0.03)

0.53 (0.03)

0.1

0.50 (0.03)

0.53 (0.04)

0.53 (0.03)

0.53 (0.03)

0.53 (0.03)

0.15

0.50 (0.03)

0.53 (0.04)

0.53 (0.04)

0.53 (0.04)

0.53 (0.04)

1

Trial Scenario: 6 Sites, p1 = 0.7, Optimal Allocation

The empirical type I error and power results are displayed in Table 3.20. For δ = 0, there is a
notable inflation in the type I error rates as the inter-site standard deviation increases. When there
is no inter-site variability, there is an inflation in the type I error rate for all methods except for
SARA 2. However, as σ increases, there is an inflation in the type I error rate for SARA 2 while
the other methods perform comparably to balanced allocation. When δ = 0.10, SARA 2 has lower
power relative to the other approaches for smaller σ. For larger σ, the five methods have similar
power. When δ = 0.15, the five designs perform comparably, however, RA randomization has the
highest power for larger σ. Overall, there is a loss of power as the amount of inter-site variability
increases for small and medium effect sizes.
For a null effect size, SARA 1/SARA 2 are the only approaches that achieve nominal levels of
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type I error when there is no inter-site variability. As σ increases, the adaptive designs perform
similarly where there is in an inflation in the type I error rates relative to the BC, particularly
SARA 2. When δ = 0.10, the pattern is similar to the naive approach where SARA 2 has lower
power for smaller σ but the methods perform comparable as the inter-site variability increases. For
δ = 0.15, the adaptive designs have higher power than the balanced case for small and large σ,
otherwise all five methods perform comparably. SARA 2 consistently maintains the same, and in
some cases more, power than balanced allocation.
Table 3.20: Scenario 6 - Empirical Type I Error and Power
Naive

GLM/GLMM

k

p1

δ

σ

BC

RA

CARA

SARA 1

SARA 2

CARA

SARA 1

6

0.7

0

0

0.06

0.06

0.06

0.06

0.05

0.06

0.05

0.05

(n=712)

0.05

0.15

0.16

0.15

0.15

0.16

0.16

0.15

0.16

0.1

0.31

0.32

0.31

0.32

0.35

0.32

0.32

0.35

0.15

0.46

0.46

0.45

0.45

0.49

0.47

0.47

0.50

0.1

0

0.81

0.80

0.80

0.80

0.78

0.80

0.80

0.78

(n=712)

0.05

0.73

0.73

0.73

0.73

0.71

0.74

0.74

0.71

0.1

0.65

0.66

0.65

0.65

0.65

0.66

0.66

0.65

0.15

0.65

0.64

0.63

0.64

0.65

0.65

0.65

0.65

0.15

0

0.80

0.82

0.82

0.82

0.81

0.81

0.81

0.81

(n=325)

0.05

0.77

0.76

0.76

0.76

0.77

0.76

0.76

0.77

0.1

0.72

0.72

0.71

0.71

0.71

0.72

0.72

0.72

0.15

0.66

0.67

0.66

0.66

0.66

0.68

0.67

0.67

1

SARA 2

Trial Scenario: 6 Sites, p1 = 0.7, Optimal Allocation

3.4.7

Incorporating a Treatment-by-Site Interaction

In Section 3.4.7, we compare the mean total number of treatment successes (SE), the expected
allocation proportions for treatment group 1 (SE) and the empirical type I error and power for
SARA models 2 and 3 (Eqns. 3.1 & 3.3, respectively). We only report the operating characteristics
calculated using a frequentist GLMM (not a naive approach), which accounts for site-based response

99

variability using random site effects, to assess whether the approaches perform as intended. We
present several scenarios to compare the results when incorporating a random treatment-by-site
interaction effect into the adaptive design. The results are similar for additional scenarios found in
Appendix B.

Scenario: 3 sites, p1 = 0.3, δ = 0, 0.15
The mean total number of treatment success, allocation proportions and empirical type I error/power for a 30% treatment group 1 success probability are presented in Table 3.21. When the
effect size is null, the two SARA designs perform comparably when there is no inter-site variability.
However, as σ increases, there is a notable increase in expected treatment successes for SARA 3
without an increase in the variability in successes. For δ = 0.15, SARA 3 maintains more expected
successes and similar variability relative to SARA 2, particularly as σ increases.
Comparison: For a null effect size, SARA 3 outperforms all other allocation approaches with
respect to treatment successes and variability as σ increases (Table 3.3). When the effect size
increases to 15%, SARA 3 gains back most of the treatment successes lost with SARA 1/SARA
2 compared to RA/CARA, with less improvement for CARA. SARA 3 performs similarly to the
RA/CARA designs, but maintains a lower variability in successes that is comparable to BC/SARA
1/SARA 2.
For δ = 0, the two SARA designs perform comparably with respect to expected allocation
proportions and variability in allocation. When the effect size is increased to 15%, SARA 3 has a
slightly larger allocation ratio relative to SARA 2 but maintains similar variability in allocation.
Comparison: For a null effect size, the allocations ratios for SARA 3 are comparable to the
other approaches (Table 3.4). SARA 3 performs similarly to SARA 1/SARA 2 with respect to the
variability in allocation. For δ = 0.15, SARA 3 has slightly larger allocation ratios than SARA
1/SARA 2 that are closer to the RA/CARA designs. However, all three SARA designs have
comparable variability in allocation ratios that is lower than the RA/CARA approaches.
For a null effect size, the two SARA designs perform similarly where there is an inflation in
the type I error rate as the amount of inter-site variability increases. When σ is small the two
methods are comparable but as σ increases, SARA 3 has better control of the type I error rate. For
δ = 0.15, the two SARA approaches have the same power when there is no inter-site variability.
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As σ increases, there is a loss of power for SARA 3 compared to SARA 2.
Comparison: For δ = 0, SARA 2/SARA 3 perform comparably and have the lowest type I error
rates compared to the other approaches (Table 3.5) when the amount of inter-site variability is
small. However, as σ increases, the RA/SARA 2/SARA 3 approaches perform similarly and have
better control of the type I error rate, with less improvement with SARA 2. For δ = 0.15, the SARA
approaches have higher power than all other methods. SARA 2/SARA 3 have more improvement
when σ is small while SARA 2 outperforms the other designs with increasing inter-site variability.
Table 3.21: Scenario - 3 sites, p1 = 0.3, δ = 0, 0.15
SARA 2

SARA 3

k

p1

δ

σ

Successes

Proportion

Power

Successes

Proportion

Power

3

0.3

0

0

176.1 (10.7)

0.50 (0.03)

0.05

176.1 (10.7)

0.50 (0.03)

0.05

(n=587)

0.05

176.4 (16.6)

0.50 (0.03)

0.17

177.3 (16.6)

0.50 (0.04)

0.17

0.1

177.3 (26.9)

0.50 (0.05)

0.40

180.7 (26.8)

0.50 (0.05)

0.38

0.15

179.7 (37.6)

0.50 (0.06)

0.53

187.5 (37.6)

0.50 (0.07)

0.51

0.15

0

57.5 (6.7)

0.59 (0.05)

0.80

57.8 (6.8)

0.60 (0.06)

0.80

(n=241)

0.05

57.6 (8.2)

0.59 (0.06)

0.75

58.4 (8.3)

0.60 (0.06)

0.74

0.1

58.6 (11.6)

0.59 (0.07)

0.70

60.4 (11.7)

0.60 (0.08)

0.67

0.15

60.5 (15.4)

0.59 (0.09)

0.65

63.3 (15.6)

0.60 (0.09)

0.60

Scenario: 3 sites, p1 = 0.5, 0.7, δ = 0.15
The mean total number of treatment success, allocation proportions and empirical type I error/power for a large effect size (δ = 0.15) are presented in Table 3.22. For a 50% treatment group
1 success probability (p1 = 0.5), SARA 3 results in more expected treatment successes without an
increase in the variability in successes, particularly as σ increases. When the treatment group 1
success probability is increased to 70%, the pattern is comparable but the improvement becomes
notable for even larger σ.
Comparison: For p1 = 0.5, SARA 3 outperforms all other allocation approaches with respect to
expected treatment success, with more notable improvement as σ increases (Table 3.9). The SARA
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2/SARA 3 designs have less variability in treatment successes than all other methods, including
balanced allocation. For p1 = 0.7, SARA 3 has slightly lower treatment success but comparable
variability relative to the other adaptive designs (Table 3.15) when σ is small. However, as σ
increases, SARA 3 gains back the loss in treatment successes, outperforming all other approaches
and maintaining similar variability.
For p1 = 0.5, SARA 3 has slightly larger allocation ratios when the inter-site variability is
small, however, the two SARA designs perform similarly for larger σ. The variability in allocation
is comparable, with marginal improvement for SARA 2. When the success probability increases to
70%, the two approaches perform similarly with respect to allocation proportions and variability.
Comparison: For p1 = 0.5, SARA 3 gains back the slight loss in adaptation for the SARA
1/SARA 2 approaches relative to the RA/CARA designs (Table 3.10) for small σ. The SARA
methods all have less variability in allocation relative to the RA/CARA designs. For larger intersite variability, SARA 3 has similar allocation ratios to the RA/CARA approaches but maintains
lower variability similar to BC/SARA 1/SARA 2. When the treatment group 1 success probability
is increased to 70%, SARA 3 performs comparably to the other five approaches (Table 3.16) with
respect to allocation ratios and variability.
For a 50% treatment group 1 success probability, SARA 3 has slightly higher power than SARA
2 when there is no inter-site variability. However, as σ increases, there is a negligible loss of power
for SARA 3. For p1 = 0.7, there is a slight loss of power for SARA 3 which diminishes with
increasing σ.
Comparison: For p1 = 0.5, SARA 3 has the highest power relative to all other approaches
(Table 3.11) when there is no inter-site variability. As σ increases, the three SARA designs have
higher power compared to the other methods, with more improvement for SARA 2 and closely
followed by SARA 3. For p1 = 0.7, the RA/SARA 2 designs (Table 3.17) have the highest power
while balanced allocation has the lowest power for smaller values of σ. However, the six approaches
have similar power as σ increases.
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Table 3.22: Scenario - 3 sites, p1 = 0.5, 0.7, δ = 0.15
SARA 2

SARA 3

k

p1

δ

σ

Successes

Proportion

Power

Successes

Proportion

3

0.5

0.15

0

147.0 (9.0)

0.54 (0.03)

0.80

147.2 (8.9)

0.55 (0.04)

0.81

(n=339)

0.05

146.3 (10.9)

0.54 (0.04)

0.77

146.7 (10.9)

0.55 (0.04)

0.76

0.1

146.5 (16.0)

0.55 (0.04)

0.71

147.9 (15.9)

0.55 (0.05)

0.70

0.15

147.5 (22.3)

0.55 (0.05)

0.69

150.5 (22.0)

0.55 (0.06)

0.67

0.15

0

204.0 (8.6)

0.53 (0.03)

0.82

204.1 (8.5)

0.53 (0.03)

0.81

(n=325)

0.05

204.1 (10.7)

0.53 (0.03)

0.76

204.3 (10.8)

0.53 (0.03)

0.75

0.1

204.1 (16.0)

0.53 (0.04)

0.68

204.9 (16.0)

0.53 (0.04)

0.67

0.15

204.7 (21.5)

0.53 (0.04)

0.67

206.4 (21.3)

0.53 (0.04)

0.67

0.7

Power

Scenario: 6 sites, p1 = 0.3, δ = 0, 0.15
The mean total number of treatment success, allocation proportions and empirical type I error/power for a larger number of sites (k = 6) are presented in Table 3.23. When the effect size
is null, the two SARA designs perform comparably when there is no inter-site variability. As σ
increases, there is a notable increase in the mean total number of treatment successes for SARA 3
without an increase in the variability in expected successes. For δ = 0.15, the pattern is similar to
a null effect size where SARA 3 maintains more expected treatment successes without an increase
in the variability.
Comparison: For a null effect size, SARA 2/SARA 3 have the highest mean total number of
treatment successes and lowest variability when there is no inter-site variability. As σ increases,
SARA 3 outperforms all other approaches with respect to the expected treatment successes (Table
3.6), achieving an additional eight successes more than next best method (RA/SARA 2) on average.
SARA 2/SARA 3 achieve similar variability that is lower than all other designs. For δ = 0.15, SARA
3 results in slightly more treatment successes than the CARA/SARA 1/SARA 2 designs and is
closer to RA randomization when σ = 0. However, SARA 3 has more expected successes relative
to all other approaches but maintains similar variability to the CARA/SARA 1/SARA 2 designs.
The RA method has the highest variability in all cases.
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For δ = 0, the two SARA designs perform comparably with respect to the expected allocation
proportions and variability in allocation. When the effect size is increased to 15%, SARA 3 has a
larger allocation ratio relative to SARA 2 but stills maintains similarity variability in allocation.
Comparison: For a null effect size, the allocation ratios for SARA 3 are comparable to the other
approaches (Table 3.7), with similar variability in allocation to the CARA/SARA approaches. RA
randomization has slightly less adaptation relative to the other five approaches as σ increases.
For δ = 0.15, SARA 3 results in larger allocation ratios than the BC/CARA/SARA 1/SARA 2
approaches that are closer to RA allocation. However, the CARA/SARA designs maintains less
variability than the RA design.
For a null effect size, SARA 3 has slightly inflated type I error rates relative to SARA 2 when
the amount of inter-site variability is small. However, as σ increases, there is better control of the
type I error rate for SARA 3. For δ = 0.15, the two SARA approaches achieve similar power for
smaller values of inter-site variability, with marginal improvement for SARA 3. As σ increases,
there is a loss of power for SARA 3 relative to SARA 2.
Comparison: For δ = 0, SARA 2/SARA 3 perform comparably and have lower type I error
rates compared to the other approaches (Table 3.8) that are slightly inflated when there is no
inter-site variability. However, as σ increases, the RA/SARA 3 designs perform similarly and
have better control of the type I error rate than the other methods, with more improvement for
RA randomization. When the effect size is increased to 15%, the CARA/SARA approaches have
higher power than RA randomization. SARA 2/SARA 3 have more improvement when σ is small
while SARA 2 outperforms all other designs with increasing values of inter-site variability.
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Table 3.23: Scenario - 6 sites, p1 = 0.3, δ = 0, 0.15
SARA 2

SARA 3

k

p1

δ

σ

Successes

Proportion

Power

Successes

Proportion

6

0.3

0

0

176.1 (10.7)

0.50 (0.03)

0.04

176.1 (10.7)

0.50 (0.03)

0.05

(n=587)

0.05

176.0 (13.5)

0.50 (0.03)

0.11

177.0 (13.5)

0.50 (0.04)

0.12

0.1

177.1 (19.8)

0.50 (0.04)

0.29

180.8 (19.7)

0.50 (0.05)

0.27

0.15

178.9 (26.7)

0.50 (0.05)

0.44

186.6 (26.6)

0.50 (0.06)

0.41

3.4.8

Power

0.15

0

57.6 (6.8)

0.59 (0.05)

0.80

58.0 (6.8)

0.60 (0.06)

0.80

(n=241)

0.05

58.0 (7.7)

0.59 (0.06)

0.76

58.7 (7.8)

0.60 (0.06)

0.77

0.1

58.5 (9.7)

0.59 (0.07)

0.71

60.1 (9.8)

0.60 (0.07)

0.68

0.15

59.9 (12.0)

0.58 (0.07)

0.65

62.5 (12.2)

0.59 (0.07)

0.62

Simulation Time per Patient

The simulation times per patient are compared to explore the trade-off of fitting increasingly
complex SARA models and computation time when performing a simulation study.
Scenario: 3 sites, p1 = 0.3, δ = 0, 0.15
The results comparing null and medium effect sizes for three sites are displayed in Table 3.24.
For δ = 0, SARA 3 has the highest simulation times for all σ. The pattern is similar for an effect
size of 15%, however, the simulation times are generally lower. Although the times are reported
per patient, thus removing the effect of different sample sizes, scenarios with larger sample sizes
(δ = 0) have increased simulation times.
In a real life application, there would not be a notable difference in computation times across
the three adaptive designs as only one patient is adaptively randomized at a time for a single trial.
However, the computation times represent a significant burden when performing a simulation study
with n patients, 1000 trials and a variety of scenarios. For example, a simulated multi-center trial
with three sites, a 30% treatment group 1 success probability, no effect size or inter-site variability,
and 1000 trials takes approximately 53 hours for SARA 1 and 2518 hours to run using the SARA
3 approach. This equates to 0.34 and 15.98 seconds for SARA 1 and SARA 3, respectively, per
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patient adaptively randomized.
Table 3.24: Simulation Time (seconds) per Patient
k

p1

δ

σ

SARA 1

SARA 2

3

0.3

0

0

0.34

10.28

15.98

(n=587)

0.05

0.25

8.94

17.51

0.1

0.24

9.07

16.31

0.15

0.18

10.37

16.30

0.15

0

0.27

4.88

9.71

(n=241)

0.05

0.25

4.89

8.79

0.1

0.15

5.56

8.77

0.15

0.15

7.65

9.84

1

SARA 3

Trial Scenario - 3 sites, P1 = 0.3, δ = 0, 0.15

Scenario: 3 sites, p1 = 0.5, 0.7, δ = 0.15
The results comparing medium (p1 = 0.5) and large (p1 = 0.5) treatment group 1 success
probabilities for a large effect size are displayed in Table 3.25. The simulation times are comparable
for both success probabilities where SARA 3 has the largest computation time while SARA 1 has
the smallest. This may be explained by the fact that both scenarios have similar sample sizes.
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Table 3.25: Simulation Time (seconds) per Patient
k

p1

δ

σ

SARA 1

SARA 2

3

0.5

0.15

0

0.28

6.18

11.84

(n=339)

0.05

0.16

6.16

10.42

0.1

0.17

6.92

10.31

0.15

0.17

7.91

11.71

0.15

0

0.29

5.90

11.33

(n=325)

0.05

0.15

5.93

9.99

0.1

0.15

6.69

9.98

0.15

0.16

7.82

11.35

0.7

1

SARA 3

Trial Scenario - 3 sites, P1 = 0.5, 0.7, δ = 0.15

Scenario: 6 sites, p1 = 0.3, δ = 0, 0.15
The results comparing null and medium effect sizes for six sites are displayed in Table 3.26.
The results are similar to three sites, where SARA 3 has the longest simulation times and a large
effect size results in shorter computation times relative to a null effect size. Overall, the simulation
times are longer for an increasing number of sites for the SARA 2/SARA 3 approaches but not for
SARA 1.
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Table 3.26: Simulation Time (seconds) per Patient
k

p1

δ

σ

SARA 1

SARA 2

6

0.3

0

0

0.33

15.12

22.20

(n=587)

0.05

0.25

13.03

24.44

0.1

0.25

13.07

22.09

0.15

0.19

14.95

22.15

0.15

0

0.29

6.93

15.21

(n=241)

0.05

0.27

6.94

13.16

0.1

0.16

8.10

13.20

0.15

0.15

9.57

15.45

1

3.4.9

SARA 3

Trial Scenario - 6 sites, P1 = 0.3, δ = 0, 0.15

Sensitivity Analysis for Prior Specification of Random Effects

Several prior specifications were considered for the sensitivity analysis (Table 3.2). Prior C
was the specification used for both the random site and treatment-by-site interaction effects in our
simulation study. The results of the sensitivity analysis for SARA 2 and SARA 3 are displayed in
Table 3.27.
For SARA 2, the results show that all five priors are comparable with respect to the mean
total number of treatment successes (SE), expected allocation proportion for treatment group 1
(SE), empirical power. Prior B has slightly more average non-convergence warnings relative to
the other distributions. For SARA 3, priors A and D result in less treatment successes, smaller
allocation ratios and more expected non-convergence relative to the other priors, particularly as
σ increases. Prior D has notably higher power than the other distributions that have comparable
power. Overall, the prior used in our simulation study, Prior C, has similar inferences to the other
specifications considered.
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Table 3.27: Sensitivity Analysis for Prior Specification of Random Effects
Model

σ

Prior

SARA 2

0.1

0.15

SARA 3

0.1

0.15

3.5

Successes (SE)

Proportion (SE)

Power

Warnings

A

55.4 (15.3)

0.64 (0.08)

0.90

0.2

B

55.4 (15.5)

0.64 (0.08)

0.90

4.1

C

55.5 (15.3)

0.64 (0.08)

0.90

0.0

D

55.5 (15.3)

0.64 (0.08)

0.90

0.0

E

55.4 (15.5)

0.64 (0.08)

0.90

0.0

A

55.8 (20.8)

0.65 (0.10)

0.78

0.4

B

55.9 (20.8)

0.65 (0.10)

0.78

2.1

C

55.8 (20.7)

0.65 (0.10)

0.78

0.0

D

55.8 (20.7)

0.65 (0.10)

0.78

0.0

E

55.7 (20.6)

0.65 (0.10)

0.78

0.0

A

56.8 (15.9)

0.65 (0.08)

0.80

1.0

B

58.1 (17.2)

0.66 (0.09)

0.80

2.0

C

57.5 (16.7)

0.66 (0.08)

0.80

0.3

D

59.0 (17.2)

0.68 (0.09)

0.80

26.4

E

56.9 (15.8)

0.65 (0.08)

0.80

1.0

A

58.1 (21.1)

0.64 (0.10)

0.78

1.0

B

60.4 (22.3)

0.66 (0.11)

0.78

2.7

C

59.4 (21.8)

0.66 (0.10)

0.78

0.5

D

61.2 (22.9)

0.67 (0.11)

0.89

28.8

E

58.8 (21.1)

0.65 (0.10)

0.78

0.5

Discussion

We extended a method that accounts for site-based response variability under the Bayesian
framework to avoid issues in estimating many parameters. We then proposed a method that also
accounts for variability in treatment effectiveness by incorporating a random treatment-by-site
interaction into the model. The simulations used larger values of inter-site standard deviation to
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promote scenarios with qualitative interactions. Accordingly, the conditional probabilities of success
specific to each treatment and center were estimated in a novel approach to skew the treatment
allocations, thus allowing the treatment success probabilities to vary across centers.
For a small success rate and null effect size, SARA 3 outperforms all other allocation approaches
with more expected treatment successes but maintains similar variability, particularly as the amount
of inter-site variability increases. The allocations ratios are comparable across all six approaches,
but the SARA approaches share lower variability in adaptation than the RA/CARA designs. The
RA/SARA 2/SARA 3 approaches have similar control of the type I error rate.
For a large effect size, SARA 3 gains back the expected successes lost with SARA 1/SARA
2 relative to the RA/CARA but maintains lower variability. SARA 3 results in larger allocation
ratios than the other SARA designs, closer to the RA/CARA approaches, but the SARA designs
achieve lower variability in adaptation. As the amount of inter-site variability increases, SARA
2/SARA 3 maintain higher power than the other designs.
As the number of sites increases, SARA 3 notably outperforms all other approaches in terms
of treatment successes while the CARA/SARA designs have the lowest variability in successes.
SARA 3 results in lager allocation ratios than the BC/CARA/SARA approaches that are closer to
RA allocation but with similar variability to the CARA/SARA designs. The RA/SARA 3 designs
perform similarly and have better control of the type I error rates. The CARA/SARA approaches
have higher power than RA randomization, with more improvement for SARA 2 with increasing
inter-site variability.
When the success rate increases, the six approaches perform more comparably with respect
to allocation ratios, variability in allocation and empirical power for a large effect size. However,
SARA 3 maintains slightly more expected treatment successes than the other methods, but with
similar variability, for increasing values of inter-site variability. It is encouraging to note that
the adaptive designs generally work better at lower success probabilities when reducing treatment
failures is most important.
By incorporating the random site and treatment-by-site effects in the SARA models, we account
for additional sources of variability introduced from the centers. This leads to an increase in
expected treatment successes, more adaptation, better control of the type I error rate and increased
statistical power. SARA 3 outperforms SARA 1/SARA 2 with respect to treatment successes and
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adaptation but at the cost of marginally less power. When accounting for site in the adaptive
allocation design, we recommend assessing the operating characteristics, and thus make inferences,
using the results from an approach that accounts for the clustering (e.g. GLMM).
In our simulation study, convergence was assessed after each model fit. In cases when the
parameter estimates did not converge, we followed Rosenberger et al. (2001) and used the previous
patient’s allocation probabilities until convergence was achieved again [20]. This approach ignores
the subsequent patient’s site when ‘updating’ the allocation probabilities. Instead, we suggest
using the last individual’s allocation weights who was randomized at the same site as the next
patient. Alternatively, the previous subject’s parameter estimates can be used to calculate sitespecific allocation weights, but instead using the subsequent patient’s site. This would allow us
to utilize the most recent data to update the randomization probabilities while also incorporating
the appropriate site information. This would be expected to have a negligible effect on the results
of our simulation study as the frequency of non-convergence is relatively low. However, this is a
more ethical approach to handling non-convergence during the adaptation process since all available
data, including site information, is being used to adaptively randomize.
The results of the simulation times demonstrate that SARA 3 has the longest computation
time while SARA 1 has the shortest. Although the simulation times are reported per patient,
thus removing the effect of varying sample sizes, scenarios with larger sample sizes have increased
simulation times. This may be explained in part by the additional computation and storing of
results for scenarios with larger sample sizes. In addition, SARA 3 takes longer due to estimating
additional parameters from the random treatment-by-site interaction effect, particularly as the
number of patients and centers increase. However, these simulation time results only pertain to
empirical research. In a real life application, the increased computation times for the SARA designs
relative to the other adaptive approaches and balanced allocation are trivial as only one patient is
adaptively randomized at a time for a single trial.
There are several limitations associated with the simulation times that should be noted when
interpreting the results. First, all simulations were run on the cluster, where scenarios were allocated
to different nodes. Each node may vary in terms of performance and speed, especially depending on
the current job queue. Second, each scenario was run as a single job containing 1000 simulations.
This increases the elapsed time due to the additional computation and storing of the iterations.
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In this chapter, Bayesian GLMMs were fit for the SARA 2/SARA 3 models and the conditional success probabilities calculated with the model parameters estimated using MCMC techniques.
Weakly informative Gaussian priors were specified for the random site and treatment-by-site interaction effects as we anticipated small effects relative to a traditional uninformative prior. A
sensitivity analysis demonstrated that the operating characteristics were robust to the selection of
the prior distribution. However, due to long simulation times, this investigation was not exhaustive.
Further work includes more extensive sensitivity analyses be performed with larger variances (smaller precisions) and with alternative prior specifications (e.g. hyperpriors) to test the robustness
of the inferences.
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CHAPTER 4
ACCOUNTING FOR LOCATION-BASED VARIABILITY

In addition to inter-center variability in treatment responses and effectiveness, treatment differences could also be attributed to social determinants of health or other lifestyle and landscape
factors that that drive patient heterogeneity. When unmeasured, these treatment differences can
manifest as spatial variability and are likely to complicate patient allocation. In Section 4.1, we
discuss spatial correlation and summarize some existing methods to account for spatial correlation
in regression modeling, particularly with incomplete covariate data. In Section 4.2, we introduce
a novel approach to adaptive allocation in clinical trials to account for more coarse location-based
variability in treatment effectiveness. Results from a simulation study are reported in Section 4.3
comparing the performance of our location-adjusted approach to both balanced and RA randomization. The results are explored and a brief discussion of the implications follows.

4.1

Background and Existing Methods

Traditionally, clinical trial researchers ignore geographic location – such as patient residential
address – as a factor that may affect the outcome because these experiments are often randomized to
reduce confounding. However, Lawson (2013) notes two cases in which location should be considered
to incorporate any spatial effects into the design and/or analysis. During the design phase, there
may be a geographical bias in the risk of disease resulting in selection bias. In the analysis phase,
location may be a confounder in the relationship between the groups and the outcome. In addition,
there may be unknown or known confounders that were not considered in the analysis. In these
cases, accounting for spatial correlation in the analysis may be important [46].
Clayton et al. (1993) express the importance of including a spatial clustering term, in addition
to an unstructured term, to account for residual geographical variation in risk when mapping disease
risk. This spatially structured random effect acts as a surrogate for these unknown or known confounders that vary smoothly throughout space and were not accounted for otherwise in the model.
The authors motivate this work with studies that explore the associations between environmental
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and socioeconomic factors with cardiovascular mortality [47, 48] as well as the association between
cancer and dietary intakes [49]. As an example, the authors fit a log-linear Poisson model of lip
cancer incidence in Scotland that includes the percentage of the population employed in agriculture,
fishing and forestry as a covariate along with both ‘heterogeneity’ and spatial ’clustering’ terms.
The results show that location acts as a confounder in the relationship between occupation and
risk of lip cancer, where individuals with these outdoor occupations have more sunlight exposure
and thus an increased risk of cancer [46, 50].

4.1.1

Spatial Correlation

Spatial autocorrelation (SA) is the correlation of a variable across space. Positive SA is characterized by similar outcome values for spatial units close together while negative spatial correlation
occurs when outcome values differ when they are close together in space. The assumption of independence in traditional statistical methods is not satisfied when SA exists and thus spatial methods
are necessary to account for this dependence [46].
Often, traditional regression models do not capture all of the variation present in the data
by simply adding selected covariates. In order to account for over-dispersion or spatial correlation
from unmeasured confounders, additional terms can be considered. One way of accounting for these
sources of variability is to incorporate additive unstructured and/or spatially structured random
effects to the linear, or even non-linear, predictor. An unstructured random effect can be used
to model uncorrelated heterogeneity (UH) and is often given an exchangeable prior, such as an
uninformative, zero-mean Gaussian distribution. Alternatively, correlated heterogeneity (CH) can
be accounted for by adding a spatially structured random effect, using either intrinsic Gaussian
conditionally autoregressive (CAR) or fully specified multivariate Gaussian prior distributions [46].
The intrinsic CAR, an improper prior distribution, was introduced into the Bayesian setting by
Besag et al. (1991). A vector of random effects u with a CAR prior have a conditional distribution,

[ui |uj6=i ] ∼ N (ūi , r/nξi ) , i = 1, . . . , n,

(4.1)

where ui is conditional1 on all other values of the vector u where j 6= i. The first and second
1

This can also be denoted as [ui |u−i ] or [ui | . . .].
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conditional moments are functions of the number of neighbors (nξi ) in the neighborhood (ξi ) and
their values. Specifically, the conditional variance (r) of the random effect is inversely proportional
to the number of neighbors. The random effects have zero mean due to a sum-to-zero constraint
P
( N
i=1 ui = 0), where the mean ūi is defined as follows:

ūi =

X

uj /nξi ,

(4.2)

j∈ξi

which is the the neighborhood (ξi ) average in the ith region.
The univariate intrinsic CAR was previously extended to the multivariate setting [51]. A multivariate CAR (MCAR) can be used to model several spatially structured random effects or regression
coefficients under the assumption that they are spatially dependent. For example, an MCAR prior
can be used to specify multiple, dependent regression coefficients in a Bayesian hierarchical spatial
0

model. This would allow the coefficients to vary across space. Random effects Si = (Si1 , . . . , Sip )
with an MCAR prior specified have a multivariate conditional distribution,




S i | S(−i)1 , . . . , S(−i)p ∼ Np S̄ i , Σ/nξi ,

where S̄ i = S̄i1 , . . . , S̄ip

0

and S̄i =

P

j∈ξi

(4.3)

Sj /nξi for the p dependent random effects in neigh-

borhood ξi (nξi neighbors) for the ith area. Here, the random effects are conditional on all other
values of the vector Sj , where j 6= i. Using a separable cross-covariance matrix Σ assumes the
spatial dependence is the same across all coefficients while a non-separable form would allow this
dependence to vary [52, 53, 54].
Since patient locations can be viewed as randomly located throughout a study surface and
each patient experiences either a treatment success or failure, a spatial model designed for marked
point pattern data will be used. Two types of Spatial Bayesian models will be covered that are
hierarchical in their parameters, Geographically Adaptive Regression (GAR) and generalized linear
spatial (GLS) models.
Geographically Adaptive Regression Model
The GAR Model is a type of geographically dependent regression, extended from geographically
weighted regression (GWR), that allows the regression relationship to vary over space (parametric
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spatial non-stationarity). Instead of global (fixed) parameter estimates in an ordinary least squares
regression model, the model is fitted at each location to allow regression coefficients to be estimated
at each location [55, 46, 56, 57]. Fotheringham et al. (2002) extended the GWR model for the
Gaussian setting as follows:

yi (s) = β0 (s) + β1 (s)x1i + β2 (s)x2i + · · · + (s),

(4.4)

where s is a particular spatial location and x1 , x2 are assumed to have spatial dependence [56].
Under the Bayesian context, spatially-structured priors on the coefficients are necessary to allow
for spatially-varying parameters. Equation (4.4) is a special case of a random-intercept and randomslope model. Using a single predictor, Lawson (2013) extended GWR to categorical outcomes under
the Bayesian GLMM framework as follows:

E(yi ) = µi
µi = g(ηi )
ηi = β0 + β1∗ x1i + Ri
Ri = β01i + µi + vi ,

(4.5)

where

β0 ∼ N (0, τβ0 )
β01i ∼ N (0, τβ01 )
β1∗ = (β1 + β11i )
β1 ∼ N (0, τβ1 )
β11i | · · · ∼ N (µβ11 , τβ11 /nξi ).

The intercept (β0 ) includes an uncorrelated random component (β01i ) while the slope has a
random main effect (β1 ) and a correlated random component (β11i ), where µβ11 = β̄11ξi with
precision τβ11 . While the random slope can be unstructured or spatially structured, putting an
improper CAR prior on this coefficient allows for a spatially-varying slope, as in the above example.
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This is what characterizes a GAR model. Specifying a spatially structured prior on the random
slope leads to a parsimonious model and allows for a more smooth (gradual changes in variation)
slope across space. The two other (optional) random components (Eqn. 4.5), forming a convolution
model, capture any residual error, or unmeasured confounding, in the data and are unstructured
(µi ) and spatially-structured (vi ).
The convolution model is less parsimonious and may have identifiability issues from the extra
random effects compared to the GAR model; however, they may have similar deviance information
criterion (DIC) values. Consequently, Lawson advises that µi + vi may need to be removed when
assuming a GAR model. The GLMM is flexible in that the outcome yi is assumed to come from
any one of the exponential family distributions. The linear predictor ηi can consist of several
uncorrelated and spatially structured random components and is connected to the mean of the
response via one of several link functions g(·) [46].
One approach to using an intrinsic CAR prior when working with point pattern data is tiling,
such as Voronoi/Dirichlet Tessellation or Delauney Triangulation, to convert to areal data. The
patient locations are used to construct the neighborhood structure and adjacency information
needed to specify a CAR prior. In tessellation, the boundaries are calculated so that each tile
around a point is closest to that point and no other. This creates natural neighborhoods where
adjoining edges of the tiles consist of natural neighbors. Tessellation is preferred over Delauney
triangulation, which uses bisectors of the tile edges to form a convex hull in the points, because
triangulation may connect more distant points that may not be in the vicinity of the patient (not
first order neighbors) [46].

4.1.2

Existing Interpolation Methods

We need to incorporate a method to predict the success probabilities at a new point in space. We
discuss several existing approaches that handle incomplete covariate information, both deterministic
and geostatistical interpolation.
Inverse Distance Weighted Interpolation
One simple approach to predict outcomes at a point, a set of points or a grid surface when the
attribute values are only available at observed locations is to use Inverse-distance weighted (IDW)
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interpolation, as mentioned in Lu and Wong (2008). IDW assumes that values closer together
are more similar than values further apart. Specifically, IDW calculates a weighted average of the
values at observed locations Si to make a prediction at a new interpolation location S0 as follows:

ŷ(S0 ) =

n
X

λi y(Si ).

i=1

Here, the interpolated value ŷ(S0 ) is a linear combination of observed values and the weights, λi ,
where
d−p
λi = Pn0i −p ,
i d0i
and d−p
oi is the inverse of the euclidean distance between the observed and new location with an
IDW power of p, or ||si − s0 ||−p . The weights for the observed locations are each calculated based
on their distance to the new location. The value of the inverse distance weighting power is set
by the user. For p → 0, the weights are similar and thus the predicted value is an average of the
neighboring observed values. However, when p > 1, weights diminish with increasing distance, with
larger p giving more weight to closer observed values.
This method is easy to implement in R (see gstat {gstat} function) and is not computationally
intensive. The default inverse distance weighting power is set to 2 to perform inverse distance
squared weighted interpolation, though this is a arbitrary selection. A drawback of IDW interpolation is that it does not provide a confidence level of the interpolation (e.g. variance) nor are the
distance weights calculated using empirical data. IDW assumes that the distance-decay is constant
throughout the study area, and thus ignores the spatial variability of the distance-decay relationship
[58, 59].
Fully Specified Covariance Model
The Generalized Linear Spatial Model (GLSM), also known as Bayesian Gaussian Kriging, is
a type of correlated heterogeneity model that specifies only one random effect for both unstructured and spatially structured heterogeneity through two parameters in the prior distribution. A
multiplicative relationship is specified for the uncorrelated and (spatial) correlated heterogeneity.
Diggle et al. (1998) propose a kriging-type model, similar to universal kriging, and use a multivari118

ate normal (MVN) prior distribution to parametrically model the spatial variation in risk. In one
application, they model the risk of Campylobacter infections at postcode locations using a spatially
varying ‘success’ probability

P (x)
= β + S(x),
log
1 − P (x)


(4.6)

where S(x) is a zero-mean stationary Gaussian process with a specified correlation function [60].
The posterior estimates were used to predict spatially-varying log odds to a grid of interest. The
authors suggest an approach to account for non-spatial extrabinomial variation by adding a nonspatial component Z to Eqn. 4.6, where Z ∼ N (0, τ 2 ) and is described as using a ‘convolution
Gaussian prior’.
The GLSM incorporates a hierarchically-centered (zero-mean) random effect with a MVN prior
that models a parametric function of the distances and spatial correlation parameter (φ) in the
variance-covariance matrix Γ. A powered exponential correlation function,

ρ(dij ) = exp(−(dij /φ)κ ),
where dij is the distance between the ith and j th locations, can be used. The simplifying assumption of a fixed smoothing parameter (κ = 1) can be considered for the spatial covariance matrix.
Additional covariance functions can be included, including the Matérn correlation function and the
disc function.
An advantage of the GLSM model is that the spatial bandwidth can be changed through the
correlation parameter; smaller φ allows for a more variable surface for the effect [45, 46]. However,
estimation in these models is often time-consuming, especially when trying to estimate some of
the spatial parameters (e.g. φ). In addition, an unadjusted model with n patients requires the
inversion and storage of an n × n matrix, which can be computationally demanding in certain
settings [61, 62].
Spline-based Model
A spline-based model is a semi-parametric approach that uses a smoothing operator to incorporate location data [46]. Nychka et al. (1998) proposed the reduced knot model, or low-rank
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kriging, which is an alternative to the kriging-type model by Diggle et al. [63]. Low-rank kriging is
a geostatistical approach that combines interpolation, or kriging, with modeling of spatial variation
in disease risk, for example. The spatially-correlated joint random effects can be used to capture
the geographical variation in the disease risk and predict the spatial effects at new locations.
A Bayesian generalized additive model (GAM), or geoadditive model, approach can be used
to achieve this. This method was first proposed by Kammann and Wand (2003) and combined
geoadditive models, specifically the low-rank kriging formulation, with additive models [64]. French
and Wand (2004) use a logistic GAM, with a mixed effects model representation, to model the
spatial variation in cancer risk in Cape Cod, Massachusetts using splines. This approach accounts
for incomplete covariate data when fitting a GAM [62]. Lawson (2013) define a Bayesian GAM for
count data to model the risk of respiratory cancer mortality in Ohio. A low-rank kriging model is
fitted with a planar trend in centroids (covariate) along with an additive spline term [46].
Using simulated case-control data to model spatial variation in disease risk, Wheeler and Calder
(2016) define the low-rank kriging model as follows:

log [P (yi = 1)/P (yi = 0)] = β0 +

p
X

βj xij +

j=i

K
X
k=1

ψk C{||si − κk ||}
(4.7)

= x0i β + zi0 ψ,
where xij are covariates, κ1 , . . . , κK are the K selected knot locations to represent the observed
locations (s1 , . . . , sn ) and z = [C{||si − κk ||/ρ}]1≤i≤n,1≤k≤K [61]. The covariance function is defined
as C{d} = (1 + |d|)e−|d| and comes from the Matérn family of covariance functions. The Gaussian
random effect ψk is specified as follows:
ψ ∼ N (0, τ ω −1 ),
ω = [C{||κi − κk ||/ρ}]1≤i,k≤K ,

where ω is the covariance matrix, τ is the precision and ρ is the spatial range parameter. The
model was used to predict spatially-varying odds ratios onto a grid, where the spatial odds at grid
0

cell j was defined as θj = exp(zj ψ).
French and Wand (2004) showed that the GAM has a GLMM representation using a reparam120

eterization of the following parameters:
z ∗ = zω −1/2 ,
ψ ∗ = ω 1/2 ψ,

where Cov(ψ ∗ ) = τ I with precision τ . Lawson (2013) and French and Wand (2004) fix the spatial
range parameter ρ as the maximum observed inter-point distance,

ρ̂ = max {||si − sj ||},
1≤i,j≤n

for simplicity in fitting the GLM and to reduce the computational burden. Specifically, by fixing ρ
and using the GLMM reparameterization, the covariance matrix can be precomputed and standard
statistical software can be used, respectively.
French and Wand (2004) comment that the smoothness of their estimate was dependent on the
choice of ρ but that the scale of their final map was insensitive. In addition, Lawson (2013) showed
that the maximum interpoint distance produced very smooth surface effects and believes that an
improved model fit could be achieved by estimating ρ [46, 62]. Accordingly, Wheeler and Calder
(2016) considered a range of candidate ρ values from 0.1 to the maximum interpoint distance (2.76),
in increments of 0.1, and selected the best model using the DIC. The authors discuss the importance
of estimating the spatial range parameter since it is used to control the degree of smoothing in the
spatial component. Estimating ρ in the model using MCMC would increase both the complexity
of the model and computation time. A spline-based model approach is faster, especially when ρ is
fixed, since a smaller covariance matrix (K × K) corresponding to the number of knots is stored
and inverted compared to a GLSM [61, 62, 64].

4.2

Methods

In Chapters 2 and 3, we incorporated site into the response-adaptive randomization framework
to account for site-based response variability and inter-center variability in treatment effectiveness.
In addition to these sources of variability across sites, treatment differences can also be attributed
to social determinants of health. Here, we consider situations where treatment effectiveness may
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vary throughout space in a clinical trial. However, SDH are often not measured or there is not
enough information or available data to capture these phenomena. Accordingly, geographic location, specifically patient residential location, will be used as a proxy for SDH since they are often
associated. For example, Wheeler et al. (2017) found an association between colonoscopy screening adherence and an area-level socioeconomic status index, where the SES index is known to have
spatial components. Variables at both the census block group- and tract-levels were included in
the index and it was shown that home ownership, race and income were among the most important
[65]. Therefore, it is necessary to account for spatially-varying treatment effectiveness in adaptive
allocation designs.
We update the allocation weights with estimated success probabilities using the subsequent
patient’s residential location to account for more coarse location-based variability when adapting.
This allows us to randomize patients to the treatment group likely to perform best at their residence.
One simple approach to calculate the predicted probabilities of success at a particular location is
to use IDW interpolation. After estimating spatially-varying success probabilities for the current
patients using a GAR model (Eqn. 4.5), IDW is used to predict the conditional probabilities to a
new location. One of the drawbacks of IDW is that it does not account for spatial variability of the
distance-decay relationship. Instead, a GLSM or low-rank kriging model (Eqn. 4.7) can be used
to model the geographical variation in treatment successes, thus accounting for these unobserved
or unknown SDH, and to interpolate the spatially-varying treatment effects. The LRK model
was selected due to the significant computation time required to implement the GLSM model into
adaptive allocation simulations.
One use of the low-rank kriging model in Spatial epidemiology is to model the spatial variation
in disease risk. The splines are employed to estimate a spatially structured random effect to capture
any unmeasured confounding while adjusting for covariates. Instead, we model the spatial variation
in the odds of a favorable response to a particular treatment (treatment success). The splines
are used in a novel approach to estimate spatially-varying treatment effects. Our objective is to
compare an an extension of response-adaptive randomization that incorporates spatial information
to account for SDH with existing allocation approaches.

122

4.2.1

LARA Model

We propose the Location-Adjusted Response-Adaptive (LARA) approach to account for spatial variability in treatment effectiveness not previously accounted for in past allocation methods.
LARA is an extension of the SARA approach when more precise geographical information is available. Specifically, we incorporate the observed patient residential locations into a Bayesian low-rank
kriging model [61, 62, 63]:

logit(pi ) = α0 +

β1 +

K
X

!
β11k C{||si − κk ||} Ti1 +

β2 +

k=1
0

K
X

!
β22k C{||si − κk ||} Ti2 +

k=1

p
X

αj Xij

j=1

0

= Xi α + zi β.
(4.8)
Here, α0 is the overall intercept, Ti1 , Ti2 are treatment group 1 and 2 indicators for the ith patient,
i = 1, . . . , n, and β11k , β22k are the spatially-varying joint treatment random effects for the k
knots selected. Let z = [C{||si − κk ||/ρ}]1≤i≤n,

1≤k≤K ,

where the covariance function is defined

as C{d} = (1 + |d|)e−|d| . The spatial range parameter ρ controls the degree of smoothing and is
specified under the assumption the degree of smoothing is the same for both treatment groups.
The separate random components for each treatment group allow treatment effectiveness to
vary over space for both groups. Specifically, β1 , β2 are (optional) overall treatment effects for
each group while β11k , β22k are interpreted as spatially-varying local deviations from the overall
treatment effects. The Xj term are p (optional) subject- and/or location-specific covariates, with
corresponding regression coefficients αj , that can be incorporated into the model.
The set of k knot locations {κ1 , . . . , κk } are representative of the observed patient residential
locations {s1 , . . . , sn }. The knots were selected using a swapping algorithm developed by Johnson
et al. (1990) which minimizes a geometric space-filling criterion. This space-filling algorithm is
implemented in the cover.design {fields} function in R [66]. French and Wand (2004) used k = 33
knots but express interest in further simulations to assess varying the number of knots. A more
smooth estimated surface may be produced with a larger knot size but requires larger matrices to
be stored and inverted. Wheeler and Calder (2016) use k = 25 knots in their models [61, 62]. As
a model is fit for each patient randomized, we selected k = 20 knots for each model to limit the
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computation time.
The priors for the regression coefficient and variances for the spatially-varying random effects
are specified as follows. The prior on the overall intercept is an informative normal: α0 ∼ N (0, τα0 ),
where precision τα0 = 1/σ 2 = 0.4 and σ 2 is the variance. The priors for the joint random effects
are specified as

β11 , β22 ∼ N (0, τβ ω −1 ),

where τβ is the precision and ω is a square covariance matrix of the pairwise distances between the
knot locations,

ω = [C{||κi − κk ||/ρ}]1≤i,

k≤K

.

The priors for the precision τβ of the spatially-varying random effects are specified using the variance
σ 2 = 1/τβ , where σ 2 ∼ Uniform(0, 2). The prior for regression coefficients for any additional
(optional) covariates could be specified as a vague Gaussian: αj ∼ N (0, τα ), where the precision
τα ∼ Gamma(0.1, 0.0001). The prior distributions for the intercept and random effects are similar
to, but less vague than, those used in Wheeler and Calder (2016) and Lawson (2013) [61, 46].
To reduce the computational burden of the simulations, we decided to fix the spatial range
parameter in our low-rank kriging model. A smaller ρ produces a more coarse surface effect and
should be used when the true surface is expected to resemble this [62]. A simple simulation
comparing different choices for ρ showed that values smaller than the maximum interpoint distance
generally resulted in smaller DIC values and lower MSE, or prediction error (results omitted).
Accordingly, ρ was fixed as one-quarter of the maximum interpoint distance,

ρ̂ =

1
× max{||si − sj ||} ∀i, j.
4

The observed distances have to be recalculated and the fixed spatial range parameter ρ̂ updated
each time a new patient is randomized to predict the treatment effects for the subsequent patient.
As each patient is recruited, the accrued data up to that point, including treatment assignments,
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observed patient outcomes and residential locations, are fit using the LARA model (Eqn. 4.8) to
predict the spatially-varying treatment effects at the residential location of the subsequent patient.
The predicted treatment effect for the tth group at the residential location for the (m + 1)st patient
is
0

θ̂m+1,t = zm+1 β̂.

(4.9)

The regression coefficients and predicted spatial treatment effects (Eqn. 4.9) are used to calculate
the estimated success probabilities for each treatment as follows:
0

p̂1i

=

exp {α̂0 + θ̂i1 + Xi α̂}
0

1 + exp {α̂0 + θ̂i1 + Xi α̂}

,
(4.10)

0

p̂2i

=

exp {α̂0 + θ̂i2 + Xi α̂}
0

1 + exp {α̂0 + θ̂i2 + Xi α̂}

.

The predicted probabilities of success account for spatial variability in treatment effectiveness.
The optimal allocation weights (Eqn.2.3) are updated using these conditional probabilities to skew
allocation towards the treatment group performing ‘best’ closest to where each patient resides. Due
to our focus on recapturing the true spatially varying treatment effects, when they exist, to account
for variability in treatment effectiveness, we do not estimate the overall treatment effects β1 , β2 nor
do we include covariates or additional random effects in our simulation study.

4.3

Simulation Study

A simulation was conducted to evaluate the performance of the location-adjusted responseadaptive design, which accounts for spatial variability in treatment effectiveness, relative to existing
allocation designs. In a real clinical trial, patient addresses can be geocoded in R (see geocode
{ggmap} function) to the corresponding geographic coordinates and census tract. If no residential
location is available, using the centroid of the zip code is one approach to include the patient data in
the randomization process. However, to simulate the patient data from a hypothetical clinical trial,
a study area with spatial coordinates u, v ∈ (0, 1) was selected and broken into g grid cells, with
each grid cell assigned a treatment success probability and effect size to create spatial variation.
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The scenarios considered and the corresponding sample size determinations are shown in Section
4.3.1 and were selected to be characteristic of a typical multi-center trial.

4.3.1

Scenarios Considered

In Scenario 1 (Figure 4.1), the unit square was split into g = 100 grid cells and the effect size
(δ = p1 − p2 ) fixed at 15%. The treatment 1 success rate was set at 10% (p1 = 0.10, p2 = 0.25) in
the 25 grid cells in the northwest corner and at 25% elsewhere (p1 = 0.25, p2 = 0.10). In Scenarios
2-4 (Figures 4.2-4.4), this ‘true’ treatment success probability surface was extended to include a
gradation in success rates across the study area to represent increasingly more continuous surfaces.
Scenarios 5 and 6 represent a ‘spatial null’ hypothesis where there is no spatial variability in the
success probabilities. There is no treatment effect in Scenario 5 (Figure 4.5) while there is a 15%
effect size (p1 = 0.25, p2 = 0.10) set for Scenario 6 (Figure 4.6). In Scenario 7 (Figure 4.7), there is
no treatment effect but the success rates are gradually increasing from 75% in the northwest corner
to 90% in the southern and eastern borders of the unit square. Scenario 8 (Figure 4.8) generates a
continuous surface (Scenario 4) for treatment group 1 but a low success rate (p2 = 0.10) with no
spatial variability for treatment 2.

Figure 4.1: Scenario 1 True Surface - Discrete Treatment Effect, Spatial Variability
Sample Size Justification: p1 = 0.10, p2 = 0.25, δ = 0.15, n = 200
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Figure 4.2: Scenario 2 True Surface - Continuous Treatment Effect, Spatial Variability
Sample Size Justification: p1 = 0.10, p2 = 0.25, δ = 0.15, n = 200

Figure 4.3: Scenario 3 True Surface - Continuous Treatment Effect, Spatial Variability
Sample Size Justification: p1 = 0.10, p2 = 0.25, δ = 0.15, n = 200

Figure 4.4: Scenario 4 True Surface - Continuous Treatment Effect, Spatial Variability
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Sample Size Justification: p1 = 0.10, p2 = 0.25, δ = 0.15, n = 200

Figure 4.5: Scenario 5 True Surface - No Treatment Effect, No Spatial Variability
Sample Size Justification: p1 = 0.90, p2 = 0.80, δ = 0.1, n = 398

Figure 4.6: Scenario 6 True Surface - Treatment Effect, No Spatial Variability
Sample Size Justification: p1 = 0.25, p2 = 0.10, δ = 0.15, n = 200
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Figure 4.7: Scenario 7 True Surface - No Treatment Effect, Spatial Variability
Sample Size Justification: p1 = 0.9, p2 = 0.8, δ = 0.10, n = 398

Figure 4.8: Scenario 8 True Surface - Treatment Effect, No Spatial Variability for Treatment 2
Sample Size Justification: p1 = 0.25, p2 = 0.10, δ = 0.15, n = 200

4.3.2

Simulation Settings

Each subject was randomly assigned to a point location within one of the g grid cells using a
homogeneous Poisson point process (rpoispp {spatstat} function [67]). Specifically, a realization
of a uniform Poisson process, which assumes Complete Spatial Randomness, was generated by
specifying an intensity function n + 100. We randomly sampled n patients without replacement
from the total n + 100 points. As each patient was recruited in the simulated trial, a U (0, 1) variate
was drawn and compared to the previous treatment group 1 allocation weight to determine the
assignment. If the value was less than or equal to the previous weight (Eqn. 2.3), the patient was
assigned to treatment group 1, otherwise they were allocated to the second treatment group. A
hard-lead required that balanced allocation be performed for the first m = 20 patients to prevent
estimator instability or convergence issues. The patient outcomes were then generated from a
Bernoulli distribution using the success probability for the g th grid cell corresponding to where the
patient resides. After each patient is randomized to a treatment group, the spatial range parameter
ρ̂ was calculated and new knots selected. Accordingly, the distance and covariance matrices z, ω
must be precomputed.
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The simulations were powered for an analysis not accounting for location-based variability by
ignoring clustering in the sample size determination (Eqn. 2.15). This is similar to previous
chapters and will allow us to see how much power LARA gains back from both balanced and RA
randomization. The sample sizes for the scenarios were calculated without complete information,
specifically the true spatial variability in the success rates. Instead, a sample size justification was
performed for the expected effect size assuming there was no spatial variation. In the case where
there was no treatment effect (Scenarios 5, 7), the sample size was calculated with a small effect
size (δ = 0.1) to allow a reasonable sample size to be recruited.
The joint posterior distribution of the regression coefficient and joint random effects were estimated using MCMC techniques implemented through the BRugs interface in R. We estimated
the posterior median of the model parameters using 4000 iterations for burn-in and 1000 iterations
from two parallel Markov chains. The two Markov chains were generated without thinning because
it has been shown to be unnecessary and inefficient, particularly due to the increased computation
time in simulation studies [43]. The initial values were specified for the overall intercept, joint
random effects (β11 , β22 ) and the precision for the random effects (τβ11 , τβ22 ) to ensure they are
reasonable and within the bounds of the priors used. For the first subject randomized following the
lead-in (e.g. patient 21), fixed starting values were used to uniquely initialize each of the Markov
chains. For both chains, a fixed starting value of zero was used for the joint random effects. For
subsequent models, the initial values are set as the posterior medians of the previous patient for
the first chain and as 0.95 times the posterior estimates for the second chain.
To evaluate the proposed allocation design, we use the operating characteristics established by
Rosenberger et al. (2008), namely balance (allocation proportion), efficiency (power, type I error)
and ethics (total number of treatment successes) [19]. We are particularly interested in the mean
total number of successes/failures (± standard error), expected allocation proportion for treatment
i
h
1
), empirical power (95% Wald Confidence Interval) and mean squared error. In
group 1 (E n1n+n
2
addition, we compare the computation time for the proposed approach relative to Chapter 3.
We expect that the Spatial Bayesian extensions will require even more computation time due
to the added complexity of the the model relative to the Bayesian GLMMs in Chapter 2. For
the LARA model, we calculate the average simulation time (seconds) per subject to compare the
effect of the increasing complexity of the models on computation times. Balanced allocation and
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RA randomization are not considered because these models are fit almost instantaneously for each
patient. The simulation times represent the amount of time (seconds) to fit each model and update
the allocation probabilities to randomize the subsequent patient in a trial. The times only account
for the n − 20 patients adaptively randomized after the initial lead-in. Each trial was run separately
and the average seconds/patient along with standard error of the simulation times were reported.
We compared the performance of LARA (Eqn. 4.8) to both balanced allocation and RA randomization (Eqn. 2.1). The balanced and RA designs do not account for spatial variation in
treatment effectiveness. We hypothesized that LARA, which accounts for location-based variability in treatment responses and effectiveness, will reduce the variability in randomization, thus
reducing improper patient allocation. There were 1000 trials simulated separately for each scenario
and the results aggregated. Due to our focus on ethics, we only considered Optimal allocation. For
a single trial scenario, the following metrics were stored: sample size, number of patients assigned
to each treatment, number of successes for each treatment, total number of successes, simulation
time and mean squared error. After all patients were recruited in a trial, the proportions of success were compared using a Pearson’s chi-squared or Fisher’s Exact test to assess the treatment
effect (H0 : p1 = p2 ). The expected cell counts were checked (> 5) to ensure the assumptions of a
chi-squared test were satisfied. Site, or specifically location here, was ignored when calculating the
empirical power to be consistent with the previous chapters. This naive approach is also convention
when analyzing multi-center trials.
We assessed the quality of the estimated conditional success probabilities, and ultimately the
predicted treatment effects, for RA randomization and the LARA design using mean squared error.
After all patients were randomized in a trial, the MSE was calculated using the true and estimated
success probabilities (Eqn. 4.10) for each treatment separately. The true success probabilities for
each grid cell correspond to the scenario being considered (Section 4.3.1). Since the spline model
results in smooth estimates, it is important to see how well LARA performs in replicating the true
success probability surface. We hypothesized that LARA would result in better predictions since
RA randomization ignores the spatial variation in treatment effectiveness and instead averages the
success rates across the study area. For the tth treatment, t = 1, 2, the squared differences between
the true and estimated success probabilities were aggregated across all g grid cells and n subjects
into a single metric as follows:
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k

M SEt =

n

2
1 XX
θg − θ̂ig I(i ∈ g).
n

(4.11)

g=1 i=1

Here, θg is the true population success probability for the g th grid cell and tth treatment, and
θ̂ig is the estimated success probability for the ith subject located in the g th grid cell. Balanced
allocation does not make predictions and therefore we are unable to calculate mean squared error
for this randomization approach.
We plotted the true and estimated surfaces for both RA randomization and the LARA design
to visually compare how both methods are estimating the conditional probabilities of success used
to update the allocation probabilities. For LARA, the posterior estimates calculated from all
patient data were used to interpolate the spatially varying treatment effects (Eqn. 4.9) to a fixed
10 × 10 grid after all patients were randomized. The predicted treatment effects were then used
to calculate the estimated success probability surface. For RA randomization, this equates to
calculating the success probabilities for each treatment using the estimates of the intercept and
slope, irrespective of the location. The estimated surfaces were aggregated and averaged across
1000 trials. We hypothesized that LARA would reduce the variability in allocation because it
incorporates a variable success probability surface into adaptive randomization whereas the RA
approach ignores the spatial information.

4.3.3

Convergence Study

In a real world application, convergence would be assessed for the fitted model after each
new patient is randomized using one of the convergence diagnostic test statistics. In practice,
visual assessment of the trace plots should accompany the convergence statistics. However, this
is not feasible in simulation studies, particularly when the model is refitted for each new patient
randomized. Accordingly, convergence was not assessed during our simulation study due to the
increased computation burden from storing and processing the raw chain data necessary to calculate
the diagnostic test statistic.
A small simulation was performed to examine the robustness of the inferences with and without
monitoring convergence. We simulated 1000 trials and for each, estimated the model parameters
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using 4000 iterations for burn-in and 1000 iterations from two parallel chains with no thinning.
The two Markov chains were initialized similarly, where the previous patient’s converged posterior
estimates were used to start the chain close to where it left off. However, when convergence was not
achieved, the previous patient’s parameter estimates that converged were used to interpolate the
treatment effects at the new residential location, calculate the location-specific success probabilities
and initialize the subsequent chains. Gelman and Rubin’s convergence diagnostic R̂, or the potential
scale reduction factor, was used as the criteria for evaluating convergence. Adaptation continued
with the more strict cutoff of R̂ < 1.1 for the parameter estimates considered [39, 40], otherwise
the previous patient’s posterior estimates were used to interpolate the treatment effects and update
the allocation probabilities. However, for the first patient after the lead-in or in the case where
the previous patient’s parameters did not converge, equal allocation was used until convergence
was achieved. We examined the robustness of the mean total number of treatment successes (SE),
expected allocation proportion1 for treatment 1 (SE), empirical power (95% confidence interval),
MSE for each treatment, mean simulation time (seconds) per patient and the average number of
non-convergence warnings per trial. The simulation time will represent the expected amount of
additional time to fit and assess the model for convergence per patient.

4.3.4

Simulation Algorithm

The basic algorithm for our simulation study is as follows.
1. Hard lead-in for the first m patients, where individuals are allocated equally between the two
treatment groups.
2. Let Fi be accrued information which includes treatment assignments, observed patients outcomes and geographic information. Use Fi for patients i = 1, . . . , m, m + 1, . . . , n to begin
adaptation, starting with patient m + 1.
3. Using the residential location for patient m + 1, fit the Bayesian low-rank kriging model (Eqn.
4.8) to predict the treatments effects

0

θ̂m+1,t = zm+1 β̂,
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and calculate the conditional probability of success for the tth treatment as follows:
0

p̂ti =

exp {α̂0 + θ̂it + Xi α̂}
0

1 + exp {α̂0 + θ̂it + Xi α̂}

, t = 1, 2.

4. Using the estimated success probabilities p̂1i , p̂2i , update the allocation weights W1 , W2 and
assign the next patient to a treatment.

W1 (Fi ) =

q q
p̂1i / p̂1i + p̂2i , W2 (Fi ) = 1 − W1 .

5. Repeat Steps 2-4 to randomize patients m + 2, . . . , n.
For a single scenario, this algorithm is repeated for N = 1000 trials.

4.4

Results

The scenarios considered are shown in Section 4.3.1.

4.4.1

Mean Total Number of Treatment Successes

The mean total number of treatment successes are displayed in Table 4.1. When there are
discrete true spatially-varying surfaces with a medium effect size (Scenario 1), the adaptive designs have more expected successes, with slightly less improvement for LARA. LARA has similar
variability in treatment successes to balanced allocation while RA randomization has the highest
variability. When the success probability surfaces become increasing more continuous (Scenarios
2-4), all three methods perform comparably with respect to treatment successes and variability in
successes, with slightly more improvement for LARA.
When there is no spatial variability and a null effect size (Scenario 5), the three methods perform
similarly, with slightly lower variability in successes for LARA. For a medium effect size (Scenario 6),
the two adaptive designs have a notable increase in total treatment successes, with the improvement
slightly lower for LARA. However, LARA has lower variability than RA randomization, similar to
balanced allocation.
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When there is spatial variability but a null effect size (Scenario 7), the three approaches are
comparable with respect to treatment success and variability, with slightly less improvement in both
for LARA. When there is only spatial variability in success rates for treatment 1 (Scenario 8), the
adaptive designs results in more treatment successes relative to the BC, but with less improvement
for LARA. In this case, LARA has similar variability in treatment successes to balanced allocation
while RA randomization has the highest variability.
Table 4.1: Mean Total Number of Treatment Successes (SE)

4.4.2

Scenario

n

BC

RA

LARA

1

200

34.8 (5.5)

36.1 (6.5)

35.9 (5.4)

2

200

34.8 (5.4)

35.0 (5.6)

35.3 (5.3)

3

200

34.9 (5.4)

34.9 (5.5)

35.4 (5.3)

4

200

34.9 (5.3)

34.9 (5.4)

35.2 (5.3)

5

398

358.3 (5.8)

358.3 (5.8)

358.3 (5.7)

6

200

34.7 (5.5)

40.4 (8.3)

36.8 (5.4)

7

398

335.2 (7.0)

335.2 (7.0)

334.9 (7.3)

8

200

26.5 (4.8)

28.0 (6.0)

27.3 (4.8)

Expected Allocation Proportion - Treatment Group 1

The allocation proportions are displayed in Table 4.2. When there are discrete true spatiallyvaryying surfaces with a medium effect size (Scenario 1), the adaptive designs have a larger allocation ratio relative to balanced case, though the improvement is lower for LARA. This explains
the increase in expected treatment successes in the adaptive designs. LARA has notably lower
variability in allocating relative to RA randomization and similar to the balanced case. When the
true success probability surfaces becomes increasing more continuous (Scenarios 2-4), the pattern is
similar where the adaptive designs have larger allocation proportions relative to balanced allocation,
with less adaptation for LARA. In addition, LARA maintains lower variability in allocating than
RA randomization. As the surface becomes increasingly continuous, the advantage in adapting for
the RA/LARA approaches diminishes, particularly for LARA.
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When there is no spatial variability and a null effect size (Scenario 5), the three methods
perform similarly with equal allocation, as expected, but with nominally more variability for RA
randomization. For a medium effect size (Scenario 6), the two adaptive designs have notably
larger allocation ratios, with the improvement slightly lower for LARA. However, LARA has lower
variability than RA randomization, similar to the BC.
When there is spatial variability but a null effect size (Scenario 7), the three approaches are
comparable with equal allocation, as expected, but with slightly more variability for the RA approach. When there is only spatial variability in success rates for treatment 1 (Scenario 8), the
adaptive designs results in larger allocation ratios, however, there is less improvement for LARA.
LARA has similar variability in allocating relative to balanced allocation while RA randomization
has the highest variability.
Table 4.2: E[n1 /(n1 + n2 )] (SE)

4.4.3

Scenario

n

BC

RA

LARA

1

200

0.50 (0.03)

0.58 (0.24)

0.53 (0.04)

2

200

0.50 (0.03)

0.53 (0.25)

0.51 (0.05)

3

200

0.50 (0.03)

0.51 (0.25)

0.51 (0.04)

4

200

0.50 (0.03)

0.51 (0.25)

0.50 (0.04)

5

398

0.50 (0.02)

0.50 (0.03)

0.50 (0.02)

6

200

0.50 (0.03)

0.69 (0.23)

0.56 (0.04)

7

398

0.50 (0.02)

0.50 (0.03)

0.50 (0.02)

8

200

0.50 (0.03)

0.61 (0.29)

0.53 (0.05)

Empirical Type I Error and Power

The empirical type I error (α) and power (1 − β) results are displayed in Table 4.3. We compare
the type I error rates for Scenarios 5 and 7 where there is a null effect size. The three methods
perform comparably, where there is a slight inflation in the type I error for LARA irrespective of
the presence (Scenario 7) or absence (Scenario 5) of spatial variability in the success rates.
Overall, there is a notable loss of power for all three methods when there is spatial variation in
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the true success probabilities. When there are discrete true spatially-varying surfaces and a medium
effect size (Scenario 1), LARA has slightly higher power than balanced allocation while there is a
notable loss of power for RA randomization. When the true success probability surfaces becomes
increasing more continuous (Scenarios 2-4), the pattern is similar where LARA outperforms the
other two approaches. As the surface becomes increasingly continuous, there is a loss of power
for all three approaches, particularly balanced allocation, and the advantage in power for LARA
diminishes. When there is only spatial variability in success rates for treatment 1 (Scenario 8),
the BC/LARA approaches have comparable power, with a slight loss of power for LARA. RA
randomization has a notable loss of power relative to the other two methods. When there is
no spatial variation in success rates (Scenario 6), the power for the BC/LARA approaches reach
nominal levels, with more improvement for balanced allocation, and a notable loss of power for RA
randomization.
Table 4.3: Empirical Type I Error and Power (95% Confidence Interval)
Scenario

n

Metric1

BC

RA

LARA

1

200

1−β

0.27 (0.24, 0.29)

0.19 (0.16, 0.21)

0.28 (0.26, 0.31)

2

200

1−β

0.09 (0.07, 0.11)

0.07 (0.05, 0.08)

0.10 (0.08, 0.11)

3

200

1−β

0.06 (0.04, 0.07)

0.06 (0.04, 0.07)

0.07 (0.05, 0.08)

4

200

1−β

0.04 (0.02, 0.05)

0.05 (0.03, 0.06)

0.06 (0.05, 0.07)

5

398

α

0.05 (0.03, 0.06)

0.05 (0.03, 0.06)

0.06 (0.04, 0.07)

6

200

1−β

0.82 (0.79, 0.84)

0.53 (0.50, 0.56)

0.80 (0.78, 0.83)

7

398

α

0.05 (0.03, 0.06)

0.05 (0.03, 0.06)

0.06 (0.04, 0.07)

8

200

1−β

0.28 (0.25, 0.31)

0.12 (0.10, 0.14)

0.27 (0.24, 0.29)

1

4.4.4

Empirical Type I Error (α) or Power (1 − β)

Mean Squared Error (MSE) by Treatment

The mean squared error results are displayed in Table 4.4. Overall, when there is spatial
variability in the true success probabilities and an effect size (Scenarios 1-4, 7-8), LARA has a
lower MSE for both treatments relative to RA randomization. There is less of an improvement for
LARA when there is a null effect size and high success rates (Scenario 7). When there is no spatial
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variability in the true success rates, the two methods are comparable for both null (Scenario 5) and
medium effect sizes (Scenario 6), with slight improvement for LARA when there is a medium effect
size.
Table 4.4: Mean Squared Error (MSE) by Treatment
Scenario

Design

1

2

3

4

5

6

7

8

4.4.5

MSE 1

MSE 2

RA

0.011

0.010

LARA

0.008

0.007

RA

0.011

0.010

LARA

0.006

0.006

RA

0.011

0.010

LARA

0.006

0.006

RA

0.010

0.010

LARA

0.006

0.005

RA

0.001

0.001

LARA

0.001

0.001

RA

0.006

0.005

LARA

0.006

0.004

RA

0.005

0.005

LARA

0.004

0.004

RA

0.009

0.005

LARA

0.005

0.003

Simulation Time per Patient

The results of the simulation times and standard errors are displayed in Table 4.5. Overall, each
scenario takes a significant amount of time to implement the LARA approach for each patient.
Although the times are reported per patient, thus removing the effect of different sample sizes,
scenarios with larger sample sizes (δ = 0) have increased simulation times. The LARA approach
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has a notable increase in computation time due to the added complexity of the model compared to
the SARA approaches in Chapter 3 (Tables 3.24-3.26).
In a real life application, these computation times are feasible as only one patient is adaptively
randomized at a time for a single trial. However, the computation times represent a significant
burden when performing a simulation study with n patients, 1000 trials and a variety of scenarios.
For example, a single simulated clinical trial with a continuous success probability surface (Scenario
4) takes approximately 3.80 hours. This equates to only 76.04 seconds for each patient adaptively
randomized.
Table 4.5: Computation Time

4.4.6

Scenario

n

Seconds/patient (SE)

1

200

67.39 (14.48)

2

200

64.03 (12.83)

3

200

67.17 (14.20)

4

200

76.04 (12.41)

5

398

147.53 (29.97)

6

200

68.93 (14.20)

7

398

153.04 (31.19)

8

200

67.66 (14.29)

Convergence Simulation

A convergence simulation was performed to explore the trade-off between monitoring convergence and both robustness of the inferences and computation time. The results of the convergence
simulation for Scenario 4 are displayed in Table 4.6. In an average trial, there were approximately
1.79 ± 1.50 convergence warnings, where either equal allocation or the previous patient’s posterior
estimates were used to adapt. Overall, the total number of treatment successes, expected allocation
proportions and MSE for each treatment are comparable with and without monitoring convergence
of the parameter estimates. However, the simulation time per patient is 1.5 times larger when
checking convergence for n = 200. This equates to an additional 2 hours (5.8 vs. 3.8 hours) of
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computation time when assessing convergence for a single simulated trial.
Table 4.6: Convergence Simulation: Scenario 4
Convergence
No
Yes

4.4.7

Successes (SE)

E[n1 /(n1 + n2 )] (SE)

Power (CI)

MSE 1

MSE 2

Seconds/Patient

35.2 (5.30)
35.2 (5.29)

0.50 (0.04)
0.50 (0.04)

0.06 (0.05, 0.07)
0.06 (0.05, 0.07)

0.006
0.006

0.005
0.005

76.04 (12.41)
115.32 (20.16)

True and Estimated Treatment Success Surfaces

When there are discrete true spatially-varying surfaces with a medium effect size (Figure 4.9),
LARA estimates a highly variable success probability surface for each treatment that resemble the
true surfaces. RA randomization estimates constant success probabilities that are averaged across
the true surface. This approach does not appear to recapture the true spatially-varying surfaces.
When the true success probability surfaces become increasingly more continuous (Figures 4.104.12), the pattern is similar where LARA estimates highly variable success probabilities surfaces
and does a better job at recapturing the true spatially-varying surfaces. As the true surfaces
become increasing continuous, the estimated success probabilities for each treatment become more
similar for RA randomization and thus do not recapture the true spatially-varying treatment effect
sizes. In addition, there is less improvement for LARA in recapturing the true surfaces as the true
surfaces become more continuous.
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(a) True Surface

(b) Estimated Surface

Figure 4.9: Scenario 1 - Treatment Success Probabilities

(a) True Surface

(b) Estimated Surface

Figure 4.10: Scenario 2 - Treatment Success Probabilities
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(a) True Surface

(b) Estimated Surface

Figure 4.11: Scenario 3 - Treatment Success Probabilities

(a) True Surface

(b) Estimated Surface

Figure 4.12: Scenario 4 - Treatment Success Probabilities
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When there is no spatial variability in the true surface and a null effect size (Figure 4.13), RA
randomization recaptures the true success probability surfaces. However, there is some noise in
estimating the true success probabilities for LARA, where there is nominal overestimation of the
true success probabilities towards the center of the study area. For a medium effect size (Figure
4.14), the patter is similar where RA randomization recaptures the true surface and the estimates
are slightly biased for LARA.

(a) True Surface

(b) Estimated Surface

Figure 4.13: Scenario 5 - Treatment Success Probabilities
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(a) True Surface

(b) Estimated Surface

Figure 4.14: Scenario 6 - Treatment Success Probabilities

When the true success probabilities vary across space and the effect size is null (Figure 4.15),
LARA estimates a highly variable success probability surface that resembles the true surfaces.
While RA randomization estimates constant success probabilities with no treatment difference, the
estimates do not vary over space to recapture the true surfaces. When there is only spatial variability
in success rates for treatment 1 (Figure 4.16), the pattern is similar where LARA outperforms RA
in recapturing the true surfaces.
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(a) True Surface

(b) Estimated Surface

Figure 4.15: Scenario 7 - Treatment Success Probabilities

(a) True Surface

(b) Estimated Surface

Figure 4.16: Scenario 8 - Treatment Success Probabilities
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4.5

Discussion

We proposed the LARA approach to account for location-based variability in treatment effectiveness by interpolating spatially-varying treatment effects. The conditional success probabilities
specific to each location were incorporated in a novel approach to skew the treatment assignments
towards the treatment performing best at each patient’s residence. We are not aware of any previous
research that incorporated location into the adaptive design framework.
When there are true spatially-varying treatment effects and a medium effect size, LARA results
in more treatment successes and larger allocation proportions while maintaining less variability in
successes than RA randomization and, in some cases, balanced allocation. LARA achieves higher
power and lower mean squared error relative to the other methods. This pattern is similar when
only the success probabilities for treatment 1 vary across space. When the effect size is null, the
three approaches perform similarly in terms of mean total number of successes, expected allocation
proportions, type I error rates. There is nominally less improvement in expected successes and type
I error but lower MSE for the LARA design. It is encouraging to note that LARA works best when
there are true spatially-varying treatment differences, when implementing this approach would be
most realistic.
When the true success surfaces are constant and there are no treatment differences, the three
approaches perform comparably with respect to treatment successes, allocation proportions, type I
error and MSE. There is slightly less improvement in the type I error rate for LARA. However, when
there is a medium effect size, the adaptive designs result in more treatment successes and larger
allocation ratios relative to the balanced case, with slightly less improvement for LARA. However,
LARA maintains lower variability in both treatment successes and adaptation and achieves lower
MSE compared to RA randomization. In addition, LARA gains back all of the power lost with the
RA method relative to balanced allocation.
There is a notable loss of power for all three methods when there is spatial variation in the
success probabilities. This can be explained by the fact that the sample size determination was
performed for a fixed effect size, ignoring spatial variability. However, the true effect sizes vary
across the study area and are often smaller than what the trial was powered for, thus the scenarios
are underpowered. In addition, we are using a naive approach that ignores location to calculate
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the operating characteristics. As trials would be designed and implemented without complete
information, specifically the spatial variability of treatment effectiveness, this phenomena would be
common in real world applications. When there was a medium effect size with spatial variability
in the success rates, the power for the BC/LARA approaches were close to nominal levels. For a
null effect size, there was a slight inflation in the type I error rate for LARA relative to the other
methods.
By interpolating spatially-varying treatment effects, LARA is able to estimate treatment success
probability surfaces that resemble the true surfaces when spatial variability exists. RA randomization ignores the spatial information and instead estimates constant success probabilities that are
averages of the true surfaces. This results in more instances of under- or over- estimation of the
true success probabilities and may lead to biased or even improper allocation. However, when there
is no spatial variability in the true surfaces, RA randomization is able to recapture the true surface
as expected, while LARA results in slightly biased estimates of the true success probabilities.
Although we use only 20 knots to represent the geographic locations, LARA may be able to
better capture the true surfaces by increasing the number of knots (e.g. k = 25) in the low-rank
kriging model. In addition, we fixed the spatial range parameter as one-quarter of the maximum
interpoint distance. However, several authors have acknowledged the importance of estimating ρ
as it controls the degree of smoothing in the spatially structured component [62, 46, 61]. This may
lead to an improved model fit and ultimately better predictions of the spatially-varying treatment
effects. Both of these approaches come at the cost of increased computation times, particularly in
our adaptive randomization simulations.
The results of the computation times demonstrate that LARA is more computationally demanding relative to the SARA approaches. Although the simulation times are reported per patient, thus
removing the effect of varying sample sizes, scenarios with larger sample sizes (null or small effect
sizes) have increased simulation times. This may be explained by the additional computation and
storing of results when there are more patient data. This problem is even more pronounced when
the posterior estimates are monitored for convergence using a convergence diagnostic statistic. In
our convergence simulation, we chose to use the previous patient’s posterior estimates to interpolate
the treatment effects necessary to update the allocation probabilities for the subsequent patient.
Alternatively, we could have coded an auto-update function to stop the chains once convergence is
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achieved, otherwise the chains would continue to update until convergence is attained. However,
we suspect this would artificially increase the simulation times by repeatedly checking and storing
the raw data. It is important to note that in a real life application the differences in computation
times would be trivial, as only one patient is adaptively randomized at a time. Convergence would
be assessed for each model fit after a new patient is adaptively randomized.
To ensure we were using the best interpolation approach for our LARA design, a small simulation
study was performed in advance to compare the performance of a GAR model (Appendix D.1) with
IDW interpolation to the low-rank kriging model (Eqn. 4.8). For the former, two independent CAR
priors were specified for each treatment indicator to allow treatment effectiveness to vary over space
for both groups. We calculated the success probabilities at the observed locations and used IDW
interpolation to predict the success probabilities to 15 fixed unobserved locations, using 5-fold
cross validation to select the inverse distance weighting power. For the LRK model, we considered
varying knot sizes (k = 15, 20, 25, 50) to see how performance was affected. LRK requires that
the number of patients be more than the number of knots when selecting candidate points for the
knot locations. We simulated 100 iterations of simulated patient locations with varying sample
sizes (n = 50, 100, 200). We compared the mean squared error and the computation times to assess
the quality of the predictions and the feasibility of the method for the adaptive randomization
simulation study. The results (Appendix D.1) show that the LRK model resulted in better quality
predictions (lower MSE) in most cases, particularly with a moderate number of knots. The IDW
approach resulted in lower computation times than LRK, with the number of knots increasing the
time but without much improvement in MSE.
We investigated scenarios where there was spatial variability in the success probabilities, both
discrete and more continuous patterns, as well as success rates that remained constant across space.
However, the scenarios may not be realistic in real life. We could conceive even more continuous,
realistic surfaces by increasing the number of grid cells and the complexity of the true success
probability surfaces. In addition, we focused on recapturing the variability in treatment effectiveness
by incorporating the spatially-varying treatment effects into the adaptive designs. Future work can
include adding covariates and other random effects, including spatially uncorrelated frailty terms,
to account for any unmeasured confounding at the subject-level. A small simulation study would
be necessary to examine which, if any, covariates and/or random effects should be included in the
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LARA model and candidate models compared using the goodness of fit (e.g. DIC). In addition, the
two independent Gaussian priors for the spatially-varying joint treatment random effects assume
independence of the two treatments. Instead, a multivariate CAR (MCAR) prior could be specified
to model the cross-correlations of the spatial random effects.
An alternative to the proposed LARA model is to extend the SARA models (Eqns. 2.13,
3.1, 3.3) to incorporate a more variable site effect in a GLMM without using spatial modeling.
Composite centers are created when small sites are ‘pooled’ together or combined with a larger site
to minimize data instability and variance inflation due to small sample sizes [12]. However, this
may lead to composites centers that are more heterogeneous and patients may respond differently
to treatments. In a similar sense, patient residential locations can be geocoded to a census unit
(e.g. tracts) and these spatial units used as a random ‘site’ effect. This would be appropriate for
trials with sparse patient locations or in studies with a small recruitment area, to ensure that the
samples sizes in each ‘site’ would be large enough to estimate the treatment effect.
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CHAPTER 5
DISCUSSION

We have proposed in Aim 1 a method to account for site-based response variability by calculating
conditional success probabilities specific to each center that can be incorporated in a novel approach
to skew the treatment allocations. In Aim 2, we extended this design to also account for variability
in treatment effectiveness under the Bayesian framework to avoid the limitations associated with
asymptotic approximations. Finally, a proxy, specifically residential location, is used for factors
that affect treatment differences to account for location-based variability in treatment responses
and effectiveness in Aim 3. This allows for a more highly variable treatment success surface to
be incorporated into the randomization method. These models were shown to be viable and are
generally at least as efficient as comparator methods.
We are not aware of any previous research that incorporated either site or patient residential
location into the response-adaptive design framework. Selvaratnam et al. (2017) proposed a GLMM
approach, which includes a center effect, to analyze data from a multi-center trial after all patients
are allocated using response-adaptive randomization [11]. The authors express the importance of
considering differences between centers and thus follow the approach of Li et al. (2012), where a
multi-center trial was analyzed using a Poisson GLMM that contained both treatment and random
center effects [68]. Since there are no closed form expressions for the asymptotic variance of the
MLEs, Selvaratnam et al. use the Gauss-Hermite quadrature method along with influence function
approaches to approximate the integrals necessary to establish the asymptotic properties of the
MLEs. The authors apply their approach to a real data set as well as perform a simulation
study. The model parameters are shown to be consistent and asymptotically normally distributed
[11]. However, the authors only consider their GLMM approach to analyze the trial data, not to
adaptively randomize the patients as in our research.
Our approach uses conditional success probabilities specific to the subsequent patient’s site or
location to skew the allocation weights in a novel way. Although our research incorporates site or
location information, the method is flexible enough to include additional covariates to adjust the
treatment assignments. Here, we substitute the estimated site-specific success probabilities from
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the GLM or GLMM/GLSM directly into the Optimal or Neyman allocation equations to update
the randomization weights. While we use the relative size of the success probabilities p̂1 , p̂2 to
adapt, previous research by Bandyopadhyay et al. (2007) used a standardized test statistic of
the treatment difference, or log-odds ratio, while Rosenberger et al. (2001) used an “Odds Ratio
Mapping” approach to transform the adjusted odds ratio to a probability that could be plugged
into one of the allocation equations [20, 21]. In addition, our approach can be easily extended to
accommodate other outcome types, including continuous and time-to-event data.
The trade-off between power and treatment failures is an expected consequence of adaptive
randomization. Adaptive methods skew the allocation ratio depending on the aim, thus the sample
sizes for each group are often unbalanced and may result in a loss of power compared to balanced
randomization. However, by accounting for an extra source of variation in the randomization
process, the variability in the allocation weights and thus treatment assignments were reduced.
Specifically, this loss of power for the proposed methods was not as notable as for RA randomization.
Therefore, our methods may reduce variability in allocation but only at the slight cost of power
compared to the balanced case. The simulations were designed with 80% power, assuming no intersite variability, which can require a relatively large sample size. Due to the additional resources
(e.g. time, money) necessary, this assumption may not be feasible or even unrealistic for some
clinical trials.
Besides the statistical performance benefits, the proposed methods have several important clinical implications. First, using the optimal allocation rule reduces the number of expected treatment
failures and is thus an ethical approach to randomization. Adaptive randomization may be more
appealing to patients because they have a higher chance of being assigned to the ‘superior’ treatment group and with our approach, to the ‘superior’ treatment group at their recruitment center
or residential location. Furthermore, by incorporating site information into the designs to account
for unmeasured constructs that may affect the outcome, such as social determinants of health,
the variability in the allocation process was reduced so more patients are assigned to the superior
treatment. Additionally, by gaining back most of the power lost with the other adaptive methods,
these approaches achieve higher power to detect a statistically significant treatment effect when
one exists at the end of a study. Importantly, this method is a step closer to personalized or precision medicine, where treatment is tailored to maximize individual patient benefit. In addition to
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incorporating site and location information, our proposed methods are flexible enough to allow for
covariates to be included to adjust the allocation.
We investigated numerous scenarios where we controlled the amount of inter-site variability,
number of sites, treatment success rates, effect sizes and the optimization criteria for the allocation,
or we manually set the true treatment success surfaces. While these scenarios are finite in scope,
having only considered a subset of the potential realistic trial conditions, they are representative of
many possible real-world scenarios. The limited number of scenarios is in part due to the extensive
computation times necessary for the simulation studies. Since the simulations were modeled as a
Phase 2 efficacy trial, there are a small number of centers which requires that enough patients be
recruited to each. This may result in convergence issues early on in the study or lead to unstable
estimates. However, natural lead-in approaches could be used to mitigate these issues, such as
those described in Thall & Wathen (2007) [22] and Sabo (2017) [69].
There is an array of logistical challenges associated with implementing any clinical trial, though
there are additional issues associated with adaptive randomization designs. For covariate-adjusted
response-adaptive randomization, the outcome and covariate data are required to be readily available in order to update the randomization schedule for the subsequent patient. This requires
infrastructure to be in place across all centers for the input and processing of patient data necessary to update the allocation weights. Since the assignment probabilities change throughout a
trial, there are ethical implications for the informed consent process. Because there is a higher
chance patients may be assigned to the ‘superior’ treatment, particularly later in the study when
enough data are available, patients may prefer to enroll later on in the study. This would introduce
bias into the randomization as some patients (e.g. less severe cases) may wait to enroll under the
assumption that they will be randomized to the ‘better’ treatment [70]. Some additional considerations include masking, use of a data safety monitoring board (DSMB) statistician, lack of standard
statistical software, sample size and power, protocol approval by regulatory agencies and budget
concerns [18, 70, 71, 72].

5.1

Future considerations:

Some future extensions of this work include the following conceptual ideas.
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 Incorporate a natural lead in early on in a trial when the sample proportions are unstable or

when there are no successes for one of the treatment groups [22], such as using a Decreasingly
Informative Prior (DIP) [73],
 Comparison of different artificial lead-in lengths where balanced allocation is used,
 Development of a method to handle subject attrition but still use their information in the

adaptive rule,
 Implement an approach for delayed subject responses, such as using auxiliary outcomes [8],
 Development of site- and location-adjusted designs to handle multiple treatments [74, 75],

multiple responses as well as different outcome types, such as continuous data [24, 25, 26, 27],
 Examination of alternate ways to utilize data when adapting, for example, Rosenberger’s

(2001) “Odds Ratio Mapping” approach [20] or calculating posterior probabilities of treatment
efficacy (e.g. Pr{pB < pA |Fn )}) [22, 32],
 Derive asymptotic properties of estimators for validity of inference from proposed designs

[76, 75, 11],
 Consider methods to reduce the computational demand, such as 1) sequential Bayesian up-

dating, where the posterior distribution is constructed so that the likelihood of the previous
patient data does not need to be calculated for each subsequent patient being randomized [77],
or 2) using only 1 Markov chain and assessing convergence using Geweke’s (1992) diagnostic
[78],
 Applying LARA and incorporating census data, such as median income or percentage of

specific race/ethnicity to adjust the allocation,
 Estimate the spatial range parameter, ρ, which controls the degree of smoothing in the spa-

tially structured component [46, 62, 61] of the LARA model,
 Comparison of Bayesian methods to test treatment effects (e.g. 95% credible interval, poste-

rior probabilities).
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APPENDIX A
R CODE RELEVANT TO CHAPTER 2

1 # # Site - Adjusted Response - Adaptive Design ( SARA 1) ##
2
3 # # load packages
4 library ( Matrix )
5 library ( lme4 )
6
7 # # function to bound probabilities between [0.01 , 0.99]
8 bound <- function ( f ) {
9

if ( f > 0 & f < 1) {

10
11

f <- f
} else if ( f <= 0) {

12
13

f <- 0.01
} else {

14
15

f <- 0.99
}

16 }
17
18 # generate site - specific probabilities
19 p1 _ 0 <- numeric ( kcent )
20 p2 _ 0 <- numeric ( kcent )
21
22 for ( l in 1: kcent ) {
23

p1 _ 0[ l ] <- rnorm (1 , mean = P1 , sd = sigm ) # random variate from N ( P1 , sigma )

24

p2 _ 0[ l ] <- rnorm (1 , mean = P2 , sd = sigm )

25
26

p1 _ 0[ l ] <- bound ( p1 _ 0[ l ]) # bounds probabilities [0.01 , 0.99]

27

p2 _ 0[ l ] <- bound ( p2 _ 0[ l ])

28 }
29
30 # # inner loop 1 ( h ) - assign site to each subject using random draw from U (0 ,1)
31 for ( h in 1: n ) {
32

# determine site patients come from and success rates for that practice

33

v <- runif (1 , min = 0 , max = 1) # values between (0 , 1)

34
35

for ( z in 1: kcent ) {

36

if ( v > (z -1) / kcent & v <= z / kcent ) {

37

YGS [h , 3] <- z

38
39

}
}

40 }
41
42 # delay updating of weights until at least the 20 th iteration , outcome has 2 levels and all sites observed
43 if ( i > 20 & dim ( table ( YGS [1: i , 1]) ) == 2 & dim ( table ( YGS [1: i , 3]) ) == kcent ) {
44

# YGS = matrix ( Outcome , Group , Site )

45

fit2 <- try ( glmer ( YGS [1: i ,1] ~ factor ( YGS [1: i ,2]) + (1 | factor ( YGS [1: i ,3]) ) , family = binomial , control =

46

glmerControl ( optimizer = " bobyqa " ) , nAGQ = 10) , silent = TRUE ) # Adaptive Gauss - Hermite Quadrature
approximation

47
48

cond1 <- try ( summary ( fit2 ) , silent = TRUE ) # use try () , summary ( fit2 ) produces error and terminates loop on cluster

49
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50

# no error , update weights if no convergence issues

51

if ( class ( cond1 ) == ’ summary . merMod ’) {
if ( is . null ( summary ( fit2 ) $ optinfo $ conv $ lme4 $ messages ) == TRUE & summary ( fit2 ) $ optinfo $ conv $ opt == 0 & class ( fit2 ) == ’

52

glmerMod ’) {
53

# no convergence warnings , successful convergence

54

blups <- as . data . frame ( ranef ( fit2 ) $ ‘ factor ( YGS [1: i , 3]) ‘) # extract conditional means of random site effects

55
56

b0 <- summary ( fit2 ) $ coefficients [1] # intercept

57

b1 <- summary ( fit2 ) $ coefficients [2] # treatment effect , reference = group 1

58
59

# site effect for next subject if not last subject in trial

60

b2 <- ifelse ( i ! = n , blups [ rownames ( blups ) == YGS [( i + 1) , 3] ,] , blups [ rownames ( blups ) == YGS [i , 3] ,])

61
62

p1 _ hat <- exp ( sum ( b0 , b2 ) ) / (1 + exp ( sum ( b0 , b2 ) ) ) # antilogit , intercept only

63

p2 _ hat <- exp ( sum ( b0 , b1 , b2 ) ) / (1 + exp ( sum ( b0 , b1 , b2 ) ) ) # intercept + b1

64
65

if ( Alloc == ’o ’) {

66

# update optimal allocation weights

67

w1 <- sqrt ( p1 _ hat ) / ( sqrt ( p1 _ hat ) + sqrt ( p2 _ hat ) )

68

w2 <- (1 - w1 )

69

}

70
71

if ( Alloc == ’n ’) {

72

# failure probabilities

73

q1 _ hat <- (1 - p1 _ hat )

74

q2 _ hat <- (1 - p2 _ hat )

75
76

# update neyman allocation weights

77

w1 <- sqrt ( p1 _ hat * q1 _ hat ) / ( sqrt ( p1 _ hat * q1 _ hat ) + sqrt ( p2 _ hat * q2 _ hat ) )

78

w2 <- (1 - w1 )

79

}

80

}

81

}

82

weight [i , 1] <- w1 # collect updated weight use to randomize subsequent patient , w2 = 1 - w1

83 }
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APPENDIX B
CHAPTER 3 ADDITIONAL TABLES

Table B.1: Scenario - 3 sites, p1 = 0.3, 0.5, 0.7, δ = 0.1
SARA 2

SARA 3

k

p1

δ

σ

Successes

Proportion

Power

Successes

Proportion

3

0.3

0.1

0

150.0 (10.2)

0.56 (0.03)

0.84

150.3 (10.3)

0.56 (0.04)

0.84

(n=587)

0.05

150.2 (16.3)

0.55 (0.04)

0.74

151.5 (16.3)

0.56 (0.04)

0.72

0.1

151.7 (26.5)

0.56 (0.06)

0.68

156.2 (26.5)

0.56 (0.07)

0.66

0.15

155.7 (37.0)

0.55 (0.08)

0.69

164.3 (37.3)

0.56 (0.08)

0.64

0.1

0

351.4 (14.0)

0.53 (0.02)

0.79

351.4 (14.0)

0.53 (0.02)

0.80

(n=775)

0.05

350.9 (21.4)

0.53 (0.03)

0.70

351.6 (21.4)

0.53 (0.03)

0.69

0.1

351.3 (34.4)

0.53 (0.03)

0.66

354.6 (34.5)

0.53 (0.04)

0.65

0.15

353.3 (48.8)

0.53 (0.04)

0.70

360.7 (48.5)

0.53 (0.05)

0.69

0.1

0

464.5 (12.3)

0.52 (0.02)

0.79

464.5 (12.3)

0.52 (0.02)

0.78

(n=712)

0.05

464.3 (19.5)

0.52 (0.02)

0.72

464.7 (19.5)

0.52 (0.02)

0.72

0.1

464.4 (31.4)

0.52 (0.03)

0.68

466.2 (31.3)

0.52 (0.03)

0.67

0.15

465.3 (44.3)

0.52 (0.03)

0.71

469.3 (43.7)

0.52 (0.03)

0.71

0.5

0.7

1

Compare to Tables 3.3, 3.9, 3.15
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Table B.2: Scenario - 6 sites, p1 = 0.5, 0.7, δ = 0.15
SARA 2

SARA 3

k

p1

δ

σ

Successes

Proportion

Power

Successes

Proportion

6

0.5

0.15

0

147.0 (9.0)

0.54 (0.04)

0.80

147.3 (9.0)

0.55 (0.04)

0.79

(n=339)

0.05

146.3 (10.6)

0.54 (0.04)

0.76

146.8 (10.6)

0.55 (0.04)

0.76

0.1

146.7 (13.4)

0.54 (0.04)

0.70

148.2 (13.5)

0.55 (0.04)

0.69

0.15

147.3 (17.3)

0.54 (0.05)

0.67

150.4 (17.1)

0.55 (0.05)

0.66

0.15

0

204.0 (8.6)

0.53 (0.03)

0.81

204.1 (8.5)

0.53 (0.03)

0.80

(n=325)

0.05

204.1 (9.9)

0.53 (0.03)

0.77

204.4 (9.9)

0.53 (0.03)

0.78

0.1

204.4 (12.7)

0.53 (0.03)

0.72

205.2 (12.7)

0.53 (0.03)

0.71

0.15

204.4 (16.5)

0.53 (0.04)

0.67

206.3 (16.3)

0.53 (0.04)

0.67

0.7

1

Power

Compare to Tables 3.12, 3.18

Table B.3: Scenario - 3 sites, p1 = 0.5, δ = 0
SARA 2

SARA 3

k

p1

δ

σ

Successes

Proportion

Power

Successes

Proportion

3

0.5

0

0

387.8 (13.9)

0.50 (0.02)

0.04

387.8 (13.9)

0.50 (0.02)

0.04

(n=775)

0.05

387.3 (21.0)

0.50 (0.02)

0.19

388.0 (21.0)

0.50 (0.02)

0.19

0.1

388.1 (33.9)

0.50 (0.03)

0.42

390.9 (33.8)

0.50 (0.03)

0.41

0.15

389.8 (48.4)

0.50 (0.04)

0.59

396.1 (47.9)

0.50 (0.04)

0.57

1

Compare to Table 3.9
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Table B.4: Scenario - 6 sites, p1 = 0.7, δ = 0.1
SARA 2

SARA 3

k

p1

δ

σ

Successes

Proportion

Power

Successes

Proportion

6

0.7

0.1

0

464.5 (12.3)

0.52 (0.02)

0.78

464.5 (12.3)

0.52 (0.02)

0.79

(n=712)

0.05

463.5 (16.5)

0.52 (0.02)

0.71

464.0 (16.5)

0.52 (0.02)

0.71

0.1

463.6 (24.3)

0.52 (0.02)

0.65

465.7 (24.2)

0.52 (0.02)

0.65

0.15

463.6 (33.2)

0.52 (0.03)

0.65

468.1 (32.8)

0.52 (0.03)

0.66

1

Compare to Table 3.18
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APPENDIX C
R CODE RELEVANT TO CHAPTER 3

1 # # Site - Adjusted Response - Adaptive Design without interaction ( SARA 2) ##
2
3 # # load packages
4 lapply ( c ( ’ Matrix ’ , ’ coda ’ , ’ BRugs ’ , ’ lme4 ’) , require , character . only = TRUE )
5
6 # inverse logit function
7 inv . logit <- function ( x ) {
8

return ( exp ( x ) / (1 + exp ( x ) ) )

9 }
10
11 # function for site - specific success probabilities , p - hat _ ij , i = treatment group , j = site
12 # reference : treatment group 1
13 site . prob <- function ( k0 = NULL , num _ s = kcent , inter = 0) {
14

# k0 = site for next subject , num _ s = total number of sites in current trial

15
16

# no interaction

17

if ( inter == 0) {

18

p2 _ hat < <- as . numeric ( inv . logit ( b0 + b1 + get ( paste ( ’d ’ , k0 , sep = ’ ’) ) ) )

19
20

p1 _ hat < <- as . numeric ( inv . logit ( b0 + get ( paste ( ’d ’ , k0 , sep = ’ ’) ) ) )
}

21
22

# trt - by - site interaction

23

if ( inter == 1) {

24

p2 _ hat < <- as . numeric ( inv . logit ( b0 + b1 + get ( paste ( ’d ’ , k0 , sep = ’ ’) ) +

25

get ( paste ( ’g ’ , k0 , sep = ’ ’) ) ) ) # site + interaction effects

26

p1 _ hat < <- as . numeric ( inv . logit ( b0 + get ( paste ( ’d ’ , k0 , sep = ’ ’) ) +

27
28

get ( paste ( ’g ’ , num _ s + k0 , sep = ’ ’) ) ) )
}

29 }
30
31 # bayesian GLMM with random site effect ( delta )
32 model <- function () {
33

for ( i in 1: N ) {

34
35

Y [ i ] ~ dbern ( p [ i ])

36

logit ( p [ i ]) <- beta0 + beta1 * G [ i ] + delta [ S [ i ]]

37
38

}

39
40

for ( j in 1: nk ) {

41
42

delta [ j ] ~ dnorm (0.0 , 1) # site - level RE , skeptical prior N (0 ,1)

43
44

}

45
46

# Choice of Priors

47

beta0 ~ dnorm (0.0 , 0.2) # N (0 ,5)

48

beta1 ~ dnorm (0.0 , 0.2) # N (0 ,5)

49 }
50
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51 # delay updating of weights until at least the 20 th patient
52 if ( i > 20) {
53
54

YGS $ group <- ifelse ( YGS $ G == 2 , 1 , 0) # dummy code for BRugs , group 1 = reference ( Aim 1)

55

dat <- list ( N = i , nk = kcent , Y = YGS $ Y [1: i ] , G = YGS $ group [1: i ] , S = YGS $ S [1: i ]) # nk = number of sites

56
57

if ( i == 21) {

58

# use frequentist GLM for starting values for first subject once adaptation begins

59

init _ fit <- glm ( YGS [1: i ,1] ~ factor ( YGS [1: i ,2]) , family = binomial ) # frequentist GLM model , no site effect

60
61

b0 . init <- summary ( init _ fit ) $ coefficients [ rownames ( summary ( init _ fit ) $ coefficients ) == ’( Intercept ) ’ , 1] # intercept

62

b1 . init <- summary ( init _ fit ) $ coefficients [ rownames ( summary ( init _ fit ) $ coefficients ) == ’ factor ( YGS [1: i , 2]) 2 ’ , 1] # trt
2 effect

63
64

l1 <- list ( beta0 = b0 . init , beta1 = b1 . init , delta = rep (0 , kcent ) ) # chain starting values

65

l2 <- list ( beta0 = b0 . init + 0.5 , beta1 = b1 . init + 0.5 , delta = rep (0 , kcent ) )

66

inits <- list ( l1 , l2 ) # list of initial values

67

inits1 <- paste ( ’ init1 ’ , ’_ ’ , Alloc , ’_ ’ , kcent , ’_ ’ , P1 , ’_ ’ , delt , ’_ ’ , sigm , ’. txt ’ , sep = ’ ’)

68

inits2 <- paste ( ’ init2 ’ , ’_ ’ , Alloc , ’_ ’ , kcent , ’_ ’ , P1 , ’_ ’ , delt , ’_ ’ , sigm , ’. txt ’ , sep = ’ ’)

69

bugsInits ( inits , 2 , c ( inits1 , inits2 ) ) # have to output inits or they will save to temp folder when fitting model

70
71

} else {

72

# starting values after 21 st patient

73

l1 <- list ( beta0 = inits . df [1] , beta1 = inits . df [2] , delta = as . numeric ( inits . df [2 + (1: kcent ) ]) )

74

l2 <- list ( beta0 = inits . df [1] + 0.5 , beta1 = inits . df [2] + 0.5 , delta = as . numeric ( inits . df [2 + (1: kcent ) ] + .05) )

75

inits <- list ( l1 , l2 ) # list of initial values

76

inits1 <- paste ( ’ init1 ’ , ’_ ’ , Alloc , ’_ ’ , kcent , ’_ ’ , P1 , ’_ ’ , delt , ’_ ’ , sigm , ’. txt ’ , sep = ’ ’)

77

inits2 <- paste ( ’ init2 ’ , ’_ ’ , Alloc , ’_ ’ , kcent , ’_ ’ , P1 , ’_ ’ , delt , ’_ ’ , sigm , ’. txt ’ , sep = ’ ’)

78
79

bugsInits ( inits , 2 , c ( inits1 , inits2 ) )
}

80
81

# fit SARA 2 model

82

model1 <- try ( BRugsFit ( model , dat , c ( inits1 , inits2 ) , numChains = 2 ,

83

parametersToSave = c ( ’ beta0 ’ , ’ beta1 ’ , ’ delta ’) ,

84

nBurnin = 2000 , nIter = 4000 , nThin = 1 , coda = TRUE , DIC = FALSE ,

85
86

BRugsVerbose = FALSE , seed = seed0 ) ,
silent = TRUE )

87
88

# no error , update weights if no convergence issues

89

if ( class ( model1 ) == ’ mcmc . list ’) {

90
91

conv <- gelman . diag ( model1 ) $ psrf [ ,1] # Gelman ’ s Rhat aka . PSRF

92
93
94

if ( is . element ( NA , conv ) == FALSE & all ( conv < 1.1) ) {
# parameters converged ( Rhat < 1.1) , use posterior estimates to update weights adapt

95
96

post <- summary ( model1 ) $ statistics # posterior estimates

97

post . mean <- post [ rownames ( post ) == ’ beta1 ’ , 1:2] # posterior mean trt effect

98
99

post . median <- apply ( rbind ( model1 [[1]] , model1 [[2]]) , 2 , stats :: median ) # calculate posterior medians

100
101

b0 <- post . median [ names ( post . median ) == ’ beta0 ’] # intercept

102

b1 <- post . median [ names ( post . median ) == ’ beta1 ’] # treatment 2 effect , reference = group 1

103
104

# extract site effects

105

blups <- as . data . frame ( as . numeric ( post . median [ names ( post . median ) % in % paste ( ’ delta [ ’ , 1: kcent , ’] ’ , sep = ’ ’) ]) )

106
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107

# output delta = site effect objects to calculate success probs

108

names1 <- paste ( ’d ’ , 1: kcent , sep = ’ ’)

109

for ( s in 1: length ( names1 ) ) {

110

assign ( names1 [ s ] , post . median [ names ( post . median ) == paste ( ’ delta [ ’ , s , ’] ’ , sep = ’ ’) ])

111

}

112
113

# if posterior estimates converged , use as initial values for next subject

114

inits . df [1] <- b0

115

inits . df [2] <- b1

116
117

for ( s0 in 1: kcent ) {

118

inits . df [2 + s0 ] <- get ( paste ( ’d ’ , s0 , sep = ’ ’) )

119

}

120
121

inits . df [3 + kcent ] <- NA # delta . var

122
123

# site - specific success probability for next subject if not last subject in trial , otherwise use current site

124

if ( i ! = n ) {

125

site . prob ( k0 = YGS [( i + 1) , 3] , num _ s = kcent , inter = 0) # outputs p1 _ hat , p2 _ hat objects

126

} else {

127

site . prob ( k0 = YGS [i , 3] , num _ s = kcent , inter = 0)

128

}

129
130

# allocation equations

131

if ( Alloc == ’o ’) {

132

w1 <- sqrt ( p1 _ hat ) / ( sqrt ( p1 _ hat ) + sqrt ( p2 _ hat ) ) # optimal allocation

133

w2 <- (1 - w1 )

134

}

135
136

if ( Alloc == ’n ’) {

137

q1 _ hat <- (1 - p1 _ hat ) # failure probabilities

138

q2 _ hat <- (1 - p2 _ hat )

139
140

w1 <- sqrt ( p1 _ hat * q1 _ hat ) / ( sqrt ( p1 _ hat * q1 _ hat ) + sqrt ( p2 _ hat * q2 _ hat ) ) # neyman allocation

141

w2 <- (1 - w1 )

142

}

143

}

144

}

145

weight [i , 1] <- w1 # collect updated weight use to randomize subsequent

146 }

1 # # Site - Adjusted Response - Adaptive Design with interaction ( SARA 3) ##
2
3 # bayesian GLMM with random site effect ( delta ) and interaction effect ( gamma )
4 model <- function () {
5

for ( i in 1: N ) {

6
7

Y [ i ] ~ dbern ( p [ i ])

8

logit ( p [ i ]) <- beta0 + beta1 * G [ i ] + delta [ S [ i ]] + gamma [ I [ i ]]

9
10

}

11
12

for ( j1 in 1: nk ) {

13
14

delta [ j1 ] ~ dnorm (0.0 , 1) # site - level RE , skeptical prior N (0 ,1)

15
16

}
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17
18

for ( j2 in 1:(2 * nk ) ) {

19
20

gamma [ j2 ] ~ dnorm (0.0 , 1) # trt - by - site interaction RE , skeptical prior N (0 ,1)

21
22

}

23
24

# Choice of Priors

25

beta0 ~ dnorm (0.0 , 0.2) # N (0 ,5)

26

beta1 ~ dnorm (0.0 , 0.2) # N (0 ,5)

27 }
28
29 YGS $ group <- ifelse ( YGS $ G == 2 , 1 , 0) # dummy code for BRugs , group 1 = reference ( Aim 1)
30 YGS $ I <- ifelse ( YGS $ G == 2 , YGS $ S , ( YGS $ S + kcent ) ) # interaction indicator variable
31 dat <- list ( N = i , nk = kcent , Y = YGS $ Y [1: i ] , G = YGS $ group [1: i ] , S = YGS $ S [1: i ] , I = YGS $ I [1: i ]) # nk = number of sites
32
33 if ( i == 21) {
34

# use frequentist GLM for starting values for first subject once adaptation begins

35

init _ fit <- glm ( YGS [1: i ,1] ~ factor ( YGS [1: i ,2]) , family = binomial ) # frequentist GLM model , no site effect

36
37

b0 . init <- summary ( init _ fit ) $ coefficients [ rownames ( summary ( init _ fit ) $ coefficients ) == ’( Intercept ) ’ , 1] # intercept

38

b1 . init <- summary ( init _ fit ) $ coefficients [ rownames ( summary ( init _ fit ) $ coefficients ) == ’ factor ( YGS [1: i , 2]) 2 ’ , 1] # trt 2
effect

39
40

l1 <- list ( beta0 = b0 . init , beta1 = b1 . init , delta = rep (0 , kcent ) , gamma = rep (0 , 2 * kcent ) ) # chain starting values

41

l2 <- list ( beta0 = b0 . init + 0.5 , beta1 = b1 . init + 0.5 , delta = rep (0 , kcent ) , gamma = rep (0 , 2 * kcent ) )

42

inits <- list ( l1 , l2 ) # list of initial values

43

inits1 <- paste ( ’ init1 ’ , ’_ ’ , Alloc , ’_ ’ , kcent , ’_ ’ , P1 , ’_ ’ , delt , ’_ ’ , sigm , ’. txt ’ , sep = ’ ’)

44

inits2 <- paste ( ’ init2 ’ , ’_ ’ , Alloc , ’_ ’ , kcent , ’_ ’ , P1 , ’_ ’ , delt , ’_ ’ , sigm , ’. txt ’ , sep = ’ ’)

45

bugsInits ( inits , 2 , c ( inits1 , inits2 ) ) # have to output inits or they will save to temp folder when fitting model

46
47 } else {
48
49
50
51

l1 <- list ( beta0 = inits . df [1] , beta1 = inits . df [2] , delta = as . numeric ( inits . df [2 + (1: kcent ) ]) ,
gamma = as . numeric ( inits . df [3 + kcent + 1:(2 * kcent ) ]) )
l2 <- list ( beta0 = inits . df [1] + 0.5 , beta1 = inits . df [2] + 0.5 , delta = as . numeric ( inits . df [2 + (1: kcent ) ] + 0.05) ,
gamma = as . numeric ( inits . df [3 + kcent + 1:(2 * kcent ) ]) + 0.05)

52

inits <- list ( l1 , l2 ) # list of initial values

53

inits1 <- paste ( ’ init1 ’ , ’_ ’ , Alloc , ’_ ’ , kcent , ’_ ’ , P1 , ’_ ’ , delt , ’_ ’ , sigm , ’. txt ’ , sep = ’ ’)

54

inits2 <- paste ( ’ init2 ’ , ’_ ’ , Alloc , ’_ ’ , kcent , ’_ ’ , P1 , ’_ ’ , delt , ’_ ’ , sigm , ’. txt ’ , sep = ’ ’)

55

bugsInits ( inits , 2 , c ( inits1 , inits2 ) ) # have to output inits or they will save to temp folder when fitting model

56 }
57
58 # fit SARA 3 model
59 model1 <- try ( BRugsFit ( model , dat , c ( inits1 , inits2 ) , numChains = 2 ,
60

parametersToSave = c ( ’ beta0 ’ , ’ beta1 ’ , ’ delta ’ , ’ gamma ’) ,

61

nBurnin = 2000 , nIter = 4000 , nThin = 1 , coda = TRUE , DIC = FALSE ,

62
63

BRugsVerbose = FALSE , seed = seed0 ) ,
silent = TRUE )
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APPENDIX D
GEOGRAPHICALLY ADAPTIVE REGRESSION LARA MODEL

GAR LARA Model

logit(pi ) = α + (β1 + β11i )X1i + (β2 + β22i )X2i + Ui + Vi + X T θ

(D.1)

Here, α is the overall intercept, X1i , X2i are treatment group 1 and 2 indicators, Ui is an unstructured random effect and Vi is a spatially structured random effect for the ith patient, i = 1, . . . , n.
Furthermore, β1 , β2 are overall treatment effects for each group while β11i , β22i are interpreted
as spatially-varying local deviations from the overall treatment effects. Instead of modeling the
spatially-varying treatment effects with an intrinsic MCAR prior, two univariate CAR priors were
considered under the assumption that the regression coefficients are independent. The separate
random components for each treatment group allow treatment effectiveness to vary over space for
both groups. The X T θ is an optional set of subject- and/or location-specific covariates. The
following priors1 are specified:
α ∼ N (0, τα ), β1 ∼ N (0, τβ1 ), β2 ∼ N (0, τβ2 ),
β11i | · · · ∼ N (µβ11 , τβ11 /nξi ),
β22i | · · · ∼ N (µβ22 , τβ22 /nξi ),

(D.2)

Ui ∼ N (0, τu ),
Vi | · · · ∼ N (ν̄i , τν /nξi ).
The hyperparameters for the CAR priors, defined as µβ11 = β̄11ξi and µβ22 = β̄22ξi , are the neighborhood averages for neighborhood ξi (nξi neighbors) and the ith area. Similarly, the hyperpaP
rameter for the independent CAR prior mean, defined as ν̄i = j∈ξi νj /nξi , is the neighborhood
average. Several unstructured or spatially structured priors (e.g. exchangeable, conditionally auto1

The priors are specified as N (µ, τ ), where τ = 1/σ 2 and σ 2 is the variance.
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regressive) could be used for the correlation structures of the random effects to account for unmeasured confounding at the subject-level. However, the unstructured and spatially structured random
effects are optional and were removed to avoid identifiability issues.
Table D.1: Comparing Low Rank Kriging and Inverse Distance Weighted Interpolation
LRK
Patients

k = 15

k = 20

k = 25

k = 50

IDW

n = 50
Time (hours)

2.46

0.94

0.94

-

0.56

MSE 1

0.048

0.041

0.044

-

0.053

MSE 2

0.044

0.045

0.043

-

0.057

1.00

1.88

1.65

10.85

1.08

MSE 1

0.029

0.029

0.034

0.047

0.043

MSE 2

0.030

0.030

0.031

0.050

0.043

2.21

4.24

3.30

22.31

0.88

MSE 1

0.018

0.021

0.021

0.039

0.028

MSE 2

0.020

0.022

0.023

0.042

0.027

n = 100
Time (hours)

n = 200
Time (hours)
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APPENDIX E
R CODE RELEVANT TO CHAPTER 4

1 # # Location - Adjusted Response - Adaptive Design ( LARA ) ##
2
3 # # load packages
4 lapply ( c ( ’ spatstat ’ , ’ maptools ’ , ’ spdep ’ , ’ BRugs ’ , ’ coda ’ , ’ fields ’) , require , character . only = TRUE )
5
6 # Bayesian Low - Rank Kriging ( LRK ) model
7 model <- function () {
8

for ( i in 1: nknots ) {

9
10

ME [ i ] <- 0 # mean =0 for REs
}

11
12

for ( i in 1: nknots ) {

13

for ( j in 1: nknots ) {

14

SOM [i , j ] <- tauS * OM [i , j ] # setting up precision matrix for REs , OM is pre - calculated knots cov , treatment group 1

15

SOM2 [i , j ] <- tauT * OM [i , j ] # SOM for treatment group 2 indicator

16
17

}
}

18
19

for ( i in 1: N ) {

20

# Likelihood

21

Y [ i ] ~ dbern ( p [ i ])

22
23

logit ( p [ i ]) <- beta0 + beta11 [ i ] * G1 [ i ] + beta22 [ i ] * G2 [ i ]

24
25

beta11 [ i ] <- inprod ( gam [] , CDZ [i , ]) # CDZ pre - calculated cov matrix between obs / knots , treatment group 1

26

beta22 [ i ] <- inprod ( gam2 [] , CDZ [i , ]) # treatment group 2

27
28

}

29
30

gam [1: nknots ] ~ dmnorm ( ME [] , SOM [ , ]) # joint random effect prior dist , treatment group 1

31

gam2 [1: nknots ] ~ dmnorm ( ME [] , SOM2 [ , ]) # treatment group 2

32
33

# Choice of Priors

34

beta0 ~ dnorm (0 , 0.4) # N (0 , 2.5)

35
36

tauS <- 1 / sigmaS # precision for trt 1

37

sigmaS ~ dunif (0 , 2) # var

38
39

tauT <- 1 / sigmaT # precision for trt 2

40

sigmaT ~ dunif (0 , 2) # var

41
42 }
43
44 # Calculate distance matrix between observed points
45 Dobs <- as . matrix ( dist ( YGS [1: i , c ( ’x ’ , ’y ’) ]) )
46
47 rho _ hat <- (1 / 4) * max ( Dobs ) # fixed rho
48
49 # Generate Knots - space filling knot locations
50 knot0 <- fields :: cover . design ( R = matrix ( c ( YGS $ x , YGS $ y ) , ncol = 2) [1: i , ] , nd = n . knots ,
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51

nn = ifelse ( i <= 100 , FALSE , TRUE ) ,

52

num . nn = min ( nrow ( YGS [1: i , ]) - ( n . knots + 1) , 100) ) # only use 100 nn when i > 100

53 knot <- data . frame ( x = knot0 $ design [ , 1] , y = knot0 $ design [ , 2])
54
55 # Calculate distance matrix between knots
56 Dknot <- as . matrix ( dist ( knot ) ) # n . knots x n . knots
57
58 # Calculate Distance and Covariance Matrices between observed [1: i ] & knot locations
59 CDZ <- matrix ( nrow = i , ncol = n . knots ) # covariance matrix for observed & knot locations
60 DOknot <- matrix ( nrow = i , ncol = n . knots ) # distance between observed & knot locations
61
62 for ( z1 in 1: nrow ( YGS [1: i , ]) ) {
63

for ( z2 in 1: n . knots ) {

64

DOknot [ z1 , z2 ] <- sqrt (( YGS $ x [ z1 ] - knot $ x [ z2 ]) ^2 + ( YGS $ y [ z1 ] - knot $ y [ z2 ]) ^2) # n . obs x n . knots

65

CDZ [ z1 , z2 ] <- (1 + abs ( DOknot [ z1 , z2 ]) / rho _ hat ) * exp ( - abs ( DOknot [ z1 , z2 ]) / rho _ hat ) # n . obs x n . knots

66

}

67 }
68
69 # Omega Matrix for Random Effects with cov applied to the knots
70 OM <- matrix ( nrow = n . knots , ncol = n . knots )
71
72 for ( z1 in 1: n . knots ) {
73

for ( z2 in 1: n . knots ) {

74
75

OM [ z1 , z2 ] <- (1 + abs ( Dknot [ z1 , z2 ]) / rho _ hat ) * exp ( - abs ( Dknot [ z1 , z2 ]) / rho _ hat ) # n . knots x n . knots
}

76 }
77
78 YGS $ G1 <- ifelse ( YGS $ G == 1 , 1 , 0) # separate treatment indicator for each group
79 YGS $ G2 <- ifelse ( YGS $ G == 2 , 1 , 0)
80 dat <- list ( N = i , Y = YGS $ Y [1: i ] , G1 = YGS $ G1 [1: i ] , G2 = YGS $ G2 [1: i ] , nknots = n . knots , CDZ = CDZ , OM = OM )
81
82 model1 <- try ( BRugsFit ( model , dat , c ( inits1 , inits2 ) , numChains = 2 ,
83

parametersToSave = c ( ’ beta0 ’ , ’ sigmaS ’ , ’ sigmaT ’ , ’ gam ’ , ’ gam2 ’) ,

84

nBurnin = 4000 , nIter = 1000 , nThin = 1 , coda = FALSE , DIC = FALSE ,

85

BRugsVerbose = FALSE , seed = seed0 ) ,

86

silent = TRUE )

87
88 # Posterior Estimates
89 post . median <- as . matrix ( model1 $ Stats ) [ , ’ median ’] # posterior median
90
91 b0 <- post . median [ names ( post . median ) == ’ beta0 ’] # intercept
92
93 psi1 <- as . numeric ( post . median [ names ( post . median ) % in % paste ( ’ gam [ ’ , 1: n . knots , ’] ’ , sep = ’ ’) ]) # psi RE , trt 1
94 psi2 <- as . numeric ( post . median [ names ( post . median ) % in % paste ( ’ gam2 [ ’ , 1: n . knots , ’] ’ , sep = ’ ’) ]) # psi RE , trt 2
95
96 sigmaS <- post . median [ names ( post . median ) == ’ sigmaS ’]
97 sigmaT <- post . median [ names ( post . median ) == ’ sigmaT ’]
98
99 # # Calculate Distance and Covariance Matrices between subsequent patient & knot locations for predictions
100 if ( i ! = n ) {
101

Unobs <- data . frame ( x = YGS $ x [ i + 1] , y = YGS $ y [ i + 1]) # subsequent patient

102 } else {
103

Unobs <- data . frame ( x = 0.5 , y = 0.5) # last patient , predict to random location (0.5 , 0.5)

104 }
105
106 CDZ2 <- matrix ( nrow = nrow ( Unobs ) , ncol = n . knots ) # covariance matrix for unobserved & knot locations
107 DUknot <- matrix ( nrow = nrow ( Unobs ) , ncol = n . knots ) # distance between unobserved & knot locations
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108
109 for ( z1 in 1: nrow ( Unobs ) ) {
110

for ( z2 in 1: n . knots ) {

111

DUknot [ z1 , z2 ] <- sqrt (( Unobs $ x [ z1 ] - knot $ x [ z2 ]) ^2 + ( Unobs $ y [ z1 ] - knot $ y [ z2 ]) ^2) # n . Unobs x n . knots

112

CDZ2 [ z1 , z2 ] <- (1 + abs ( DUknot [ z1 , z2 ]) / rho _ hat ) * exp ( - abs ( DUknot [ z1 , z2 ]) / rho _ hat ) # n . Unobs x n . knots

113

}

114 }
115
116 b11 <- CDZ2 % * % psi1 # predicted trt 1 effect at unobserved location ( subsequent patient )
117 b22 <- CDZ2 % * % psi2 # predicted trt 2 effect
118
119 # location - specific success probability for next subject
120 p1 _ hat <- pts $ p1 _ hat [ i + 1] <- as . numeric ( inv . logit ( b0 + b11 ) )
121 p2 _ hat <- pts $ p2 _ hat [ i + 1] <- as . numeric ( inv . logit ( b0 + b22 ) )
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